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Abstract 
Approximately 233,000 Australians and 150 million people worldwide have chronic 
infection with hepatitis C virus (HCV) that can lead to hepatic fibrosis, liver failure 
and cancer. To date, therapy for HCV infection is improving but still has significant 
side effects and is specific to a particular HCV genotype. Drugs targeting host factors 
should avoid these problems but a major barrier to their design and development is the 
incomplete understanding of the virus replication cycle. Therefore improved insight 
into the stages of the HCV life cycle will facilitate the development of novel 
antivirals, by targeting host proteins involved in specific stages of the virus life cycle. 
To find novel host factors involved in HCV infection, a mass spectrometry based 
SILAC (Stable isotope labelling with amino acids in cell culture) screen of the 
secreted proteome of HCV infected hepatocytes was conducted which identified a 
transmembrane protein calsyntenin-1 as a factor highly secreted by infected cells (44-
fold) as compared to uninfected control.  
This SILAC result was further confirmed by increase in calsyntenin-1 protein levels 
of HCV infected cells and their supernatant by western blot and densitometry 
analysis. HCV RNA and infectivity levels were reduced in silenced calsyntenin-1 
HCV infected cells measured by qPCR and infectivity assays (TCID50). The 
association of calsyntenin-1 with kinesin light chain 1 (KLC1) was observed using 
Deltavision microscopy. Based on these original observations it was hypothesized that 
calsyntenin-1 plays a specific role in HCV pathogenesis. 
To investigate if calsyntenin-1 is involved in HCV early infection, we studied its 
association with early endosomes using live cell imaging on Deltavision microscope 
and imageJ analysis. A direct role of calsyntenin-1 was observed in transport of early 
 xxi 
endosomes using GFP tagged early endosome and RFP tagged calsyntenin-1 plasmid 
constructs by live cell imaging. Moreover, siRNA mediated knock down of 
calsyntenin-1 led to unavailability of early endosomes at the plasma membrane, 
reduced their velocity and disrupted their function. This early endosome blockade 
restricted HCV entry into hepatocytes resulting in reduction of HCV infection. 
Furthermore, HCV Pseudoparticle assay confirmed that calsyntenin-1 is not involved 
in receptor mediated HCV entry but at a later stage of virus uptake by early 
endosomes. 
To further examine the role of calsyntenin-1 in HCV replication, association between 
HCV replication complexes and calsyntenin-1 was studied using subgenomic 
replicons based transient assay and live cell imaging. Calsyntenin-1 was found to be 
required for the establishment of new HCV replication complexes during HCV 
replication while its silencing reduced their formation, disrupted their transport and 
restricted their distribution within the cell.  
To further investigate association of calsyntenin-1 with export of HCV virions, we 
studied endosome based secretory pathways. The function of calsyntenin-1 in the 
exosome secretion of HCV from infected cells was observed using sucrose density 
gradient fractionation and western blot analysis. The siRNA-mediated knockdown of 
calsyntenin-1 showed its association with intracellular trafficking of multivesicular 
bodies and recycling endosomes by affecting their distribution within HCV infected 
cells and also reduced exosome infectivity as determined by Deltavision microscopy 
and infectivity assay (TCID50) analysis.  
In conclusion, our results suggest that calsyntenin-1 in involved in multiple stages of 
HCV replication cycle as an important host factor. The uptake of viral particles into 
 xxii 
early endosomes, the trafficking of replication complexes and the egress of virus 
containing exosomes involve kinesin-1 based transport, and this trafficking is 
dependent on the membrane adaptor qualities of calsyntenin-1.    
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CHAPTER 1: GENERAL INTRODUCTION 
1.1 Hepatitis C virus 
1.1.1 Epidemiology and Disease Burden 
Chronic Hepatitis C is one of the most common causes of cirrhosis and liver 
transplantation worldwide. It is estimated that up to 3% (180 million people) of 
the world’s population are infected with Hepatitis C virus (HCV), 130 million of 
whom have chronic infection so are at risk of developing cirrhosis (WHO., 2008). 
In Australia, over 233,000 estimated people (~1.2%) are living with chronic 
hepatitis C (Razavi et al., 2014). Furthermore, there is a 3-9% risk of developing 
cirrhosis after 20 years in community based studies, while risk of liver failure or 
hepatocellular carcinoma is as much as 4% per annum (Freeman et al., 2001). 
Until recently, therapy for HCV involved treating patients with an 
interferon/ribavarin combination that stimulates antiviral immunity.  However, 
this strategy has significant side effects and shows a success rate (viral 
eradication) of less than 50% for HCV genotype 1 infection (Razali et al., 2007). 
Despite recent improvements in therapy with the availability of direct acting 
antiviral (DAA) drugs, in Australia these drugs still need to be used in 
combination with interferon and ribavirin, increase drug side effects and are only 
approved for genotype 1. Therefore discovery of new effective antiviral drugs 
against HCV is a high research priority. 
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1.1.2 HCV Genome  
HCV is the member of genus Hepacivirus of the family Flaviviridae (Maniloff et 
al., 1995). It is an enveloped virus with a positive, single-stranded RNA genome 
of ~9.6 kb length flanked by 5` and 3` un-translated regions (UTR) (Friebe et al., 
2002). The 5 'UTR has a ribosome binding site  (IRES - Internal ribosome entry 
site) that starts the translation of a 3010 amino acid polyprotein that is later 
cleaved by cellular and viral proteases into 10 active structural and non-structural 
(NS) proteins (Liew et al., 2004). These proteins are arbitrarily divided into three 
structural (core, E1, and E2) and six non-structural proteins (NS2, NS3, NS4A, 
NS4B, NS5A, and NS5B) while p7 is currently unassigned into either category 
(Forns & Bukh., 1999) (Figure 1.1).    
Core protein is a highly basic, RNA-binding protein, which forms the viral 
nucleocapsid. It interacts with numerous cellular proteins and affects host cell 
functions such as gene transcription, lipid metabolism, apoptosis and various 
signalling pathways; it also induces steatosis (fatty liver) and promotes 
development of hepatocellular carcinoma (HCC) (Moriya et al., 1998; Hope et al., 
2002; Tellinghuisen et al., 2005). E1 and E2 are envelope glycoproteins belonging 
to the type I transmembrane protein group, with C-terminal hydrophobic anchors. 
These two proteins form non-covalent heterodimers representing building blocks 
for the viral envelope (Wakita et al., 2005). P7 is a 63-amino acid polypeptide, 
which separates structural and non-structural HCV proteins and has been reported 
to form hexamers with ion channel activity (Griffin et al., 2003; Pavlovic et al., 
2003).  
  Chapter(1:(General(Introduction( ( ( ( ((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((
 3 
The rest of the HCV genome encodes non-structural proteins NS2-NS5. NS2 (250 
amino acids), NS3 (500 amino acids), and NS4A proteins interact to mediate the 
processing of the NS region of the polyprotein. NS3 (500 amino acids) is both a 
proteolytic cleavage enzyme and a helicase, which facilitates unwinding of the 
viral genome for replication. NS4B with NS5A induces specific membrane 
alterations to form the membranous web, which serves as a scaffold for the 
formation of viral replication complexes (Egger et al., 2002; Gosert et al., 2003). 
NS5A interacts with a variety of cellular proteins and affects regulation of cell 
growth, interferon signalling, and lipid metabolic pathways (Blight et al., 2000). 
NS5b is the RNA-dependent RNA polymerase needed for viral replication 
(Houghton., 1996).  
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Figure 1.1 Hepatitis C virus - structure and genome organization. A) Structure 
of HCV showing arrangement of HCV structural genes. B) Proteins encoded by 
HCV genome, describing HCV structural and non-structural genes and their 
known functions (Reproduced from Expert Reviews in Molecular Medicine, 
(2003) Cambridge University Press). 
 
1.1.3 HCV Replication Cycle 
HCV pathogenesis is a highly dynamic process, with a viral half life in the blood 
of just a few hours and clearance of an estimated 1012 virions per day in an 
infected individual (Neumann et al., 1998). Different steps of the HCV virus life 
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cycle include attachment, entry, uncoating, RNA replication, virion assembly and 
egress, as described below. 
1.1.3.1 Virus Attachment and Entry 
Virus entry includes the steps from particle binding to the host cell up to the 
delivery of the viral genome to its replication site within target hepatocytes 
(Figure 1.2).  This process relies on specific interactions between virus 
components, mainly envelope proteins and multiple cellular factors (Burlone & 
Budkowska., 2009). HCV circulates encapsulated within a lipoviral particle 
similar to very-low-density lipoprotein (VLDL) particles ((Komurian-Pradel et 
al., 2004). These circulating structures are rich in triglyceride, viral RNA, core 
protein and VLDL structural components i.e. apolipoprotein-B (apoB) and 
apolipoprotein-E (apoE) (Andre et al., 2002). By circulating within this lipoviral 
particle the virus evades the immune system (Gastaminza et al., 2010). Lipoviral 
particles attach to the hepatocyte by binding to the LDL-receptor, after initially 
recognizing glycosaminoglycan on the cell surface (Monazahian et al., 1999; 
Morikawa et al., 2007).  
The four essential receptors involved in virus binding and entry are CD81, 
scavenger receptor B type 1 (SRB1), claudin and occludin. The HCV envelope 
glycoprotein coat (especially E2) interacts with CD81 and SRB1 and forms a 
complex necessary for a productive infection to occur (Sabahi., 2009). The 
necessity for claudin and occludin highlights the importance of the tight junction 
in viral entry. Internalisation of the viral particle occurs via clathrin-mediated 
endocytosis (Blanchard et al., 2006).              
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Figure 1.2 HCV Entry Process. After receptor mediated entry, hcv enters the 
early endosome by clathrin-medated endocytosis (Lanford et al., 2009). 
 
 
Once inside the cell, the encapsulated viral particle is transported to early 
endosomes by largely undetermined mechanisms. Acidification inside the early 
endosomes causes conformational rearrangements in viral glycoproteins, which 
lead to fusion of viral and endosomal membranes and subsequent uncoating 
(Blanchard et al., 2006). The requirement for endosomal acidification has been 
confirmed by siRNA studies targeting ATP6V0A1, a host factor involved in this 
process, which when silenced results in decreased infection with HCV (Coller et 
al., 2009). Thus, transport and acidification of the early endosomes are two 
critical steps in the virus life cycle, as they facilitate the release of the viral 
genome into the cytoplasm.    
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1.1.3.2 HCV Replication 
HCV RNA (positive strand) released into the cytoplasm is translated into the viral 
polyprotein. Translation is initiated by an internal ribosome entry site (IRES) 
located in the 5’-Untranslated region (UTR) of HCV, which utilises factors of the 
host cell translational machinery, including the 40s and 60s ribosomal subunits 
and eIF3 (Boehringer et al., 2005). RNA translation occurs at the rough 
endoplasmic reticulum (RER) yielding a single polypeptide (~ 3010 amino acids), 
which is cleaved by host and viral proteases into ten mature viral polypeptides, 
which are arbitrarily divided into structural and non structural proteins (Jones et 
al., 2010). All proteins are directly or indirectly (NS3 via NS4A) associated with 
the endoplasmic reticulum membrane, where they exert their functions (Figure 
1.3) (Rehermann., 2009).  
 
 
 
 
     Figure 1.3 Topology of HCV proteins (Bartenschlager et al.,2010) 
  
A structure called ‘the membranous web’ (Figure 1.4) is formed by distinct 
membrane alterations, induced by viral proteins (NS4B and NS5A) and consists 
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of numerous small vesicles (diameter 80 to 180mm) embedded in a membranous 
matrix (Gosert et al., 2003). It is the site where viral RNA is amplified by the 
NS5A RNA-dependent RNA polymerase, in association with other non structural 
proteins and host factors, including cyclophilin A (Bartenschlager et al., 2010). 
The membranous web facilitates the build up of RNA replication complexes (RC) 
and acts as a scaffold for viral RNA replication. It also protects the RNA from 
cellular RNAases. The membranous web is induced by NS4B and resembles 
“sponge-like inclusions”, as seen by electron microscope in the livers of HCV-
infected chimpanzees (Hijikata et al., 1991). 
Replication complexes consist of vesicles measuring 80 to 180 nm in diameter, 
embedded in a membrane matrix and appear as dot like structures several microns 
in diameter by immunofluorescence microscopy (Lin et al., 1994). The molecular 
processes involved in the formation of membranous web and replication complex 
are poorly understood. It has been shown by several studies that the membranous 
web also contains heterogeneous single membrane vesicles, double membrane 
vesicles and multi-membrane vesicles. (Ferraris et al., 2010; Romero-Brey et al ., 
2012; Ferraris et al ., 2013). More recently, double membrane vesicles have been 
suggested to be the sites of HCV RNA replication and involve an important role 
for HCV NS5A (Romero-Brey et al., 2012, Ferraris et al., 2013). This role is 
either direct, in association with viral RNA replication, or indirect, via host cell 
regulation to favour virus replication. Its key role is probably as a transport 
vehicle, which brings newly synthesised RNA from replication sites to lipid 
droplets for encapsidation (Miyanari et al., 2007; Evans et al., 2004). However 
this motility and efficient HCV replication is dependent on the microtubule 
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network and cytoplasmic dynein molecular motor, along with host factors 
including vesicle associated protein-A (VAP-A) and (early endosome marker) 
Rab5a (Eyre et al., 2014).  
 
 
 
 
 
 
 
 
Figure 1.4 Membranous Web (a) Low-power overview of a Huh-7 cell 
harbouring a subgenomic HCV replicon. A distinct membrane alteration, named 
the membranous web (arrows), is found in the perinuclear region of the cell. 
Scale bar represents 1 µm. (b) Higher magnification of a membranous web 
(arrows) with small vesicles embedded in a membrane matrix. Scale bar 
represents 500 nm (Reproduced from Teis et al., 2009). 
 
RNA replication occurs in a semi-conservative and asymmetric manner (Figure 
1.5). The positive stranded HCV genome is copied into negative strand RNA 
which base pairs with the input strand to produce a double stranded replicative 
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form (RF). The negative strand RNA then acts as a transcriptional template for the 
synthesis of large amounts of nascent plus stranded RNA, via a replicative 
intermediate (RI) (Bartenschlager et al., 2010).  
 
 
 
 
 
 
 Figure 1.5 RNA Replication Model (Reproduced from Bartenschlager et al., 
2010).  
 
1.1.3.3 HCV Replication Complexes 
Replication complexes (RCs) are membrane-associated structures consisting of 
viral proteins, replicating RNA, cellular membranes and host factors involved in 
virus replication (Figure 1.6). There are two reported populations of HCV RCs 
(i.e. large and small), which have distinct dynamic features when observed in live 
cells using NS5A-GFP constructs. Large structures represent membranous webs 
with limited movement, while small dot like structures (possibly small RCs) show 
microtubule associated active transport (Wolk et al., 2008). Thus HCV RCs 
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involve intracellular transport mechanisms and depend primarily on the dynamic 
organisation of ER and microtubule network (Wolk et al., 2008). The RC 
associated membranes are derived from endoplasmic reticulum and contain the 
majority of HCV non-structural proteins (NS3, NS4A, NS4B, NS5A, and NS5B). 
NS3 is a RNA helicase and also a serine protease requiring NS4A as a cofactor 
that plays a key role in the enzymatic activities of replication complexes. NS4B is 
responsible for inducing the membranous web. Whereas NS5A is an essential part 
of RCs and plays an indispensible role in viral replication through a range of 
functions that are only now starting to become clear. 
 
 
 
 
 
 
 
Figure 1.6 Hypothetical Model for Hepatitis C Virus Replication Complex. (1) 
Virus genome translation leads to structural (pink) and non-structural (green) 
proteins. (2) Non-structural protein NS4B induces viral replication complex 
formation by specific membrane alterations. (3) Replication complex consisting of 
HCV non-structural proteins, viral RNA and host factors (Reproduced from 
Miller and Krijnse-Locker., 2008).  
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NS5A is a proline-rich, hydrophilic phosphoprotein (Macdonald & Harris., 2004) 
that has no intrinsic enzymatic activity. Its main function is to act as an adaptor 
protein for a variety of host signalling factors, including factors involved in 
membrane trafficking and lipoprotein synthesis pathways (He et al., 2006; Alvisi 
et al., 2011; Moriishi et al., 2012). The N-terminus of NS5A forms a 30-amino 
acid long amphipathic α-helix (Brass et al., 2002). This is conserved across HCV 
isolates and its disruption leads to the loss of membrane localization and 
replication ability (Brass et al., 2002; Elazar et al., 2013). The α-helix has a polar 
cytosolic face which mediates protein interactions involved in RC formation and 
function. Its hydrophobic face is inserted in the cytoplasmic side of the ER 
membrane (Penin et al., 2004). NS5A is said to act as a transport vehicle, bringing 
newly synthesized RNA from RCs to lipid droplets for encapsidation, thus 
playing a critical role both in RNA replication and viral assembly (Evans et al., 
2004; Miyanari et al., 2007). 
1.1.3.4 Assembly and Egress  
After polyprotein translation, HCV core protein which forms the virus capsid, is 
located on the cytosolic side of the ER membrane. Thus virus assembly is thought 
to start in the cytosol before virus maturation and release via secretary pathways 
(Jones et al., 2010). HCV core protein promotes accumulation of lipid droplets 
(LDs) (Abid et al., 2005) and in association with NS5A recruits viral RCs to LD-
associated membranes at the virus assembly site (Miyanari et al., 2007). There is 
no conclusive data available for events that direct virus genome packaging into 
the capsid, except for the transport of viral RNA from RCs to core on LD surface. 
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Currently it is believed that HCV maturation and release involves the VLDL 
pathway, which is usually involved in export of triglycerides and cholesterol from 
the liver (Gibbons et al., 2004). It has been observed that extracellular virus 
particles can be associated with VLDLs and are known as lipo-viro-particles 
(LVPs), which display low to very low buoyant densities compared to 
intracellular infectious particles (Andre et al., 2002). This difference suggests a 
maturation event during egress from the cell (Jones et al., 2010). These LVPs are 
composed of triglycerides, viral RNA, core protein and VLDL structural 
components i.e. apoB and apoE (Chang et al., 2007). On the other hand, ER 
membrane derived RC vesicles also contain apoB and apoE, as well as 
microsomal triglyceride transfer protein (MTP), which is required for VLDL 
assembly. So there appears to be a link between HCV and VLDL assembly, either 
before or during the initial phases in virus assembly (Gastaminza et al., 2008; 
Huang et al., 2007) (Figure 1.7).  
Another cellular pathway involved in HCV release is the endosome pathway 
(Corless et al., 2010). It depends on several endosomal-sorting complex required 
for transport (ESCRTs) proteins, which incorporates target proteins into a 
multivesicular body (MVB) for degradation. Subsequently, ATP hydrolysis by an 
oligomeric protein called Vps4 (an AAA ATPase) dissociates ESCRTs from 
MVB for recycling (Babst et al., 2008). More recently, HCV virion release has 
been shown to require ESCRT-III and Vps4 (Corless et al., 2010), which are 
involved in the biogenesis of the multivesicular body (MVB), a late endosomal 
compartment (Phan et al., 2009). Of note, late endosomes have also been 
implicated in the budding of several other viruses, including retroviruses (Booth 
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et al., 2006), rhabdoviruses (Craven et al., 1999), filoviruses (Kolesnikova et al., 
2004), arena viruses (Strecker et al., 2003), and hepatitis B virus (Watanabe et al., 
2007). However, little is known about the role of late endosomes in the HCV life 
cycle. 
 
 
Figure 1.7 HCV RNA Replication and Virus Production. 1) Newly synthesized 
viral RNA is translated into the viral polyprotein. 2) Non-structural genes 
associate with host factors while HCV core is translocated onto the lipid droplet. 
3) Replication complex synthesizing + and – strands of RNA. 4) Core protein is 
recruited to ER membranes and positive strand HCV RNA is encapsidated by 
HCV core. 5) HCV capsid envelopment. 6) VLDL binds to viral particles to form 
LVP before or after budding. 7) Egress of viral particles into ER lumen with 
VLDL and ApoE (Kohji Moriishi and Yashiharu Matsuura., 2012). 
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1.1.4 Treatment of Hepatitis C  
In the last two decades, HCV therapy options have improved tremendously as a 
result of advancements in our understanding of the virus life cycle. It is expected 
that sustained virological response (SVR) rates will reach >90% for all HCV 
genotypes in 2015, with the advent of fixed dose, oral, single daily interferon-free 
treatments, with reduced side effects (Jayasekera et al., 2014). Traditionally, HCV 
has been treated by PEGylated interferon-α injection in combination with 
ribavirin tablets for six to twelve months (Fried et al., 2002). However interferon 
therapy involves many challenges and has significant adverse side effects 
including depression, infection, anaemia and liver decompensation. 
Recently a range of new compounds have been developed, collectively termed 
DAAs, which target specific steps in the HCV life cycle. The first generation of 
DAAs against HCV was approved in 2011 in Australia and included telaprevir 
and boceprevir. They are HCV NS3/4A protease inhibitors and inhibit viral 
replication in HCV-infected host cells. They have shown improved SVR (60-70% 
vs 45-50%) and for the last few years were standard of care for HCV genotype 1 
infections, in combination with pegylated interferon and ribavirin. Pegylated 
interferon is the form that has been used since early 2000s, with PEG-moity that 
increases serum half life and allows single weekly dosing (instead of every 1-2 
days), with more stable serum levels and higher SVR rates (Manns et al., 2014; 
Fried et al., 2002). 
Simeprevir (NS3/4A protease inhibitor) was approved in Australia in late 2014 
and has now replaced telaprevir and boceprevir as “standard of care” for treating 
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HCV genotype 1, in combination with peginterferon and ribavirin. It is given once 
daily (instead of three times per day), has fewer side effects, and provides higher 
rates of SVR, up to 80% for treatment of naïve patients (Jacobson et al., 2014; 
Manns et al., 2012).  
Other second and third generation DAAs have now progressed through phase 2-3 
clinical trials. These allow combination of all oral and interferon-free therapy, 
with SVR rates >90%. Newer DAAs include NS3 protease inhibitors (paretaprevir 
and vedroprevir), NS5A inhibitors (daclatasvir, ledipasvir and ombitasvir) and 
NS5B polymerase inhibitors, both nucleos(t)ide analogues (sofosbuvir) and non-
nucleos(t)ide inihibitors (tegobuvir, dasabuvir and elbasvir). These new treatment 
combinations are shorter duration, with improved SVR rates and less adverse side 
effects (Wyles et al., 2014). Although DAAs were initially developed to target 
genotype 1, many newer DAAs are effective against most HCV genotypes in vitro 
(Wyles et al., 2014).   
The nucleotide analogue sofosbuvir, which inhibits the NS5B RNA polymerase, 
is now recommended in USA as first line treatment for most HCV genotypes 
(Lawatiz et al., 2013). Sofosbuvir has been licensed in Australia but is not 
subsidized to date due to its high cost (US$84,000 for a 12 week course). Phase 
III studies published in NEJM in April 2014 showed SVR of 94-99% in HCV 
genotype 1 patients, using combination oral treatment with ledipasvir and 
sofosbuvir for 12 weeks (Afdhal et al., 2014). This is likely to be the next 
approved HCV treatment in USA and hopefully in Australia within 1-2 years. The 
other most advanced combination is the Abbvie “3D” combination, which 
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includes co-formulated NS3/4A protease inhibitor ABT-450 (paretaprevir) with 
ritonavir (ABT-450/r), non-nucleoside polymerase inhibitor ABT-333 
(dasabuvir), NS5A inhibitor ABT-267 (ombitasvir) and ribavirin. In phase 3 
studies this combination showed similar response rates to sofosbuvir/ledipasvir 
(Poordad et al., 2014), but is more complex and most active against genotype 1 
(Kowdley et al., 2014). Another oral treatment involving NS5A inhibitor 
daclatasvir in combination with NS5B polymerase inhibitor sofosbuvir showed 
high SVR rates in previously untreated patients with HCV genotype 1, 2, or 3 
infection, and is also close to market now (Sulkowski et al., 2014). 
One of the major obstacles in combating HCV infection is the fast virus mutation 
rate  (in vivo viral mutation rate is 2.5× 10⁻⁵ mutations per nucleotide per 
genome replication) (Riberiro et al., 2012), which results in resistance emerging 
rapidly against antivirals targeting viral proteins (Bartenschlager et al., 2013). An 
alternative approach is to target host factors essential for the virus life cycle, 
which should minimize the risk of viral resistance and provide antiviral activity 
against all HCV genotypes. Although drugs targeting cyclophilin A (Pawlotsky,. 
2014) and miR-122 (Janssen et al., 2013) have provided a proof of principle for 
this approach, many other host targets are still to be identified, following a better 
understanding of the virus life cycle.  
1.1.5 HCV in-vitro Models 
For HCV, development of a permissive and robust cell culture model was a major 
challenge. Generation of subgenomic replicons capable of stable replication in 
human hepatoma cells was the first discovery (Lohmann et al. 1999). This was 
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followed by establishment of infectious retroviral particles, pseudotype with HCV 
glycoproteins, for HCV entry studies (Bartosch et al. 2003; Hsu et al. 2003). 
However the major breakthrough came with the discovery of a novel HCV isolate 
that can replicate efficiently in Huh7 cells (Kato et al., 2003; Kato et al., 2001). 
This genotype 2a clone originated from a Japanese patient with fulminant 
hepatitis, and was called JFH1 (Wakita et al., 2005). Importantly, it was the first 
strain to reliably produce infectious virus in Huh7 cells, allowing recreation of the 
entire HCV life cycle in vitro (Wakita et al., 2005). More recently, the Jc1 strain 
was developed, which is a chimeric virus containing the structural genes from 
J6CF and non-structural genes from JFH1, both genotype 2a strains.  This 
chimeric virus replicates more efficiently than JFH1, achieving titres of about 106 
infectious units per ml (Pietschmann et al. 2006). 
HCV subgenomic replicons (SGR) have developed based on the JFH1 HCV strain 
(genotype 2a), which express non-structural proteins NS3 to NS5B and contain a 
firefly luciferase gene (Targett-Adams et al., 2005). This replicon was further 
developed by Jones et al to develop JFH1 based SGRs that incorporate GFP in the 
C-terminal region of NS5A, allowing real time visualization in live cells (Jones et 
al., 2007) (Figure 1.8). 
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Figure 1.8 Open reading frames of different HCV constructs. (Top) JFH1, 
(Middle) Jc1 and (bottom) SGR-Luc-JFH1(Steinman et al., 2007; Targett-Adams 
et al., 2005) 
 
 
 
The most widely used host cells for HCV propagation are Huh7 and Huh7.5 cells. 
The Huh7 cell line was derived from a patient with hepatocellular carcinoma and 
was the first cell line shown to support HCV replication (Lohmann et al. 2003). 
The Huh7.5 cell line is a derivative, isolated from Huh7 cells that had been 
infected with a HCV subgenomic replicon, then cured using interferon-alpha 
(Blight et al. 2002; Murray et al. 2003). They allow HCV to replicate to higher 
levels than in Huh7 cells due to a defect in the innate antiviral defence signalling 
pathway, after mutational inactivation of retinoic acid-inducible gene I (RIG-I) 
(Sumpter et al. 2005). 
1.2 Endosomal Trafficking Pathways 
In higher eukaryotes, several endocytic trafficking pathways regulate the 
internalization of various lipid membranes, receptors and extracellular fluid. 
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These pathways are either clathrin dependent or independent, including 
phagocytosis and pinocytosis (Marko et al., 2010). Almost all the internalized 
cargo molecules are either recycled back to the plasma membrane or degraded in 
late endosomes and lysosomes. The sorting stations where all these diverse 
internalized molecules converge and their fates are decided are the early 
endosomes (Mayor et al., 1993).  
 A variety of proteins and lipids mediate internalization and endosomal sorting. 
An important group of endocytic regulators are Ras-associated binding (Ras) 
proteins, which are small GTP binding proteins that undergo cycling between a 
GTP bound active state and a GDP bound inactive state. They are localised to 
intracellular membranes in their active form and regulate binding to different Rab 
effectors, which carry out various endocytic processes such as vesicle tethering, 
budding and motility. Different Rab proteins are associated with particular 
endosomes and are responsible for endosome-endosome and endosome-plasma 
membrane fusion (Pfeffer, 2001; Zerial and McBride, 2001; Deneka and van der 
Sluijs, 2002; Grosshans et al., 2006). Clathrin-mediated internalization involves 
four distinct classes of endosomes. These are differentiated on the basis of the 
kinetics with which they accumulate endocytic tracers, their appearances, cellular 
localization and occurrence of specific markers. 
1.2.1 Early Endosomes  
Early endosomes form the first highly dynamic compartment that receives 
internalized cargo from the plasma membrane and is the major sorting endosome 
in the endosomal trafficking pathway. Early endosomes are complex pleomorphic 
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structures including thin tubular extensions (~ 60 nm diameter) and large vesicles 
(~ 400 nm diameter) (Gruenberg et al., 1989). These morphological alterations are 
functionally important, as recycling cargos cluster in tubular membranes, while 
large vesicles contain membrane invaginations leading to degradative 
multivesicular bodies (MVBs) (Mellman., 1996). These two distinct 
compartments originate from the same early endosomes, but exhibit differences in 
their acidification properties. The pH increases to ~ 6.5 in tubular extension 
whereas it decreases from 6.2 to ~ 5.5 in the lumen of large multivesicular bodies 
(Mayor et al., 1993; Mellman, 1996). 
Rab5 and Rab4 are the primary Rab proteins localized to early endosomes and are 
responsible for particular early endocytic events (Gorvel et al., 1991; Bucci et al., 
1992; Daro et al., 1996).  Other less characterized Rab proteins such as Rab10 
(Babbey et al., 2006), Rab14 (Junutula et al., 2004), Rab21 (Simpson et al., 2004) 
and Rab22 (Mesa et al., 2001, 2005) are also involved in the early endosomal 
pathway. 
Rab5 is the most studied and analyzed Rab of the early endocytic pathway. Rab5 
regulates cargo entry from the plasma membrane to early endosomes, 
phosphotidylinopcistol-3-phosphate (PtdIns(3)P) lipid enrichment of early 
endosomes, motility of early endosomes on actin and microtubular tracks and 
activates several signalling pathways from early endosomes (Benmerah, 2004; 
Schenck et al., 2008). Rabex-5 (guanine nucleotide exchange factor) activates 
GDP bound Rab5 to GTP bound at the early endosome and as a result Rabaptin-5 
is recruited. Rabaptin-5 binds GTP-Rab5 and maintains Rebex-5 levels by 
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positive feedback, thus stabilizing GTP-bound Rab5 on early endosomes (Marko 
et al., 2010). Furthermore, highly maintained levels of active Rab5 are required to 
attract other effector proteins to early endosomes to perform specific functions, 
including endosome trafficking and sorting (Grosshans et al., 2006). A variety of 
vital Rab5 effectors include PtdIns(3)P-kinase/hVPS34/p150 (VPS34), early 
endosomal antigen-1 (EEA1), APPL1 and APPL2 (Adaptor protein containing PH 
domain, PTB domain and Leucine zipper motif), SNAREs (soluble N-
ethylmaleimide-sensitive factor attachment protein receptors) and Rabenosyn-5 
(Marko et al., 2010). 
The crucial and most important function of early endosomes is to sort internalized 
cargos and direct them to their particular intracellular destinations in a precise and 
highly controlled manner. Most endocytosed ligands are degraded, but their 
receptors are recycled back to the plasma membrane for additional rounds of 
internalization (Dunn et al., 1989). For example, proteins like the transferrin 
receptors and low-density lipoprotein (LDL) receptors are recycled back to the 
cell surface, whereas low-density lipoprotein itself and epidermal growth factor 
receptor (EGFR) are degraded in late endosomes/lysosomes (Herbst et al., 1994). 
Ligands dissociate from their receptors in the moderately acidic (pH 6.3 to 6.8) 
environment of the early endosome lumen. The tubular part of endosomes with a 
bigger membrane area has receptors that are recycled back to the cell surface. On 
the other hand, soluble ligands make their way to multivesicular compartments 
and ultimately enter late endosomes (Mellman, 1996) (Figure 1.9). 
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Figure 1.9 Endosomal Pathway. Early endosomes are formed as the first 
compartment to receive incoming cargo, which is further divided into different 
endosomal types such as Rab7 (late endosomes), Rab4 and Rab11 (recycling 
endosomes) (Reproduced with permission from Stenmark H., 2009). 
 
1.2.2 Recycling Endosomes 
Cells are dependent on the endocytic and exocytic pathways to communicate with 
their surroundings. Endocytosed receptors reach peripheral early endosomes, 
mediating responses to external stimuli. These molecules then either undergo 
degradation in the late endosomal/lysosomal pathway, or are recycled back to the 
plasma membrane (Maxfield & McGraw., 2004). Recycling to the plasma 
membrane can be mediated by peripheral early endosomes, or by a distinct 
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subpopulation of endosomes, which have higher pH  (~ 6.4) and are located 
deeper in the cell, around the microtubule-organizing centre (MTOC) (Perret et 
al., 2005). These heterogeneous tubular vesicles are called recycling endosomes 
and play a dynamic role in trafficking activity, thereby connecting the endocytic 
and exocytic pathways (Murray et al., 2005). 
The most well studied recycled protein is transferrin receptor, which binds diferric 
transferrin at the cell surface. After binding transferrin, the TfnR is endocytosed 
through clathrin-coated vesicles to reach early/sorting endosomes. Subsequently, 
this complex of transferrin:transferin receptor returns to plasma membrane either 
directly by rapid recycling or via recycling endosomes (Grant and Donaldson, 
2009).  
The most extensively studied Rab family small GTPase marker on recycling 
endosomes is Rab11, which regulates protein recycling (Grant and Donaldson, 
2009; Stenmark, 2009). Recycling Endosomes are thought to be involved in 
interactions with a multiprotein complex called the exocyst, which contains Sec5, 
Sec6, Sec8, Sec10, Sec15 and Exo70 proteins. It mediates recruitment of 
materials to areas of membrane growth. So recycling endosomes play a vital role 
in regulation of many cellular processes that depend on trafficking, including 
epithelial cell-cell adhesion, epithelial polarity, cytokinesis and cell fate 
determination (Sven., 2006). 
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1.2.3 Late Endosomes/Multivesicular Bodies (MVBs) 
As described above (section 1.2.1) the early endosome is a sorting compartment 
that determines the fate of endocytosed materials. Proteins can be recycled back to 
the plasma membrane, transferred to the trans-Golgi network (TGN) or may be 
degraded in lysosomes. As a result of lysosomal sorting, proteins are transported 
to late endosomes (or multivesicular bodies), which are represented by a small 
GTPase of the Rab family, Rab7. Early endosomes not only fuse with incoming 
cargo but also undergo different events of fission, thereby separating, recycling or 
degrading cargos (Poteryaev et al., 2010). Endosomal transport is not yet fully 
understood, but two models have been proposed. One is that early and late 
endosomes are stationary objects and transport occurs using transport carriers. 
Vonderheit and Helenius observed in 2005 that budding of the Rab7 domain 
occurs from Rab5 positive endosomes (Vonderheit and Helenius., 2005). The 
other possibility is that early endosomes become late endosomes in a Rab 
conversion model. Studies supporting this model have shown that the Rab7 
domain appears on early endosomes and Rab5 positive endosomes are converted 
into Rab7 positive endosomes by ATP conversion (Rink et al., 2005).  
Multivesicular bodies (MVB) are distinct and dynamic organelles in the endocytic 
pathway that harbour vesicles in their lumen. Incorporation and sorting of 
materials in these vesicles is a crucial process that involves ESCRT and has been 
studied extensively (Piper & Katzmann 2007). The ability to incorporate 
transmembrane proteins and lipids to intraluminal vesicles is of utmost 
importance, as they can be degraded in lysosomes or released by exocytosis.   
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Mature MVBs are spherical in shape, carrying intraluminal vesicles ~50 nm in 
size (Gruenberg & Stanmark 2004). Proteins specific to MVBs are few because 
they use these organelles en route to other cellular destinations. Rab proteins 
associated with MVBs include Rab5, Rab7, Rab27 and Rab35, while luminal 
vesicles present tetraspanins including CD63. The basic and most extensively 
studied functions of MVBs are the regulation of cell signalling and release of 
exosomes. Ubiquitin is the main signal for sorting proteins into MVBs for 
degradation, and is covalently attached to membranous protein cargo. Cargoes are 
recognized by different sorting complexes and are delivered to the MVB lumen 
(Hanson & Cashikar., 2012).  
1.2.4 Exosomes 
Different types of cells shed small vesicles that are key players in intercellular 
communication. Three types of these vesicles have been identified so far. The first 
group are microvesicles, which directly bud from the plasma membrane and range 
from 100 nm to 1 µm in diameter. The second group includes apoptotic bodies 
produced as a result of apoptosis, measuring 50 to 500 nm in diameter. Exosomes 
are the third type of shedding vesicles and are released following exocytosis of 
microvesicular bodies or late endosomes (Dragovic et al., 2011; Kalra et al., 
2012). The major difference between all of these vesicles is the shape, as only 
exosomes show a specific and characteristic well-rounded morphology, while the 
rest are heterogeneous (Conde et al., 2008). Exosomes originate in the 
intraluminal vesicles of MVBs and exocytose from the cell by plasma membrane 
fusion (Simons et al., 2009). Invagination of the membrane of late endosomes 
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results in the formation of intraluminal vesicles, which begin to accumulate 
inside; the resulting structure as a whole is termed a MVB (Mullock et al., 1998).   
MVB fusion with the plasma membrane regulates exosome secretion, which is 
still not well understood. However it has been shown that intracellular calcium 
changes in mast cells, human erythroleukemia cells, cultured cortical neurons and 
oligodendrocytes induce exosome release (Faure et al., 2006; Kramer et al., 
2007). Exosomes contain unique protein and lipid content: proteins involved in 
membrane trafficking including Rab GTPases, annexins and flotillins; MVB 
biogenesis specific proteins, such as integrins and tetraspanins e.g. CD63, CD9, 
CD81, CD82; conserved proteins like heat shock cognate 70kDa protein (hsp70) 
and CD63; cytoskeleton related proteins including tubulins, myosin, β-actin and 
other proteins like major histocompatibility complex (MHC) class I and II 
molecules (Simons et al., 2009; Thery et al., 2009; Simpson et al., 2009). 
Exosomes play a crucial role in many biological processes including injury and 
the immune response, through transfer of antigens, antigen presentation (Thery et 
al., 2002; Duijvesz et al., 2011) and shuttling of proteins, mRNA and micro RNAs 
between the cells (Valadi et al., 2007). They are also responsible for cell-to-cell 
communication and transfer of genetic information between them (Valadi et al., 
2007). Another emerging role of exosomes is in the transfer of pathogen-derived 
antigens and virulence factors (Masciopinto et al., 2004) between cells, but their 
contribution towards immune control and clearance of infection by the host is still 
unclear. From a therapeutic perspective, exosomes may be useful for tumour 
vaccines (Tan et al., 2010), and also as effective gene delivery vehicles and tools 
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for regenerative medicine, as they can cross the blood-brain barrier (Alvarez et al., 
2011).  
1.3 HCV and Exosomes 
Exosomes are cell-derived vesicles, present in almost all biological fluids, 
including blood, urine, and cell culture medium (Van der Pol et al., 2012; Keller 
S., et al., 2006). They are enclosed in a phospholipid bilayer, measure 30-100 nm 
in diameter and are formed by intracellular invaginations of multivesicular body 
membranes. The MVB is a late endocytic compartment, which fuses with the 
cell's plasma membrane and liberates its internal micro vesicles into the outer 
environment, where they are called exosomes. Exosomes are cup-shaped 
structures under electron microscopy and generally express markers of their 
endosomal origin on the surface, including LAMP1, LAMP2b and ALIX-1 
proteins, as well as tetraspanins CD9, CD63 and CD81 (Simpson et al., 2008; 
Thery et al., 2009).  
The sorting of ubiquitinated proteins on MVBs is mediated by the endosomal 
sorting complex required for transport pathway. The first complex that binds the 
cargo on endosomes is ESCRT-0, which has an important component, Hrs (Asao 
et al., 1997; Komada and Kitamura, 1995). Hrs has also been reported to be 
involved in the HCV exosomal pathway, playing an important role in HCV 
release.  Furthermore, HCV core protein and the envelope protein E1 have been 
observed in the intraluminal vesicles of MVBs (Tamai et al., 2012). 
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One study reported the presence of viral RNA in exosomes isolated from plasma 
of HCV-infected patients (Masciopinto et al., 2004) but there was no evidence of 
exosome-mediated transmission of infection probably because of not using 
standard procedure for exosome isolation. Recent studies have proposed that the 
exosome secretory pathway could be involved in HCV virus assembly and release 
from hepatocytes (Tamai et al., 2012). Exosomes derived from hepatocytes have 
been shown to transfer HCV RNA to plasmacytoid dendritic cells, triggering their 
activation and interferon-α production (Dreux et al., 2012).  A recent study 
demonstrated that exosomes can transfer HCV to other hepatocytes and are 
partially resistant to antibody neutralization, thus contributing further to the 
known immune evasive properties of the virus (Ramakrishna et al., 2012). In 
hepatitis B virus infection, cell-to-cell transfer of IFN-α induced antiviral activity 
is mediated by exosomes. IFN-α is an approved treatment of chronic HBV 
infection with a response rate of 30–40%. The IFN-α induced antiviral response 
was transmitted through exosomes, from liver non-parenchymal cells to HBV-
infected hepatocytes (Li et al., 2013). This intercellular transfer of exosomes 
bypassed the viral inhibition of interferon-induced gene expression, restoring the 
antiviral state in virus-infected cells (Li et al., 2013).    
 
In spite of all the research into the role of exosomes in HCV transmission, there 
are some discrepancies, which need to be addressed. Technically it is a challenge 
to completely separate viral particles from exosomes, because both have 
overlapping densities. The buoyant density of exosomes is 1.10-1.19 g/ml, while 
that of HCV virus particles is 1.06 to 1.16 g/ml in blood or infected cell 
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supernatant (Dao et al., 2012). Furthermore, neutralizing antibodies (from patient 
sera) directed against HCV surface glycoproteins enhance rather than neutralise 
exosomes isolated from cells containing a HCV subgenomic replicon (SGR), 
which produce only non-structural proteins. These results suggest the possibility 
of different mechanisms for transmission of HCV, either as discrete viral particles 
or in exosomes (Cosset et al., 2014). However there are still many unanswered 
questions regarding the role of exosomes in HCV transmission.  
1.4 SILAC Screening and Identification of Calsyntenin-1 
To look for novel cellular proteins involved in HCV replication, preliminary work 
in our laboratory compared cell culture media from infected and uninfected cells, 
to look for altered proteins. Cell culture media from HCV (JFH1) infected hepatic 
(Huh7) cells was compared with media from uninfected Huh 7 cells, using Stable 
isotope labelling with amino acids in cell culture (SILAC) based mass 
spectrometry screening (CLAIR: Comparison of isotope-labelled amino acid 
incorporation rates). This is a reliable technique, which involves incorporation of 
labelled amino acids into proteins for mass spectrometry-based quantitative 
proteomics. It relies on the metabolic incorporation of amino acids with 
substituted stable isotopic nuclei into proteins. Two different cell populations are 
grown under identical culture conditions, except that the media for one of them 
contains a light or heavy form of a particular amino acid. When the cells grow, 
that particular amino acid is incorporated into newly synthesized proteins. After a 
number of cell divisions, supernatants are subjected to mass spectrometry, which 
is an analytic technique that utilizes the degree of deflection of charged particles, 
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by a magnetic field, to find the relative masses of molecular ions and fragments. 
The mass to charge ratio (m/z) of the fragments is recorded by a detector that 
quantifies sorted ions in the form of peaks. The metabolic incorporation of amino 
acids into proteins results in a mass shift, which is detected by the mass 
spectrometer. When both samples are mixed, the ratio of peak intensities in the 
mass spectrum reflects the relative protein abundance (Figure 1.10). 
In this experiment, HCV-infected and uninfected control cells were labelled with 
“Heavy” or “medium” isotopes of arginine (Cambridge Laboratories U-13C6 
units–15N4 arginine CNLM-539 or U-13C6 arginine CLM-2265 0.021 g/l) and 
lysine (Cambridge Laboratories U-13C6 units-15N2 lysine CNLM-291 or 4,4,5,5-
D4 lysine CNLM-2640 0.0365g/l), respectively. After 48 h, media from infected 
and control cells was mixed in equal proportions and proteins were analysed by 
mass spectrometry. Incorporation of amino acid isotopes results in a shift in 
molecular mass to charge (m/z) ratio. Peak heights were measured, and their ratios 
used to determine the relative abundance of proteins from both samples.  
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Figure 1.10 SILAC (Stable isotope labelling with amino acids in cell culture). 
Two cell populations are labelled with different isotopes and then incorporation 
of specific amino acid into newly synthesized protein is determined using mass 
spectrometry. This detects differences in protein abundance between different 
samples. 
 
One of the proteins that was found to be most increased in media from infected 
cells was calsyntenin-1, with an infected/uninfected ratio of 43.53 (i.e. 44-fold 
increase). This was the first time that calsyntenin-1 had been found to be 
upregulated in media from HCV-infected cells, but its significance was unclear. 
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Thus, the major aim of this project was to determine the role of calsyntenin-1 
in the HCV life cycle. Different stages of the life cycle, including HCV entry, 
replication and egress, were studied in detail with respect to the potential role 
of calsyntenin-1. 
Interestingly, a recent report characterizing the proteome of calsyntenin coated 
organelles in neurons showed that these vesicles contain components of the 
endosomal trafficking pathway (Steuble et al., 2010). As detailed in section 
1.1.3.1, HCV entry involves early endosomes, which undergo acidification to 
release virus into the cytoplasm. We therefore hypothesised that calsyntenin-1 
may be involved in HCV transport following receptor-mediated entry. However it 
may also play roles later in the life cycle, including assembly and egress, 
particularly as there was increased secretion of calsyntenin-1 into the supernatant 
of infected cells. 
1.5 Calsyntenins 
Calsyntenins are type I trans-membrane proteins that are members of the cadherin 
superfamily (Hintsch et al., 2002; Vogt et al., 2001). They are Ca2+-binding 
proteins that localize to postsynaptic membranes in excitatory neurons, where 
they modulate calcium-mediated postsynaptic signalling and cell adhesion. In 
birds and mammals, there are three types of calsyntenin i.e. Calsyntenin-1, 
Calsyntenin-2 and Calsyntenin-3, with a single ortholog in nematodes (CASY-1) 
(Vogt et al., 2001; Hintsch et al., 2002; Ikeda et al., 2002). Calsyntenin-2 and 
calsyntenin-3 are found in GABAergic neurons (Hintsch et al., 2002). 
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1.5.1 Calsyntenin-1 
Calsyntenin-1 (also known as Alcadein-α) is a member (140 - 150 kDa) of the 
Alcadein family of molecules, which are expressed in the ER/Golgi and on the 
plasma membranes of almost all neurons (Vogt et al., 2001). It is a type 1 
membrane spanning protein and is evolutionarily conserved. The calsyntenin-1 
gene has been mapped to chromosome 1p36 by genomic sequence analysis 
(Hintsch et al., 2002). Calsyntenin-1 protein is abundant in neurons, where it takes 
part in transport of vesicles, especially along axons (Ludwig et al., 2009; Hintsch 
et al., 2002). It is reported to interact with kinesin light chain 1 (KLC1), through 
C-terminal intracellular domain sequences (Araki et al., 2007; Konecna et al., 
2006).  
Calsyntenin-1 is a type 1 transmembrane cargo docking protein with a role in 
kinesin-1 mediated trafficking (Hintch et al., 2002). There are two calsyntenin-1 
splice variants i.e. calsyntenin-1 isoform 1 and calsyntenin-1 isoform 2. Isoform 1 
is the key gene product, while isoform 2 has 10 extra amino acids in the N-
terminal extracellular domain. Mature human calsyntenin-1 is a 953 amino acid 
(aa) type I transmembrane protein. It contains two cadherin domains (aa 38 - 265) 
in its extracellular region (aa 29 - 859) and a 101 aa cytoplasmic tail. Extracellular 
cleavage occurs between Met825 and Ala826, releasing a 115 kDa soluble 
extracellular domain. Isoforms involve a 78 aa substitution for aa 917 - 981, plus 
deletions of aa 72 - 81 and 507 – 525 (Araki et al., 2004). It is reported that the 
cytoplasmic domain of calsyntenin-1 contains two tryptophan- and aspartic acid 
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(WD)-rich sequences, separated by an asparagine-proline (NP) motif and an 
acidic region (Araki et al., 2007)  
1.5.2 Calsyntenin-1 Cleavage 
Calsyntein-1 is a type I transmembrane protein which is constitutively cleaved by 
disintegrin and metalloproteinase (ADAM) 10 or 17 enzymes. Cleavage at its 
trans-membrane domain is a critical step for its activation, modification and for its 
proper functioning. This is similar to other membrane bound proteins that undergo 
proteolysis, either constitutively or in response to external stimuli (Maruta et al., 
2012).  
Cleavage of calsyntenin-1 gives rise to a N-terminal extracellular ectodomain and 
C-terminal intracellular fragment (Hata et al., 2009). The C-terminal intracellular 
fragment is further digested by c-secretase to produce a N-terminal fragment 
(NTF) and C-terminal fragment (CTF), as shown in figure 1.11 (Araki et al., 
2004). However, the role of constitutive cleavage of type I membrane spanning 
proteins remains unclear (Maruta et al., 2012).  
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Figure 1.11 Post-translational processing of calsyntenin-1. The calsyntenin-1 
protein consists of 981 amino acids and undergoes two sequential constitutive 
cleavages. The final cleavage results in a N-terminal peptide and C-terminal 
cytoplasmic fragment.  
 
1.5.3 Role of Calsyntenin-1 in Endosomal Trafficking in Neurons 
Calsyntenin-1 is expressed predominantly in kidney and brain, while low levels 
are present in heart, skeletal muscle, liver, placenta, pancreas and lung (Ludwig et 
al., 2009). Previous studies of calsyntenin-1 in neurons have focused on its role in 
transporting axonal vesicles containing amyloid precursor protein (APP). An 
siRNA mediated loss of calsyntenin-1 interrupted this trafficking, leading to 
altered APP processing and up regulation of amyloid-β (Aβ). This is the condition 
seen in Alzheimer's disease, which shows accumulation of Aβ within amyloid 
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plaques (Vagnoni et al., 2012). A recent report characterising the proteome of 
calsyntenin coated organelles in neurons showed that these vesicles contain 
components of the endosomal trafficking pathway i.e. early and recycling 
endosomes (Araki et al., 2004).   
Different domains of calsyntenin-1 after cleavage events are involved in different 
endosome based pathways in neurons. Two types of endosomal populations are 
characterised which contain calsyntenin-1 with (1) APP and early-endosomal 
markers (Rab5A); and (2) recycling endosomal markers (Rab11) and no APP 
(Figure 1.12). It has also been reported that Rab5 positive early endosomes 
contain calsyntenin-1 in the cleaved form (CTF), while its full-length form is 
present in TGN derived, APP positive carriers (Steuble et al., 2010) (Figure 1.12).  
Another recent study highlights the involvement of calsyntenin-1 in endosomal 
transport in different neuronal compartments, by showing an in vivo role of 
calsyntenin-1 in endosomal dynamics; and their transport from cell body to axons 
(Ponomareva et al., 2014). These studies further indicated a role of calsyntenin-1 
in endosome-based trafficking; involving early and recycling endosomes. 
Therefore, we hypothesised a possible role for this protein in HCV pathogenesis, 
involving endosomal pathways. 
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Figure 1.12 Calsyntenin-1 mediated, kinesin-1 dependent vesicle transport. 
Calsyntenin-1 is involved in two pathways: 1) APP and Rab5-positive early 
endosome pathway. 2) Rab11-positive, APP-negative recycling pathway (Hirano 
& Takeichi.,  2012). 
 
1.6 Intracellular Transport Mechanisms 
Mammalian cells are enclosed by a plasma membrane and have complex 
intracellular structures, resulting in slow internal diffusion rates. To overcome this 
obstacle, cells have developed active intracellular transport mechanisms, which 
direct materials to the appropriate compartments (Kamal & Goldstein., 2000). 
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1.6.1 Cytoskeleton 
The cytoskeleton is a network of protein fibres throughout the cytoplasm that 
gives cells a definite shape. It is dynamic, constantly destroying fibres, renewing 
them, recycling the building blocks and even producing them de novo (Alberts, 
Bruce., 2008). It consists of three different types of filaments: a) Microfilaments, 
which are composed of actin; b) Intermediate filaments with 70 different types of 
building blocks, including keratins or lamins and c) microtubules, made up of 
tubulins (Herrmann et al., 2007). The two main transport systems involve either 
actin filaments (for short range transport) or microtubules (for long range 
transport). Transport of membrane bound vesicles along cellular microtubules is 
mediated by the cytoskeletal molecular motors kinesin and cytoplasmic dynein.  
Actin filaments are localized near the plasma membrane, while microtubules are 
present throughout the cell. Most viruses bypass the actin barrier by entering the 
cell via the endocytic route, either by interactions with tubulins or by the 
endogenous endocytic pathway (Luby-Phelps, 2000; Dohner and Sodeik, 2005; 
Smith & Enquist, 2002). 
1.6.1.1 Actin Filaments  
Actin filaments promote intercellular communication, maintain cell shape and 
movement, assist phagocytosis, and regulate the distribution of organelles within 
cells (Pollard et al., 2009). The actin cytoskeleton is highly dynamic and is mainly 
controlled by members of the RHO-family GTPases, which regulate several signal 
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transduction pathways, thereby linking the cytoskeleton with membrane receptors 
(Schmitz et al., 2000).  
Actin filaments (F-actin) dynamically play a vital role in the process of 
endocytosis, including membrane invagination involving clathrin coated pits, 
vesicle formation and transport of vesicles away from the plasma membrane. 
Local disruption of actin filaments paves the way for nascent vesicles to go deep 
down into the cytoplasm and to interact with microtubules (Apodaca, 2001). 
1.6.2 Microtubules 
Microtubules are the most vital component of the cytoskeleton and spread 
throughout the cytoplasm. These are polarized cytoskeletal filaments, which 
transport (based on their polarity) different cellular cargoes such as membranous 
organelles and proteins to their particular subcellular destinations (Gunderson, 
2002). They are involved in maintaining cell shape, by coordinating with 
microfilaments and intermediate filaments (Vale., 2003), while on the other hand 
they also play a vital role in cellular processes like mitosis, secretion, cell motility 
and cell polarization.  
In eukaryotes, microtubules are formed by the polymerization of alpha and beta 
tubulin heterodimers into linear protofilaments (Li et al., 2012). One microtubule 
consists of 10 - 15 protofilaments, forming a 24 nm wide hollow cylinder (Figure 
1.13). The polar nature of microtubules depends on the association of alpha and 
beta heterodimers and displays different polymerization rates at each end. The fast 
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growing plus end comprises beta tubulin, while alpha tubulin is oriented towards 
the minus end (Conde & Cáceres., 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Microtubule structure, showing the arrangement of tubulin 
macromolecules. Microtubules are formed by the polymerization of tubulin 
heterodimers. The plus end has alpha-tubulin while beta-tubulin is present at the 
minus end of the microtubule structure. (Adapted from 
http://www.utm.utoronto.ca/~w3bio315/picts/lectures/lecture11/Microtubule2.jpg 
 
 
The plasma membrane of most epithelial cells has an apical domain at the cell 
apex which are localized to the lumen of their respective organ, while the rest of 
the membrane has a basolateral domain. In contrast, hepatocytes have several 
apical poles and basolateral domains. Apical poles constitute a network of bile 
canaliculi, into which bile is secreted, whereas the basolateral surface faces 
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sinusoidal blood circulation. The maintenance of this polarized nature is due to 
tight junctions and is very important for proper liver functioning (Decaens et al., 
2008). HCV particles in the blood enter the hepatocyte via receptors expressed at 
the basal surface, in contrast to many other viruses like rhinovirus, respiratory 
syncytial virus, influenza, enteroviruses and rotavirus, that infect the polarized 
epithelial linings via the apical membrane (Harris et al., 2013). Figure 1.14 shows 
microtubule organization in different cell types and directions of motor mediated 
trafficking. 
 
 
 
 
 
 
 
 
 
Figure 1.14 Diagrams of microtubule organisation in a variety of cell types. (A) 
Non-polarised cell (B) polarised cell (C) ciliated cell (D) neurone (E) rod 
photoreceptor. + and -, Polarity of microtubules; Nuc, nucleus. Likely directions 
of motor-mediated movements are indicated (reproduced with permission from 
Goldstein and Yang, 2000). 
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1.6.1.3 Kinesin and Dynein Motors 
Mammalian cells contain complex intracellular structures that result in slow 
diffusion rates in the cell. That is why cells have developed active intracellular 
transport systems for the transport of materials to their appropriate destinations 
(Kamal et al., 2000). The most common method is through membrane bound 
vesicles carried by molecular motors attached to the cytoskeleton. Kinesin or 
cytoplasmic dynein motors are responsible for long-range vesicle transport along 
microtubules, while myosin motors mediate short range transport along actin 
filaments (Goldstein., 2001). Microtubules are polarised, and typically grow out 
from the MTOC (minus end) towards the plus end (Figure 1.15). 
The kinesin family of motors typically moves cargo towards the plus end of 
microtubules, while cytoplasmic dynein is the main minus-end directed motor 
(Goldstein., 2001). Kinesin use microtubules as a “rail” to conduct anterograde 
(plus-end directed) transport in neuronal axons, or towards the cell periphery in 
non-polarised cells, by utilizing chemical energy from ATP (Hirokawa et al., 
2005). Kinesin motors are a heterotetramer complex composed of two heavy 
chains and two light chains (Hirokawa et al., 1989). On the other hand, 
cytoplasmic dyneins are minus-end directed motors that use microtubules to drive 
retrograde transport in axons and transport towards the nucleus in non-polarised 
cells (Brown., 2003) (Figure 1.16). 
It is been reported that kinesin light chain 1 (KLC1) binds to the intracellular 
cytoplasmic domain of the type 1 membrane spanning protein calsyntenin-1 
(Vagnoni et al., 2011). Moreover, calsyntenin-1 mediates trans-Golgi network exit 
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of β-amyloid precursor protein (APP) in neuronal cells (Konecna et al., 2006). 
This phenomenon has been extensively studied in neurons because of their 
particular requirement for long-range transport along axons.  
 
 
 
 
 
 
 
Figure 1.15 Kinesin and Dynein move along a microtubule in opposite 
directions. Kinesin and dynein consist of two parts called light and heavy chains. 
Light chains bind cargo while heavy chains carry out ATP hydrolysis (Adopted 
from http://creationrevolution.com/walking-molecules-%E2%80%93-simple-cell-
%E2%80%93-part-4/). 
 
Kinesin undergoes conformational changes with the help of ATP to generate 
motile force for anterograde transport within the cell. Two members of the kinesin 
family interact with early endosomes i.e. kinesin 1 and kinesin 3 (Hirokawa et al., 
2009). Specifically, Kif5b and Kif16b are involved in the trafficking and tubule 
formation of early endosomes (Hoepfner et al., 2005, Nath et al., 2007).  
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Figure 1.16 Intracellular transport mechanism involving microtubular motors 
kinesin and cytoplasmic dynein, which bind vesicular cargos and mediate plus 
and minus end directed movement respectively.  (Adopted from 
https://wikispaces.psu.edu/display/Biol230WFall09/The+Cytoskeleton). 
 
 
1.7 Calsyntenin-1 and Kinesin Light Chain 1 
In calsyntenin-1 two-conserved L/M-E/D-W-D-D-S motifs in the cytoplasmic 
domain, termed KBS1 and KBS2, are responsible for its interaction with KLC1, 
via its tetratricopeptide repeat (TPR) domains (Figure 1.17). Mutations in these 
motifs abolish binding of calsyntenin-1 to KLC1 in vitro and alter calsyntenin-1 
mediated transport in neurons. The interaction of calsyntenin-1 with KLC1 acts as 
an adapter to the microtubule based motor for vesicular cargo. Calsyntenin-1 links 
TGN derived carriers (endosomes) to kinesin-1 motors and mediates anterograde 
transport along axons (Steuble et al., 2010). Phosphorylation of KLC1 ser460 is a 
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mechanism for regulating the binding and trafficking of calsyntenin-1 (Araki et 
al., 2007).  
 
 
 
 
 
 
 
 
Figure 1.17 Model explaining the Calsyntenin-1/Kinesin-1 cargo docking 
complex. In vivo the transport complex is composed of four calsyntenin-1 
molecules and one kinesin-1 motor, based on 1:2 stoichiometry (Ludwig et al., 
2009). 
 
Furthermore, calsyntenin-1 is not just a passive cargo of kinesin-1, but activates 
kinesin-1 without requiring any other host factors (Kawano et al., 2012; Cai et al., 
2007). The function of the N-terminal domain of calsyntenin-1, which contains 
two cadherin like structures, is still unknown (Maruta et al., 2012). 
Overexpression of calsyntenin-1 and KLC1 induce aberrant membrane stacks at 
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the ER or Golgi, which interrupt Golgi structure and block exit of TGN mediated 
calsyntenin-1. In neurons, this disruption leads to impaired exit of TGN derived 
amyloid precursor protein (Ludwig et al., 2009).  
1.8 Role of Cytoskeleton in HCV Pathogenesis 
Viruses hijack the endocytic pathway for their replication and progression, as they 
typically encode few genes and depend on host factors for their survival. It has 
been extensively shown in different studies that the retrograde and anterograde 
movement of viruses in the cell is dependent on microtubules and their associated 
motors i.e. kinesin and dynein (Dohner et al., 2005; Dodding and Way, 2011). It 
is now well known that microtubules are the key players in the transport of 
viruses from the cell periphery to the perinuclear region, but the exact mechanism 
adopted by different viruses is still under investigation (Shu-Lin et al., 2014). 
It has been reported that MTs play a key role in the early stages of HCV infection, 
leading to an established, productive infection. It was shown using the JFH1 cell 
culture model that drugs which disrupt microtubules (nocodazole), inhibit tubulin 
polymerization (vinblastin), or stabilize microtubules (paclitaxel), hindered early 
steps of HCV infection. In contrast, an actin inhibitor (cytochalasin D) showed no 
direct effect on HCV (Roohvand et al., 2009). Previous studies have shown an 
association of HCV non-structural proteins (NS5A and NS5B) with vesicle-
associated membrane protein-associated protein (VAP) subtype A (VAP-A) and 
VAP subtype B (VAP-B), suggesting an important role in the formation of 
replication complexes (Gao et al., 2004; Hamamoto et al., 2005). Significantly, 
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both VAP subtypes are also involved in vesicle transport (Lapierre et al., 1999) 
and interactions with microtubule networks (Soussan et al., 1999). 
Lipid droplets are lipid-containing structures or adiposomes present in lipid 
storing cell organelles like adipose tissue and regulate the storage and hydrolysis 
of neutral lipids (Martin et al., 2006; Mehta., 2013). It has been shown that HCV 
assembly occurs in association with lipid droplets (LDs), which are coated by 
HCV core protein (Miyanari et al., 2007). Colocalization of core and Adipocyte 
differentiation-related protein (ADRP) by confocal microscopy confirms an 
association between core and LDs (Serfaty et al., 2001). It is well established that 
LDs move in Huh7 cells in a microtubule dependent manner (Targett-Adams et 
al., 2008). The presence of the motor proteins kinesin and dynein has been 
confirmed by several co-immunoprecipitation studies with ADRP (LD protein) 
and by immunoflourescence (Gross et al., 2006; Bostrom et al., 2005). It is 
believed that the formation and growth of LDs is dependent on these motor 
proteins and microtubules (Andersson et al., 2006).  
HCV replicates in the ER regions close to the nucleus, in close proximity to LDs 
(Targett-Adams et al., 2003). HCV core protein induces redistribution of LDs to 
the perinuclear region, a process that involves microtubules and cytoplasmic 
dynein (Boulant et al., 2008). The interaction between lipid droplets and 
endosome trafficking is attributed to the presence of GTPase Rab5 and Rab11 on 
the LD surface (Schmitz et al., 1985).  
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1.9 Summary  
The Hepatitis C Virus (HCV) RNA genome of 9.6 kb encodes only 10 proteins, 
so is highly dependent on host hepatocyte factors to facilitate replication. In this 
project we initially aimed to identify the host factors involved in the egress of 
viral particles. By screening the supernatant of HCV-infected hepatocytes using 
SILAC based proteomics, we identified the transmembrane protein calsyntenin-1 
as a factor predominantly secreted by infected cells.  
Using a HCV cell culture model we systematically analysed the role of 
calsyntenin-1 at various stages of the HCV life cycle, including entry, replication 
and egress. We show that calsyntenin-1 mediates the export of a subpopulation of 
viral particles, secreted through exosomes, and is also involved at several stages 
of HCV replication cycle. Calsyntenin-1 is involved in early stages of the viral 
replication cycle, namely the uptake of virus into early endosomes, and also the 
function of the replication complex. It mediates these functions through its 
interaction with KLC1, facilitating transport along the microtubule network. The 
involvement of calsyntenin-1 in multiple stages of HCV replication demonstrates 
its importance to the virus. This makes calsyntenin-1 a potential host target for 
inhibiting HCV replication, which could guide the development of new antiviral 
compounds, for use in combination with existing DAAs.  
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1.10 Hypothesis and Aims 
Our hypothesis is that “Calsyntenin-1 is involved in the transport of HCV during 
HCV early infection; replication and egress via exosomes, by acting as an adaptor 
to kinesin light chain 1”.  
In this thesis, this hypothesis will be tested in the following specific aims: 
1. To evaluate how calsyntenin-1 is involved in HCV pathogenesis  
2. To study the effect of calsyntenin-1 on HCV early infection, by evaluating its 
association with early endosomes and kinesin light chain-1. 
3. To investigate the association of calsyntenin-1 with the establishment and 
transport of HCV replication complexes. 
4. To examine the role of calsyntenin-1 in HCV assembly and egress.
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CHAPTER 2:  MATERIALS & METHODS  
2.1 Materials 
2.1.1 Chemicals and Reagents 
Mouse monoclonal antibodies against HCV core 1b (C7-50) (ab2740), KLC1 
(ab23586), EEA1 (ab70521) and Rab11A (ab170134) were purchased from 
Abcam. J2 antibody for dsRNA (J2-1406) was purchased from Scions, Hungary. 
HCV anti-mouse monoclonal core antibody (C65185M) was purchased from 
Meridian life sciences, USA. HCV rabbit anti-core (308) antibody and sheep 
polyclonal antibody against HCV NS5A were gifts from Dr. John McLauchlan 
and Professor Mark Harris (University of Leeds, UK), respectively. Antibodies 
against CD63 (CBL553), Calsyntenin-1 (3176-1), and Transferrin receptor (13-
6800) were purchased from Millipore, Epitomics, and Invitrogen, respectively. 
DAPI (4', 6-diamidino-2- phenylindole), Alexa 488-conjugated Donkey-anti-
Rabbit secondary antibody, Alexa 594-conjugated Donkey-anti-sheep secondary 
antibody and Prolong GOLD mounting medium was purchased from Invitrogen. 
Horseradish peroxidase (HRP) conjugated secondary antibodies and Duolink In 
situ Detection Reagents were purchased from Sigma-Aldrich. Chambered cover-
glass slides for live cell imaging were purchased from Lab-TekTM II 
Bovine serum albumin (BSA) was purchased from Sigma-Aldrich. 100% (w/v) 
Foetal calf serum (FCS) and Opti-MEM media were purchased from Gibco BRL. 
Dulbecco`s Modified Eagle Medium (DMEM) and phosphate buffered saline 
(PBS) were purchased from Lonza.  
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Taq DNA Polymerase (recombinant), Lipofectamine® RNAiMAX (13778100), 
Superscript III First Strand cDNA Synthesis kit, RNAiMAXTM transfection 
reagent, Taq Polymerase, deoxynucleotides, 10,000X SYBR green, DTT and 
Trizol®LS Reagents were purchased from Invitrogen. T7 RiboMAXTM Express 
Large Scale RNA production System was purchased from Promega. Primers were 
purchased from Geneworks and TaqMan® primer probes were purchased from 
Applied Biosystems. MasterAmp PCR optimization kit was purchased from 
Epicentre Biotechnologies. Calsyntenin-1 siRNA was purchased from OriGene 
(SR307847).  
Tetramethylethylenediamine (TEMED), ammonium persulphate (APS), Triton X-
100 were purchased from Sigma-Aldrich. DCTM protein assay kit, 30% 
acrylamide and nitrocellulose paper were purchased from Bio-Rad. PageRulerTM 
Plus pre-stained protein ladder, SuperSignal West pico-chemiluminescent 
substrate and SuperSignal West femto- chemiluminescent substrate were 
purchased from Thermo Scientific. Polyvinylinede fluoride membrane was 
purchased from Millipore.  
2.1.2 Cell Lines  
Huh 7 is a human hepatocellular carcinoma cell line of epithelial-like tumorigenic 
cells that was originally isolated from a liver tumor in a 57-year-old Japanese 
male in 1982 (Nakabayashi et al. 1982). Huh 7 and Huh 7.5 cell lines were kind 
gifts from Dr John McLauchlan (MRC Virology Unit, Glasgow, UK) and 
Associate Prof. Michael Beard (Hepatitis C Virus Pathogenesis Laboratory, 
Adelaide, Australia), respectively. The Huh 7 cell line was derived from a patient 
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with hepatocellular carcinoma and was the first cell line shown to support HCV 
replication (Lohmann et al. 2003). The Huh 7.5 cell line is a derivative, isolated 
from Huh7 cells that had been infected with a HCV subgenomic replicon, then 
cured using interferon-alpha (Blight et al. 2002; Murray et al. 2003). These cell 
lines were incubated in normal culture condition (37 °C, 5% CO2). 
2.1.3 Plasmids 
Sub-genomic replicons based on JFH1 i.e. pSGR-luc-JFH1, pSGR-luc-JFH1-
GND for transient replication assay and pSGR-EGFP-Luc-JFH1 for live cell 
imaging were kindly provided by Dr John McLauchlan (MRC Virology Unit, 
Glasgow, UK) and pEGFP-N1 and pDsRed-Monomer-C1 plasmids were 
purchased from OriGene. Jc1 is a GT2a/2a chimera consisting of J6CF- and 
JFH1-derived sequences was a gift from Dr. Thomas Pietschmann (TWINCORE, 
Germany).  
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2.2 Methods 
2.2.1 Preparation of HCV RNA  
Plasmids for HCV sub genomic replicons (pSGR-luc-JFH1 & pSGR-luc-JFH1-
GND) were transfected (2 µl) into 10 µl XL10-Gold®Ultracompetent Cells 
(Stratagene) and cloned as described below in section 2.2.6. The plasmids were 
linearized at the end of the HCV genome after 3` UTR with the restriction 
enzyme XbaI (Promega) while JC1 was linearized using MluI (Biolabs) overnight 
at 37 °C according to manufacturers instructions.  
The 4 terminal nucleotides produced by linearization were removed by treatment 
with 1 µl mungbean nuclease (New England Biolabs) for 45 min at 30 °C, 
resulting in the correct 3’-end of the HCV DNA. Mungbean nuclease was 
inactivated with the addition of 0.1 % w/v SDS and the DNA purified by 
phenol/chloroform extraction and ethanol precipitation before being resuspended 
in RNase free water. After precipitation and purification of plasmid DNAs, HCV 
RNA was transcribed in vitro using the T7 RiboMAXTM Express RNAi System 
(Promega). RNA was then quantified using a NanoDrop ND1000 
spectrophotometer and RNA integrity was checked by agarose gel 
electrophoresis. 
2.2.2 Transfection 
Huh 7 cells were cultured in T150 flasks until they were 50%-80% confluent. 
Cells were then dissociated with trypsin (0.25% for 3 min) to get a single cell 
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suspension and washed twice in 40 ml PBS. 2 ×107 cells per electroporation were 
re-suspended in 800 µl PBS and were then transferred to 4 mm electroporation 
cuvettes. Ten µg purified viral RNA was added to each cuvette and gently mixed. 
Electroporation was performed with a single pulse at 0.34 kV, 974 µF. 
Electroporated cells were transferred to T25 flasks and mixed with 5 ml complete 
media (DMEM+ 10% FCS). Cells were then incubated at 37 °C for 3 days and 
viral protein expression was checked by fluorescence microscopy using an 
antibody against HCV NS5A (Gift from Professor Mark Harris, University of 
Leeds, UK) (Section 2.2.7.2).  
Transfection of pSGR-EGFP-Luc-JFH1, pEGFP-Rab5a and pDsRed-CLSTN-1 
plasmids into cultured cell lines for live cell imaging was performed using 
FuGENE HD Transfection Reagent (Promega), according to manufacturer’s 
instructions. In brief, cells were cultured in 4-chambered cover-glass slides (Lab-
Tek II) for one day before transfection. One µg DNA plasmid and 3 µl FuGENE 
HD were mixed with 100 µl of Opti-MEM, generally with a DNA:FuGENE ratio 
of 1:3. After 15 minutes of incubation at room temperature the transfection 
mixture (40 µl) was added to each chamber containing 1 ml media and cells were 
incubated in normal culture condition (37 °C, 5% CO2). Cells were then observed 
live on Deltavision microscope for different time points as needed. 
2.2.3 RNA extraction  
Total RNA was extracted from cell culture monolayers using the Qiagen RNeasy 
Kit, according to the manufacturer’s instructions. All buffers were ready to use. 
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In brief, cells in six well plates were lysed in 350 µl of RNeasy Lysis buffer and 
transferred to a new RNase free tube. Next, 350 µl of 70% ethanol was added to 
each cell lysate and mixed thoroughly. Total 700 µl of sample solution was 
applied to a RNeasy spin column with collection tube and centrifuged for 30 
seconds at 10,000 RPM. The flow-through was discarded and 700µl wash buffer 
RW1 was added to each spin column and centrifuged for 30 seconds at 10,000 
RPM. After transferring the spin column to a clean tube 500 µl of second wash 
buffer RPE was applied to each column and the tubes centrifuged as above. This 
step was repeated; RNA was eluted from the spin column with 50µl of RNase 
free water and centrifuged for 1 minute at 10,000 RPM into a clean, RNase free 
tube. Eluted RNA was quantified using a NanoDrop ND1000 spectrophotometer 
and stored at -80 °C for subsequent experiments. Extraction of RNA from 
supernatants was performed using trizol® LS reagent (Invitrogen) following the 
manufacturer’s instructions. 
2.2.4 cDNA Synthesis  
cDNA was reverse transcribed from total RNA using M-MLV reverse 
transcriptase (Promega) according to the manufacturer’s instructions. In brief, 0.5 
µg RNA and 250 ng/µl random hexamer prmiers (Invitrogen) were added to a 
sterile RNase free microcentrifuge tube in a total volume of ≤ 15 µl water. The 
mixture was incubated at 70 °C for 5 minutes to melt the mRNA secondary 
structure. The tubes were immediately cooled on ice for at least 1 minute. A 
reaction mixture containing 1× M-MLV reaction buffer (Promega), 0.5 µM each 
dNTPs (Invitrogen), 40 units RNase Ribonuclease (RNase) Inhibitor (Invitrogen) 
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and 200 units M-MLV RT was prepared and added to primer/template tube. 
Samples were mixed gently and incubated for 60 minutes at 37 °C. The 
synthesized cDNA was stored at -20°C for further experiments. 
2.2.5 Construction of Fluorochrome-tagged constructs  
Primer sequences for amplification of Rab5a and various domains of the 
calsyntenin-1 gene are listed in the table 2.1 below. Oligonucleotide primers, 
incorporating EcoRI, BamHI and/or XhoI restriction endonuclease sites, were 
designed using Primer3 software (Rozen and Skaletsky, 2000) (http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi.  
Table 2.1: Forward and Reverse Primer Sequences for Rab5A and 
Calsyntenin-1 Coding Regions. 
Genes Insertion Primer sequence 
Full Length Rab5F Xho1 5` TTTTTGCATGCGGCTAGTCGAGGCGCA 3` 
Rab5R BamH1 5` 
AAAAAGGATCCAGTTACTACAACACTGATTCCT 
3` 
Full Length 
Calsyntenin-1 
XhoCAF Xho1 5’ TTTTTCTCGAGGCGCGAGTTAACAAGCAC 3` 
EcoCTR EcoR1 5`AAAAAGGAATTCGTAGCTGAGGGTGGAGTC 3` 
Calsyntenin-1 
C-Terminal 
fragment 
XhoCTF Xho1 5’ TTTTTCTCGAGGAACACCACCGCTCCTTTGTTG 
3’ 
 
EcoCTR 
 
EcoR1 
 
5`AAAAAGGAATTCGTAGCTGAGGGTGGAGTC 3` 
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PCR amplification was performed using the Hybrid PCR Sprint Thermal Cycler 
(Thermo Scientific), high fidelity KOD Hot start DNA polymerase (Novagene) 
and MasterAmp PCR optimization kit (Epicentre Biotechnologies). PCR reaction 
components are listed in Table 2.2. 
 
      Table 2.2 PCR Reaction Contents 
Components Volume Final 
Concentration Rab5a Calsyntenin-
1 
2X Buffer D for KOD Hot 
Start DNA Polymerase 
including dNTPs 
10 µl 10 ul 1 X 
Forward Primer 
(10µM) 
1 µl 1 µl 0.5 µM 
Reverse Primer 
(10µM) 
1 µl 1 µl 0.5 µM 
 
Template cDNA 1 µl 5 µl  
KOD Hot Start DNA 
Polymerase 
(1U/µl) 
0.4 µl 0.4 µl 0.02 U/ µl 
Total Reaction volume 20 µl 20 µl  
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PCR reaction conditions for the amplification of Rab5a comprised initial 
denaturation at 95 °C for 3 minutes, followed by 30 cycles of 95 °C for 30 
seconds, 55 °C for 30 seconds and 72 °C for 3 minutes, with final extension of 72 
°C for 10 minutes. On the other hand, Calsyntenin-1 PCR reaction conditions 
included initial denaturation at 95 °C for 3 minutes, followed by 40 cycles of 95 
°C for 30 seconds, 59 °C for 30 seconds and 72 °C for 3 minutes, with final 
extension of 72 °C for 10 minutes. PCR products were separated by agarose gel 
electrophoresis and DNA bands were visualized under ultraviolet light on a Gel 
Documentation system (FisherBiotec).  
2.2.6 Cloning  
Amplified purified PCR product from the Rab5a, full length calsyntenin-1 and 
calsyntenin-1 CTF amplification, pDsRed-Monomer-C1 plasmid and pEGFP-N1 
were digested with corresponding restriction endonucleases (Table 2.3), gel 
purified by phenol/chloroform extraction and ethanol precipitation before being 
resuspended in RNase free water, and PCR products were inserted by ligation 
using T4 DNA ligase Kit (New England Biolabs) according to manufacturer’s 
instructions. For cloning into plasmid, 2 ul of the each ligated product was added 
to 10 ul XL10-Gold®Ultracompetent Cells (Stratagene) and incubated on ice (4 
oC) for 10 minutes. Heat shock was given to the cells by placing them in a 
waterbath at 42 oC for 1 minute, the cells were put back on ice for 1-2 minutes, 
then spread on LB-agar plates containing ampicillin (100 µg/ml) or kanamycin 
(30 µg/ml) and incubated overnight at 37 °C. After 16 hours, bacterial colonies 
were selected and prepared for DNA plasmid extraction.  
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Table 2.3 List of Restriction Endonuclease used for Digestion of Live Cell 
Imaging Constructs. 
 
 
 
 
 
 
 
 
 
DNA plasmid extraction was performed using QIAprep Spin Miniprep Kit 
(QIAGEN) according to manufacturer’s instructions. Gene specific PCR was 
performed to check for the presence of the gene of interest in isolated plasmids. 
One colony from bacteria containing suitable plasmids was selected and maxi 
prep for DNA plasmid extraction was performed using Plasmid Maxi Kit 
(Qiagen) according to the manufacturer’s instructions. It provides a sufficient 
quantity of the plasmid for future use.  
Correct sequence of the inserted genes was confirmed by sequencing. A total 12 
µl mix of 1 µg of selected plasmids and 9.6 µM of the primers was sent to 
Australian Genome Research Facility to perform the sequencing. Four sequencing 
Template Endonucleases  
pDsRed-Monomer-C1 
plasmid 
Xho1 &  EcoR1 
 
pEGFP-N1 Xho1 &  BamH1 
Rab5a Xho1 &  BamH1 
Full length calsyntenin-1 Xho1 &  EcoR1 
CTF -calsyntenin-1 Xho1 & EcoR1 
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reactions were run for each gene with forward and reverse primers and then 
consensus sequence was obtained. This consensus DNA sequence was matched 
with the original sequences of the gene by nucleotide-BLAST (Basic Local 
Alignment Search Tool) software online (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
2.2.7   Immunofluorescence Studies 
2.2.7.1 Live cell imaging 
To perform live cell imaging, pEGFP-Rab5a, pDsRed-FLC and pDsRed-CTF 
expression constructs and HCV construct pSGR-EGFP-Luc-JFH1 were 
transfected into Huh 7 cells using FuGENE HD Transfection Reagent (Promega), 
according to manufacturer’s instructions. In brief, 1 × 105 cells/well were cultured 
in DMEM using chambered coverglass (Lab-TekTM II) plates for one day before 
transfection. 1 µg DNA plasmid and 3 µl FuGENE HD were mixed with 100 µl of 
Opti-MEM, generally with a DNA:FuGENE ratio of 1:3. After 15 minutes 
incubation at room temperature the transfection mixture (30-50 µl) was added to 
each well containing 1 ml media and cells were incubated in normal culture 
condition (37 °C, 5% CO2). Cells were then imaged live at various time points 
post-transfection, as detailed in the results section for each experiment. Velocity 
was measured using inbuilt imaging software. 
2.2.7.2   Immunofluorescence 
To perform Immunofluorescence labelling, cells were cultured on glass sterilized 
coverslips fitted in 24-well plates overnight, at a population of 1 × 105 cells/well. 
The next day DMEM media was removed and cells were washed with phosphate 
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buffer saline. Cells were then fixed with methanol (-20 °C for 20 minutes) or 4% 
paraformaldehyde (25 oC for 10 minutes) and permeabilised using 0.1% Triton X-
100. The blocking step was performed using PBS with 10% FCS for 1 hour. Cells 
were stained with primary antibodies diluted in blocking buffer and incubated for 
1 hour at room temperature or at 4°C overnight in a humidity chamber. Cells were 
washed 3 times with PBS + 1% FCS, for 5 min each time, then cells were labelled 
with fluorophore–conjugated secondary antibodies and DAPI (4',6-diamidino-2-
phenylindole) for nuclear staining (1/1000 for 5-10min). After 1-hour incubation 
in the dark, coverslips were washed (PBS + 1% FCS) 3 times for 10 minutes and 
mounted on microscopy slides using Prolong GOLD mounting medium 
(Invitrogen). Pictures were taken using 60 × and 100 ×objectives on a Deltavision 
Microscope (Applied Precision, Olympus IX 71). Primary and secondary 
antibodies used for Immunofluorescence staining are listed in Table 2.4. Working 
dilution for all secondary antibodies was 1:2000 in 1 % FCS/PBS and incubated 
for 1 hour at room temperature (25 °C). 
Proximity ligation assay was performed for colocalization studies of different 
proteins using the Duolink Insitu assay (Olink Bioscience), according to the 
manufacturer’s instructions. 
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Table 2.4: Primary and Secondary Antibody Dilutions and Incubation Timings 
for Immunofluorescence labelling. 
 
 
Primary Antibody Working dilution Secondary 
antibody 
Anti HCV Core 1:200 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 
488/594 anti 
Mouse IgG 
Anti HCV-NS5a 1:10000 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 594 
anti 
Mouse IgG 
Anti- Rab11a 1:100 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 488 
anti Mouse IgG 
Anti-Calsyntenin-1 1:100 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 488 
anti Rabbit IgG 
Anti-EEA-1 1:100 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 488 
anti Rabbit IgG 
Anti-Transferrin 
Receptor 
1:100 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 488 
anti Mouse IgG 
Anti-CD63 1:100 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 594 
anti Mouse IgG 
Anti-Kinesin Light 
Chain 1 
1:100 in 10% 
FBS/PBS, 
overnight 4°C 
Alexa Fluor 594 
anti Mouse IgG 
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2.2.8   Real Time PCR 
2.2.8.1   qPCR for Calsyntenin-1 
Real-time quantitative polymerase chain reaction (qPCR) for CLSTN-1 
expression was performed using the Rotor-Gene 6000 (Corbett Research, Sydney, 
NSW, Australia) and SYBR Green (Invitrogen). For each real-time qPCR 
reaction conditions and all reagents are listed in Table 2.5. The primer sequences 
were as follows: 
  qpcrForward:  5’ CAGGATTGAGTATGAGCCGG 3’  
                          qPCRreverse:  5’ GAGTAGGTGTCTCGGTCGCAG 3’ 
Table 2.5 Real time PCR Reaction conditions for Calsyntein-1 using SYBR 
green mix.  
Components Volume Final 
Concentration 
Platinum SYBR Green 
qPCR Master Mix 
(Invitrogen) 
5 µl 1X 
Forward Primer (10 uM) 0.3 µl 0.3 µM 
Reverse Primer (10 uM) 0.3 µl 0.3 µM 
Diluted cDNA Template 0.5 µl  
dH2O 3.9 µl  
Total Reaction Volume 10 µl  
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2.2.8.2   qPCR for HCV 
A Taqman probe (Applied Biosystems) was used for virus RNA copies within the 
cells. RNA levels were normalized to 18S ribosomal RNA that gave comparable 
results. Taqman gene expression assay details used for real-time qPCR are listed 
in Table 2.6.  
Table 2.6 HCV Real-time qPCR reaction contents using Taqman gene 
expression assay. 
 
Components Volume Final 
Concentration 
Master AMPTM 2X PCR 
PreMix D (Epicentre) 
5 µl 1 X 
Taqman Gene expression 
assay 
0.2 µl 0.2 X 
Taq DNA Polymerase 
Recombinant 5U/ul 
(Invitrogen) 
0.2 µl 1 U 
Diluted cDNA Template 0.5 µl  
18s rRNA 0.2 µl  
dH2O 3.9 µl  
Total Reaction Volume 10 µl  
 
 
Real-time qPCR reaction conditions comprised initial denaturation at 95 °C for 
10 minutes, followed by 45 cycles of 95 °C for 15 seconds and 60 °C for 45 
seconds. qPCR results were analyzed using Rotor-gene 6000 Corbett software. 
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The fold change of each gene was calculated using the Delta-delta Cycle 
threshold (ΔΔCt) data analysis method. 
2.2.9 Silencing of Calsyntenin-1 using siRNA 
Calsyntenin-1 expression was silenced using Calsyntenin-1 siRNA from OriGene. 
50uM of siRNA (scrambled control and calsyntenin-1 separately) was mixed with 
85ul of Opt-MEM per reaction. Fore each siRNA reaction, 1.4 µl of 
Lipofectamine® RNAiMAX was added to 85 µl of Opt-MEM. The mixture was 
incubated at room temperature for 30 minutes before adding to the cells. Cells 
were incubated for 48 hours (37 °C, 5% CO2) before further experiments. 
2.2.10 Tissue Culture Infectious Dose (TCID50 Infectivity Assay) 
Uninfected Huh 7 cells were placed in a 96-well plate at a population of 1 × 104 
cells per well in DMEM media and incubated overnight.  The next day 
supernatant from Jc1 infected Huh 7 cells (passaged twice) was added in 1:5 serial 
dilutions to 200 µl media in each well and returned to the incubator for 72 hours. 
Cells were then fixed with methanol for 20 minutes at -20 °C and blocked with 
PBS + 2% FCS for 15 minutes. To prevent endogenous peroxidase interference, 
cells were incubated with 0.3% H2O2 in PBS for 20 minutes. Cells then were 
stained for HCV with anti NS5A antibody at a 1:10,000 dilution (in PBS) for 1 
hour and washed twice with PBS for 5 minutes. Secondary HRP-conjugated anti-
sheep antibody, at a dilution of 1:1000, was added to the cells for 1 hour and 
infected cells were identified using the ImmPACT DAB Peroxidase Substrate 
(Vector laboratories). Cells were examined with an Olympus CK2 inverted 
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microscope at 20 × magnification and a well was counted as positive if there was 
at least one infectious focus identified. The TCID50/ml was calculated using the 
the method as described in the Spearman and Kaerber method (Carrere-Kremer et 
al., 2004).   
2.2.11    Protein Extraction 
2.2.11.1 Protein Extraction from Cells 
Cellular protein was extracted from cell culture monolayers using RIPA (Radio-
Immunoprecipitation Assay) buffer (Sigma). First, DMEM media was removed 
from six well plates and cells were washed in ice cold PBS. Cells in each well 
were scraped and 600 µl of cell suspension in PBS transferred to Eppendorf tubes 
that were then centrifuged to pellet the cells. RIPA buffer containing a mix of 
phosphatase inhibitor cocktail 2 (Sigma), Complete protease inhibitor cocktail 
(Roche), Phenylmethanesulfonyl fluoride (PMSF) and sodium fluoride was added 
to the cell pellet in each tube. Cell pellets were resuspended in lysis buffer by 
pipetting, and incubated on ice for 30 minutes. The lysates were then centrifuged 
at 14,000 RPM for 10 minutes at 4 °C, and supernatant containing extracted 
protein was transferred to a clean tube. Protein samples were then aliquoted and 
stored at -80 °C for future experiments. Protein extraction from supernatants was 
performed using Trichloroacetic acid (Sigma).  
2.2.11.2  Protein Extraction from Supernatants (Extracellular) 
To extract protein from supernatants, 1 volume of trichloroacetic acid (TCA) 
stock was added to 4 volumes of supernatant, incubated for 10 min at 4 °C, 
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centrifuged at 14,000 RPM for 5 min, then supernatant was removed, leaving the 
protein pellet intact. The protein pellet was washed twice with 200 µl cold 
acetone then dried by placing tube in 95 °C heat block for 5-10 min to drive off 
acetone. For SDS-PAGE, 2× or 4× sample buffer was added (with or without β-
ME) and the sample heated for 10 min at 95 °C before loading sample onto a 
polyacrylamide gel. 
2.2.11.3  Blood Plasma Albumin Removal and Protein Extraction  
Ethics approval was obtained from the Human Research Ethics Committees of 
Sydney West Area Health Service and the University of Sydney 
(HREC2002/12/4_9(1564). All subjects gave written informed consent, blood 
samples were collected from uninfected and HCV infected patients and then 
centrifuged at 4500 RPM for 10 min. Supernatant was used to remove albumin 
before extracting protein using ArumTM Affi-GelR blue mini kits and columns 
(Bio-Rad laboratories) according to manufacturer’s instructions. Protein 
extraction was performed using TCA precipitation as described above in section 
2.2.11.2. 
2.2.12 Protein Quantification 
Protein concentrations were determined using the Bio-Rad DC assay kit with 
purified bovine serum albumin (Sigma) as a standard.  Briefly, 20 µl of reagent S 
was added to 1ml of reagent A. Then 5 µl of standard and samples were 
transferred to a clean microtiter plate and 25 µl of reagent A+S was added to each 
well. Next 200 µl reagent B was combined with each well content and after 15 
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minutes incubation at room temperature the absorbance was read at 750 nm using 
a Wallac Victor1420 Multilable counter microplate reader.  
2.2.13 Polyacrylamide Gel Electrophoresis (PAGE)  
10% separating gel and 5% stacking gel were cast in a Bio-Rad Mini-
PROTEAN® Tetra Cell gel tank. 20-50 µg protein samples were prepared in  
1×SDS (Sodium Dodecyl sulphate) PAGE sample buffer (62.5 mM Tris-HCl pH 
6.8, 2.5 % SDS, 0.002 % Bromophenol Blue, 0.7135 M (5%) β-mercaptoethanol, 
10 % glycerol) by heating to 95 °C for 5 minutes, loaded onto gel and run at 100 
V for 2 hours in SDS running buffer. PageRulerTM Plus Prestained protein Ladder 
(Thermo Scientific) was used as protein marker. Resolved protein was transferred 
to a Nitrocellulose (Bio-Rad) or Polyvinylinede fluoride (Millipore) membrane in 
transfer buffer overnight at 35V. 
2.2.14 Western Blot Analysis 
Following protein transfer, membranes were blocked with 5% skim milk 
(Diploma) in TBST buffer (20 mM Tris-HCl, pH 7.4, 500mM NaCl, 0. 1% 
Tween) for 1 hour with gentle agitation. Incubation with primary antibodies in 5% 
skim milk/TBST was performed overnight at 4 °C. Membranes were then washed 
three times with TBST and incubated with the appropriate horseradish 
peroxidase-conjugated secondary antibodies for 1 hour at room temperature, with 
gentle agitation, and rinsed three times as above. Probed membranes were 
visualized using SuperSignal West Pico Chemiluminescence kit (Thermo 
Scientific) and exposed to Kodak BioMax Film for different exposure times. 
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Primary and secondary antibodies used in western blot analysis are listed in Table 
2.7. All secondary antibodies were used in 1:10000 dilution in 5% skim 
milk/TBST and incubated for 1 hour at room temperature (25 °C). 
Table 2.7 List of primary and secondary antibodies used in western blot 
analysis 
 
Primary Antibody Working Dilution Secondary 
Antibody 
β-actin (Sigma) 1:10000 in 5% 
skim milk/TBST, 1 
hour RT 
 
Anti Mouse-IgG 
(Sigma) 
 
Calsyntenin-1 
(Epitomics) 
1:1000 in 5% skim 
milk/TBST, 24-48 
hours incubation 
Anti Rabbit-IgG 
(Sigma) 
Early Endosome 
Antigen 1 
(Abcam) 
1:1000 in 5% skim 
milk/TBST, 24 
hours incubation 
Anti Rabbit-IgG 
(Sigma) 
Transferrin 
(Invitrogen) 
1:500 in 5% skim 
milk/TBST, 
overnight 
incubation 
Anti Mouse-IgG 
(Sigma) 
CD63 (Millipore) 1:1000 in 5% skim 
milk/TBST, 24-48 
hours incubation 
Anti Mouse-IgG 
(Sigma) 
HCV Core 
(Abcam) 
1:1000 in 5% skim 
milk/TBST, 24-48 
hours incubation 
Anti Mouse-IgG 
(Sigma) 
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2.2.15 Dual Renilla Luciferase Assay 
Luciferase activity was quantified using Luciferase Assay System (Promega) in 
transfected cells, according to manufacturer’s instructions. Briefly cells were 
harvested at different time points post-transfection and lysed in 100 µl of lysis 
buffer for each well. Cell lysates were transferred to clean tubes and centrifuged 
to remove cell debris. Clear supernatant (20 µl) was mixed with 100 µl luciferase 
reagent and emitted light was measured using a Wallac Victor1420 Multilable 
counter microplate reader.  
2.2.16 Concentration of HCV Virus (PEG precipitation) 
Supernatant from HCV (Jc1 strain) infected cells was collected from T150 tissue 
culture flasks (200 ml) and filtered through a 0.45 µm MillEX-HV 
(MILLIPORE), to remove cellular debris. Filtered supernatant was then mixed 
with the appropriate volume of 40% (W/V) polyethylene glycol (PEG 8000) 
(Promega) to give a final concentration of 8% (W/V) and incubated overnight at 4 
°C with gentle agitation. Tubes were then centrifuged at 8000 g for 20 minutes at 
4 °C. The supernatant was discarded and the pellet resuspended in 2 ml complete 
media or TNE (Tris and NaEDTA) buffer, for sucrose density gradient analysis. 
Samples were then used to perform TCID50 or RNA extraction from extracellular 
HCV virions.  
2.2.17 Sucrose Density Gradient Analysis 
Concentrated virus from the supernatant of HCV infected cells was subjected to 
sucrose gradient density.  Samples were overlaid on top of a stepwise density 
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gradient of sucrose, prepared from 60% to 10% (w/w) sucrose, and centrifuged at 
35,000 RPM for 16 hours using a SW-41 Rotor and Beckman Optima XL-100K 
Ultracentrifuge.  10 fractions were collected sequentially from the bottom of the 
tubes and analysed further.  
2.2.18 Exosome Isolation 
HCV (Jc1) infected Huh7 cells were silenced for calsyntenin-1 (using siRNA) for 
48 h and serum free supernatants were collected. Exosomes were isolated from 
serum free supernatants using ExoQuick-TC kit (System Biosciences) according 
to manufacturers instructions. 
2.2.19 ImageJ software 
Image was opened in imageJ, split into RGB (Red, Green, Blue) channels, 
threshold was adjusted and area of interest was selected. Then used the plugin 
“measure” in analyze drop down menu that gave a table of measurements for our 
required area of the cytoplasm. Then percentage of cell area containing early 
endosomes was measure by formula;  
Percentage area = d/(a-c) × 100 
where  a = area of total cytoplasm in the cell, c = area of nucleus and d = area of 
cytoplasm showing early endosomes (Boulant et al., 2008). 
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CHAPTER 3:  IDENTIFICATION OF CALSYNTENIN-
1 AS A HOST FACTOR INVOLVED IN HCV 
PATHOGENESIS. 
 
3.1 Introduction  
Approximately 233,000 Australians and 150 million people worldwide have 
chronic infection with hepatitis C virus (HCV), which can lead to hepatic fibrosis, 
liver failure and cancer (WHO, 2014; Razavi et al. 2014). Until recently, therapy 
for HCV involved treating patients with an interferon/ribavarin combination that 
stimulates antiviral immunity.  However, this strategy has significant side effects 
and shows a success rate (viral eradication) of less than 50% for HCV genotype 1 
infection (Razali et al., 2007). Despite recent improvements in therapy with the 
availability of direct acting antivirals (DAAs), in Australia early DAAs still need 
to be used in combination with interferon and ribavirin, increase overall drug side 
effects and are only approved for HCV genotype 1. The HCV genome encodes 
only ten proteins, so the virus relies heavily on host factors to aid its replication 
within the cell (Li et al., 2009). Drugs targeting host factors should avoid these 
problems, but a major barrier to their design and development is our incomplete 
understanding of the virus replication cycle. Therefore improved insight into the 
stages of the HCV life cycle will facilitate the development of novel antivirals, by 
targeting host proteins involved in specific stages of the virus life cycle.  
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3.2 Background to the Project 
To characterise the differences in the secretomes of HCV infected and uninfected 
cells, we used stable isotopic labeling with amino acids in cell culture (SILAC). 
SILAC is a mass spectrometry based technique that involves incorporation of a 
label into proteins for mass spectrometry based quantitative proteomics. Two 
different cell populations are grown in identical culture media except that one of 
them contains a light or heavy form of a particular amino acid. When cells grow, 
that particular amino acid is incorporated into newly synthesized proteins. After a 
number of cell divisions, supernatants are subjected to mass spectroscopy and 
peaks are obtained. The differential labelling of amino acids incorporated into 
proteins results in a mass shift, which is detected by the mass spectrometer 
(Chapter 1, Figure 1.10). 
For our experiment we used the JFH1 HCV cell culture model, which is a 
genotype 2a strain capable of reproducing the entire HCV life cycle in vitro and 
which ONLY grows efficiently in Huh7 cells (or derivatives) (Wakita et al., 
2005). In our experiment, JFH1 infected and uninfected control Huh7 cells were 
grown to the same confluency in 10 cm dishes, in media labelled with either 
“Heavy” or “Medium” isotopes of arginine (Cambridge Laboratories U-13C6 
units–15N4 arginine CNLM-539 or U-13C6 arginine CLM-2265 0.021 g/l) and 
lysine (Cambridge Laboratories U-13C6 units-15N2 lysine CNLM-291 or 4,4,5,5-
D4 lysine CNLM-2640 0.0365 g/l), respectively. After 48 hours of incubation, 
proteins were extracted and analysed by mass spectrometry. Levels of 
“housekeeping” proteins albumin and alpha-2-macroglobulin were comparable 
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between samples, confirming that equal cell numbers were analysed. Expression 
of several proteins increased or decreased significantly (> 2-fold) in JFH1 infected 
cells. Among them, calsyntenin-1 showed the largest increase, with an 
infected/uninfected ratio of 43.53 in the supernatant from HCV infected cells 
(Figure 3.1) and the abundant protein values are shown in table 3.1 (Tay et al., 
unpublished). 
 
 
 
 
 
 
 
Figure 3.1 SILAC Screen. Quantitative proteomic comparison using stable isotopic 
labeling with amino acids in cell culture (SILAC), showing up-regulation of proteins 
in HCV infected media compared to control. The asterisk * indicates the largest 
increase (44-fold) in calsyntenin-1 protein in the supernatant of HCV infected cells 
(Tay et al., unpublished).  
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!Table 3.1 Abundant Proteins in HCV-infected cells Supernatant (SILAC 
Screen)  
 
No. 
 
Name of Protein 
Huh 7  
(M/H) 
HCV-infected 
(H/M) 
 
1 Stathmin 0.111598 8.960699 
2 Fatty acid synthase 0.143507 6.968284 
3 Myosin light chain 6B 0.178100 5.614822 
4 Calsyntenin-1 0.022970 43.535510 
5 Keratin, type I cytoskeletal 18 0.116395 8.591463 
6 Keratin, type I cytoskeletal 19 0.214083 4.671096 
7 Pyruvate kinase isozymes M1/M2 0.1950501 5.126888 
8 Growth/differentiation factor 15 0.120521 8.297337 
9 Alpha-enolase 0.255944 3.907111 
 
Although calsyntenin-1 has not previously been studied in the context of HCV, a 
literature search revealed that it was among >30 essential host factors identified in 
a small interfering RNA (siRNA) screen (Li et al., 2009). This study involved a 
two-part genome wide siRNA screen using infectious JFH1 virus and the 
Huh7.5.1 human hepatoma cell line to identify cellular genes essential for HCV 
infection and replication. Part one of the study identified specific factors linked to 
early HCV infection while part two revealed proteins involved later in the 
replication cycle. In part one of the study, knock down of the calsyntenin-1 gene 
inhibited HCV infection. More specifically, it reduced the number of HCV core 
expressing cells after incubation with infectious virus. This suggests that 
calsyntenin-1 is involved in early infection (probably entry step) of the HCV. 
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Calsyntenin-1 is a membrane-bound adaptor protein for the microtubule based 
motor kinesin 1 in neurons (Steuble et al., 2010). Calsyntenin-1 binds specifically 
to kinesin light chain 1 (KLC1), facilitating the trafficking of vesicular cargo 
along the microtubule network (Vagnoni et al. 2011). Identification of 
calsyntenin-1 in our proteomic screen, as well as in the published siRNA screen 
of essential host factors for the HCV life cycle, suggested an important role in 
hepatocytes and justified further investigation.  
Live cell imaging of virions and microtubules provides direct evidence that many 
types of viruses move along microtubules (Dohner et al, 2005). This interaction 
can occur at various stages of the virus life cycle, including entry, replication and 
egress  (Dodding and Way 2011). A recent study emphasizes the in vivo role of 
calsyntenin-1 in neuronal endosomal dynamics, during their transport from cell 
body to axons (Ponomareva et al., 2014). In neurons, calsyntenin-1 also mediates 
anterograde endosomal movement, through the trans-golgi network (TGN) and 
finally out of the cell (Ludwig et al., 2009). Importantly, HCV is thought to use 
the early endosomal and exosome route for entry and egress in hepatocytes 
(Coller et al., 2012; Dreux et al., 2012), suggesting a possible link and a 
mechanism for our observations.  
Based on its proven role in endosomal transport in neurons, calsyntenin-1 is a 
likely candidate to mediate transport of HCV within infected hepatocytes, and 
may also be involved in its egress from the cell. We used the highly infectious 
chimeric HCV strain Jc1 for subsequent experiments because of its high 
infectivity. This chapter examines the role of calsyntenin-1 in HCV dynamics, 
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using a siRNA silencing strategy. It also investigates the interaction between 
calsyntenin-1 and KLC1 in hepatocytes, as this has only been studied previously 
in neurons. 
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3.3 Experimental Outline And Results 
3.3.1 Optimization of virus constructs (Jc1 & JFH1) in Huh7 and Huh7.5 
cell lines. 
An important first step in the present study was to determine the best HCV culture 
model and hepatocyte cell line for our experiments, to provide a better 
understanding of the virus life cycle. The most commonly used HCV cell culture 
models are JFH1 and Jc1. JFH1 is a genotype 2a clone originated from a Japanese 
patient with fulminant hepatitis that can replicate efficiently in Huh7 cells (Kato 
et al., 2001; 2003). Importantly, it was the first strain to reliably produce 
infectious virus in Huh7 cells, allowing reproduction of the entire HCV life cycle 
in vitro (Wakita et al., 2005). More recently, the Jc1 strain was developed, which 
is a chimeric virus containing the structural genes from J6CF and non-structural 
genes from JFH1, both genotype 2a strains (Pietschmann et al., 2006). This 
chimeric virus replicates more efficiently than JFH1, achieving titres of about 10
6 
infectious units per ml (Pietschmann et al. 2006).  
The Huh7 cell line was derived from a patient with hepatocellar carcinoma and 
was the first cell line shown to support HCV replication (Lohmann et al. 2003). 
The Huh 7.5 cell line is a derivative, isolated from Huh7 cells that had been 
infected with a HCV subgenomic replicon, then cured using interferon-alpha. 
They usually allow HCV to replicate to higher levels than in Huh7 cells, due to a 
defect in the innate antiviral defence signalling pathway, following mutational 
inactivation of retinoic acid-inducible gene I (RIG-I) (Sumpter et al. 2005). 
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However, the Huh7 line is highly heterogeneous, with permissiveness to HCV 
infection varying widely among different clones from laboratories around the 
world. The reason is unclear, but seems to involve varying activity of innate 
immune signaling, in particular RIG-I (Gale Jr. and Foy., 2005). 
Until recently, our group had used the standard JFH1/Huh7 cell model, but for 
this study we wanted to achieve the highest virus titres possible, to maximise 
infection for immunofluorescence studies. Therefore, to find the best combination 
of virus and cells for this project, a comparison study of these cell lines and virus 
constructs was performed, in different combinations as follows. 
3.3.1.1 Comparison of replication efficiency of Jc1 and JFH1 HCV strains in 
Huh 7 and Huh 7.5 cell lines. 
To compare the replication efficiency of Jc1 and JFH1 RNA, we synthesized 
HCV RNA from DNA plasmids containing Jc1 (40pFK-JFH1J6C-846) and JFH1 
(pJFH1) genomes, as detailed in Materials and Methods section 2.1.3. HCV RNA 
(Jc1 or JFH1) was electroporated into Huh7 or Huh7.5 cell lines as described in 
methods section 2.2.2. They were maintained in normal cell culture conditions 
until 80% of cells were infected (usually 10-14 days). After 2 weeks, total RNA 
was extracted from infected cells and HCV RNA levels were quantified by real-
time quantitative PCR analysis (qPCR).  
HCV RNA quantification using specific Taqman primers/ probe showed 
approximately 2-fold increase in Jc1 RNA expression compared to JFH1 RNA in 
both cell lines (Figure 3.2). We also observed that Jc1 RNA expression was 
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significantly higher (p-value = 0.017) in Huh7 cells as compared to Huh7.5 cell 
line. This shows that our Huh7 cell line clone is more permissive for Jc1 RNA 
replication than Huh 7.5 cells (Figure 3.2).  
 
 
 
 
 
 
 
 
  
Figure 3.2 Replication efficiencies of Jc1 and JFH1 RNA in Huh7 and Huh7.5 
hepatoma cell lines. Naïve cells (Huh7 & Huh7.5) were electroporated with HCV 
RNA and then maintained in cell culture for 1-2 weeks until they reached 80% 
confluency. Total RNA was then extracted, normalized to 18S and analysed by 
qPCR. n=3, Error bars indicate Standard Error of the Mean (SEM),  p-value* = 
0.017. 
 
3.3.1.2 Calculation of HCV infectivity titres using Jc1 and JFH1 infected Huh 
7 and Huh 7.5 cell lines. 
To assess infectivity efficiency of both HCV constructs, naïve Huh7 and Huh7.5 
cells were infected with supernatant from HCV (Jc1 & JFH1) infected Huh7 and 
Huh7.5 cells. After 72 h, cells were fixed with methanol, immuno-labelled with 
anti-NS5A antibody and infectious foci were counted. Viral titre calculations were 
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carried out using TCID50 infectivity assay, as described in section 2.2.10. We 
observed that Jc1 showed higher infectivity than JFH1, and was more infectious 
in Huh7 cells than Huh7.5 (Figure 3.3). This suggests that use of Jc1 virus 
construct in Huh7 cells is much more efficient than JFH1.   
 
 
 
 
 
 
 
 
 
Figure 3.3 Comparison of Jc1 and JFH1 viral titres in Huh7 and Huh7.5 cells 
using TCID50 based infectivity assay. Supernatants from HCV (Jc1 or JFH1) 
infected cells (Huh7 or Huh7.5) were used to infect naïve Huh7 or Huh7.5 cells in 
serial dilutions (1:5). After 72 h, immunolabelling for NS5A was performed, 
infectious foci were counted and viral titre values were calculated using TCID50 
calculator (Section 2.2.10). n=3, Error bars indicate Standard Error of the Mean 
(SEM). 
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3.3.1.3 Evaluation of Jc1 and JFH1 initial replication ability in Huh7 and 
Huh7.5 cell lines, using a time course. 
To evaluate the initial infection efficiency, naïve Huh7 and Huh7.5 cells were 
infected with supernatant from HCV (Jc1 or JFH1) infected Huh7 and Huh7.5 
cells respectively, or from uninfected negative controls. After 24 h and 72 h, total 
RNA was extracted from cells and quantified using qPCR as detailed in Methods 
section 2.2.8. Our experiment showed significantly higher HCV RNA levels at 24 
h and 72 h, with Jc1 than JFH1, in either Huh7 cells (Figure 3.4A) or Huh7.5 cells 
(Figure 3.4B).  
Together, the data in Figures 3.3 and 3.4 show that, compared with JFH1, not only 
does Jc1 infect a higher percentage of cells, but a larger amount of HCV RNA is 
produced. Once again, in our hands Huh7 cells supported higher levels of HCV 
replication than Huh7.5 cells. However, it was not clear from these experiments 
whether this was because Huh7 cells produced higher titer virus than Huh7.5 
cells, or whether they were more easily infected. To clarify this, cross over 
infection studies were performed, as follows. 
 
 
 
 
 
Chapter(3:(Identification(Of(Calsyntenin61(As(A(Host(Factor(Involved(In(HCV(
Pathogenesis.(
(
! 84!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 HCV RNA expression at early times after infection with HCV 
supernatant (Jc1 or JFH1). Naïve Huh7 or Huh7.5 cells were infected with 
supernatant, collected from HCV (Jc1 or JFH1) infected Huh7 and Huh7.5 cells 
respectively. After 24 and 72 hours of infection, total RNA was extracted and 
HCV RNA levels were quantified by HCV specific qPCR analysis. (A) Jc1 and 
JFH1 RNA expression in Huh7 cells. (B) Expression of Jc1 and JFH1 RNA in 
Huh7.5 cell line. p value * <0.05 and *** <0.0001. NC; Negative Control, n=3, 
Error bars indicate Standard Error of the Mean (SEM). 
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3.3.1.4 Selection of the best cell line receptive for Jc1 showing efficient 
replication and infectivity.  
To clarify the most productive and receptive cell line for highly infectious Jc1 
propagation in our experiments, we electroporated both Huh7 and Huh7.5 cells 
with Jc1 RNA in parallel, then after (10 days) we took the supernatant and used it 
to infect naïve Huh7 and Huh7.5 cells, in a crossover study. After 72 h, total cell 
RNA was extracted and HCV RNA quantified using qPCR. At the same time, 
infected cells grown in parallel were fixed, NS5A immunolabelling was 
performed, infectious foci were counted and viral titres were calculated by 
TCID50, as detailed in chapter 2 (section 2.2.10).  
In naïve Huh7 cells, we observed significantly higher (p value <0.0001) HCV 
replication efficiency following infection with virus particles produced by Huh7 
cells, compared to Huh7.5 derived virus (Figure 3.5A). On the other hand, Jc1 
virus particles from Huh7 cells showed slightly higher infectivity in Huh7.5 rather 
Huh7 cells (Figure 3.5B). Virus from Huh7.5 cells was less infectious in both cell 
lines.  
In summary, Huh7 cells appeared to support higher intracellular levels of HCV 
RNA (Figure 3.5A), and to produce higher virus titres (Figure 3.5B). However, 
Huh7.5 cells appeared slightly more permissive to infection, as a higher 
proportion of them became infected than Huh7 cells (Figure 3.5B), regardless of 
which cell line the virus was produced in. Therefore we decided to use Jc1 virus 
and the Huh7 cell line for our experiments, as this combination produced the 
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highest virus titres, and the cells that did become infected supported higher levels 
of virus replication. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Comparison of HCV RNA (Jc1 & JFH1) replication efficiencies and 
viral titres in Huh7 and Huh7.5 cell lines. Naïve Huh7 cells and Huh7.5 cells 
were infected with supernatant from either Jc1 infected Huh7 or Huh7.5 cells, in 
various combinations. (A) After 72 hours, total RNA was extracted and quantified 
using qPCR. (***p-value <0.0001). n=3, Error bars indicate Standard Error of 
the Mean (SEM). (B) For viral titres, NS5A immunolabelling was performed after 
72 hours of infection and infectious foci were counted (n=1). Viral titre values 
were calculated using TCID50 calculator (Section 2.2.10).  
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3.3.2 Identification of Calsyntenin-1 as a host factor up regulated in HCV 
infection  
 To confirm the results from our SILAC screen (Figure 3.1), conditioned media 
and cell lysates from Jc1 infected Huh7 cells (72 h) and uninfected Huh7 control 
cells were analysed for calsyntenin-1 by SDS PAGE and western blot, using C-
terminal specific antibody (Epitomics Cat #3176-1). This antibody was raised 
against a synthetic peptide corresponding to the C-terminal intracellular domain 
of calsyntenin-1, which undergoes cleavage in cells to produces two fragments, 
the soluble N-terminal fragment (NTF) and the C-terminal fragment (CTF), the 
membrane bound stump (Figure 3.7). Therefore as well as full length calsyntenin-
1 (150 kDa), the two cleaved fragments of calsyntenin-1 were also detected by 
our antibody i.e. N-terminal fragment i.e NTF (115 kD) and C-terminal fragment 
(CTF) (33 kD) (Figure 3.7). We used rabbit monoclonal antibody for western blot 
but appearance of more than one band could be because of alternative splicing. 
In cell lysates from HCV infected cells, compared to uninfected controls, we 
observed a decrease in full-length calsyntenin-1, but an increase in its cleaved 
fragments (Figure 3.7). In contrast, full-length calsyntenin-1 (150 kD), but not its 
cleavage products, was detected in supernatant from HCV infected cells, but no 
calsyntenin-1 was detected in media from uninfected controls (Figure 3.6 A). 
Importantly, for this experiment we used the Jc1 strain of HCV, instead of the 
JFH1 strain we used for our initial SILAC screen (Figure 3.1). This therefore 
confirms our initial findings, i.e. increased detection of calsyntenin-1 in the 
supernatant of HCV infected cells, using both a different technique (western blot) 
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and different virus strain (Jc1). There appeared to be an overall increase in 
intracellular calsyntenin-1, particularly of its cleaved fragments. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Calsyntenin-1 is involved in Hepatitis C Virus infection. Huh7 cells were 
infected with HCV (Jc1) containing supernatant for 72 hours, total protein was 
extracted and western blot analysis was performed. (A) Full western blot using c-
terminal specific calsyntenin-1 antibody detected 150 kD, 115 kD and 33 kD bands in 
cell lysates, corresponding to full length calsyntenin-1, NTF and CTF respectively. 
However in supernatants from Jc1 infected Huh7 cells only the full length 150 kD 
band was detected and complement 3 protein was the loading control. ß-actin was 
used as a housekeeping control. n=3. (B) & (C) Graphs showing calsyntenin-1 band 
intensities in cell lysate (115 k D)  and supernatant (150 kD) respectively. Error bars 
indicate Standard Error of the Mean (SEM).  
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As outlined in more detail in the Introduction (Chapter 1, section1.5.2), 
calsyntein-1 is a type I transmembrane protein which is constitutively cleaved by 
disintegrin and metalloproteinase (ADAM) 10 or 17 enzymes. Cleavage at the 
trans-membrane domain is a critical event during its activation, modification and 
proper functioning. This is similar to other membrane bound proteins that undergo 
proteolysis, either constitutively or in response to external stimuli (Maruta et al., 
2012). Cleavage of calsyntenin-1 gives rise to a N-terminal extracellular 
ectodomain and C-terminal intracellular peptide (Hata et al., 2009). The C-
terminal intracellular peptide is further digested by c-secretase to produce a N-
terminal fragment (NTF) and C-terminal fragment (CTF), as shown in figure 3.7 
(Araki et al., 2004). However, the role of constitutive cleavage of type I 
membrane spanning proteins remains unclear (Maruta et al., 2012).  
 
 
 
 
 
 
Chapter(3:(Identification(Of(Calsyntenin61(As(A(Host(Factor(Involved(In(HCV(
Pathogenesis.(
(
! 90!
       
 
 
Figure 3.7 Post-translational processing of calsyntenin-1. Calsyntenin-1 protein 
consists of 981 amino acids and undergoes two sequential constitutive cleavages. 
The final cleavage results in a N-terminal peptide and C-terminal cytoplasmic 
fragment. Our calsyntenin-1 antibody (Epitomics cat # 3176-1) was a synthetic 
peptide corresponding to C- terminal intracellular peptide. Asterisk * shows the 
detected protein bands which we observed in section 3.3.2.  
 
To confirm increased amounts of calsyntenin-1 protein in HCV infected cells and 
to examine its intracellular distribution, HCV infected and Huh7 cells were 
immuno-labelled with the same calsyntenin-1 antibody and imaging was 
performed by fluorescence microscopy (Deltavision). As shown in Figure 3.8A, 
there was an increased amount of calsyntenin-1 in HCV infected cells, compared 
to controls (n=10). Furthermore, calsyntenin-1 was more widely distributed in 
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HCV infected cells; rather Huh7 suggesting altered trafficking of calsyntenin-1 
associated vesicles during HCV infection.  
To investigate the in vivo secretion of calsyntenin-1 into HCV infected patients’ 
blood, total protein was extracted from plasma and western blot analysis was 
performed. The plasma samples obtained from HCV infected patients (n=3) and 
uninfected people (n=3) showed variable results (Figure 3.8B). Serum levels of 
calsyntenin-1 varied considerably among patients within in each group, with no 
clear difference in levels between groups. This suggests that regulation of 
calsyntenin-1 in human blood in vivo is more complex than in our simple in vitro 
model. Furthermore, calsyntenin-1 in blood plasma may not solely be coming 
from the liver, but also from other body organs, or may be degraded. 
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Figure 3.8 Calsyntenin-1 and Hepatitis C Virus infection. (A) Immunolabelling for 
calsyntenin-1 in control and Jc1 infected Huh7 cells, showing increased expression in 
HCV infected cells (n=10). (B) Western blot showing full-length calsyntenin-1 (150 
kD) in blood plasma samples from HCV infected and uninfected control patients 
(n=3) using complement 3 protein as control (110 kD).  
 
 
3.3.3 Silencing the Expression of Calsyntenin-1 in Huh 7 Cells Using siRNA 
To investigate the effect of decreased calsyntenin-1 expression on HCV infection, 
we used siRNA to silence calsyntenin-1 within cells. We used siRNA because 
there is no chemical inhibitor available for calsyntenin-1. Calsyntenin-1 siRNA 
(50 µM) was used to silence calsyntenin-1 expression in Huh7 cells, as described 
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in methods (section 2.2.9). Levels of calsyntenin-1 mRNA were quantified by 
qPCR and confirmed 80-90% reduction in cells treated with siRNA, compared to 
scrambled controls (Figure 3.9A). Immunolabelling for calsyntenin-1 also 
confirmed reduced expression in silenced cells, compared to controls (Figure 
3.9B).  
 
 
 
 
 
Figure 3.9 Silencing of Calsyntenin-1 in Huh 7 cells. Huh 7 cells were silenced 
using 50 µM siRNA. After 48 hours, calsyntenin-1 expression was examined by qPCR 
and immunofluorescence microscopy. (A) Graph confirming ~ 90 % reduction in 
calsyntenin-1 mRNA levels in cells treated with 50 µM siRNA (n=3) (B) 
Immunolabelling for calsyntenin-1 (green) in Huh7 cells (>10 cells/treatment) treated 
with scrambled RNA (control) or Calsyntenin-1 siRNA. Scale bar 20 µm, 100 × 
magnification.  
Control siRNA Calsyntenin-1 Calsyntenin51 
A B 
Control 50uM
0
100000
200000
300000
400000
500000
siRNA Concentration
Ca
lsy
nt
en
in
-1
 m
RN
A
 le
ve
ls
Chapter(3:(Identification(Of(Calsyntenin61(As(A(Host(Factor(Involved(In(HCV(
Pathogenesis.(
(
! 94!
3.3.4. Effect of decreased calsyntenin-1 expression on HCV infection 
To examine the effects of calsyntenin-1 knock down on HCV infection, Huh7 
cells were treated with calsyntenin-1 siRNA for 48 hours (scrambled siRNA for 
control), and then infected with supernatant from HCV (Jc1) infected cells for 24-
48 hours. RNA was extracted and qPCR was performed for HCV RNA. This 
showed almost 90% significant  (p-value <0.05) reduction in HCV infection in the 
absence of calsyntenin-1 (Figure 3.10A). 
To confirm a reduction in the number of infected cells, Jc1 supernatant was added 
to the silenced calsyntenin-1 Huh7 cells in a 96 well plate, in 1:5 serial dilutions, 
and cells were incubated for 72 hours. Immuno-staining for HCV NS5A protein 
and TCID50 calculations were performed as detailed in Chapter 2, section 2.2.10. 
There was a significant 60 % reduction (p-value < 0.05) in infectious foci in 
calsyntenin-1 silenced cells, compared to control cells treated with scrambled 
RNA control (Figure 3.10B). 
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Figure 3.10 Calsyntenin-1 knockdown leads to reduction in HCV RNA expression 
and infectivity. Huh7 cells were silenced for calsyntenin-1 for 48 hours and then 
infected with Jc1 supernatant. After 48 hours, HCV infection was assessed using 
qPCR and TCID50 based infectivity assay. (A) HCV RNA expression was significantly 
decreased compared to control (p-value* <0.05) (n=3). (B) The number of HCV 
infected cells was also reduced in silenced cells, using NS5A antibody and TCID50 
calculation (p-value* <0.05), n=3, Error bars indicate Standard Error of the 
Mean (SEM). 
 
To confirm reduction in the total amount of HCV protein, western blotting and 
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cell lysates and HCV core protein was detected by western blot. In parallel, 
infected cells were fixed, labelled using HCV core antibody and examined by 
immunofluorescence microscopy. These studies confirmed that in the absence of 
calsyntenin-1 there was a decreased amount of HCV core protein 24 hours after 
infection (Figure 3.11A). Immunofluorescence confirmed a dramatic reduction in 
the number of infected cells following calsyntenin-1 knockdown, suggesting a 
role for calsyntenin-1 at early stages of HCV infection. Interestingly, the few cells 
that became infected appeared to have normal levels of HCV core expression, 
suggesting that perhaps these cells were not transfected effectively with siRNA 
(Figure 3.11B). HCV core labelling was not very clear in immunofluorescence 
studies so we choose proximity ligation assay (as detailed in 3.3.5.1) to show the 
association of calsyntenin-1 and HCV core to confirm this hypothesis. HCV-
infected Huh 7 cells and control uninfected Huh 7 cells were fixed with 4% PFA 
and proximity ligation assay was performed (section 2.2.7.2). We found an 
association between HCV Core and calsyntenin-1 showing their interaction within 
HCV infected cells (Figure 3.11C).  
 
 
 
 
 
 
 
Chapter(3:(Identification(Of(Calsyntenin61(As(A(Host(Factor(Involved(In(HCV(
Pathogenesis.(
(
! 97!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Decrease in HCV protein expression in calsyntenin-1 knock down 
Huh7 cells infected with Jc1. (A) Western blot showing decreased HCV core in 
Calsyntenin-1 silenced Huh 7 cells 24 hours after HCV infection, compared to control 
cells. (B) Immunolabelling showing reduction in the ability of HCV to infect 
calsyntenin-1 silenced Huh7 cells (>5 fields/treatment). (C) Association of 
calsyntenin-1 with HCV core in HCV-infected Huh7 cells (>10 cells 
counted/treatment) as shown by proximity ligation assay (as detailed in section 
3.3.5.1). 
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3.3.5. Calsyntenin-1 is associated with Kinesin light chain 1 in Huh7 cells 
Calsyntenin-1 is a membrane bound protein that acts as an adapter molecule, 
linking vesicular cargo to the molecular motor kinesin 1, through interactions with 
KLC1 (Konecna, et al., 2006). In neurons it is involved in the anterograde 
transport of vesicles along microtubules by kinesin (Ludwig et al., 2009). Recent 
evidence also points towards a role for calsyntenin-1 in the trafficking of early 
endosomes in neurons (Steuble et al., 2010).  
Early endosomes have been shown to play an important role in the early post-
entry stages of HCV infection (Lai et al., 2010), with acidification inducing 
breakdown of the viral envelope, releasing the genome into the cytoplasm for 
viral replication. Knock down of early endosome associated proteins with siRNA 
resulted in failure of the virus to establish infection (Lai et al., 2010). Therefore 
we hypothesized that calsyntenin-1 plays a role in the transport of early 
endosomes within the hepatocyte, through its interaction with KLC1, and is 
involved in the early stages of HCV infection. 
To examine this possibility, co-localisation studies for KLC1 and calsyntenin-1 in 
Huh7 cells were performed using immunofluorescence. Calsyntenin-1 colocalised 
with KLC1 throughout the cell (Fig. 3.12) which is consistent with our hypothesis 
that calsyntenin-1 acts as an adapter protein for kinesin 1 motor-based transport in 
hepatocytes, as it does in neurons.  
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Figure 3.12 Calsyntenin-1 is associated with Kinesin light chain 1 in Huh7 
hepatoma cells. Huh7 cells were fixed with 4% PFA and immunostaining was 
performed using (a) anti-calsyntenin-1 antibody with Alexa-488 conjugated 
secondary (b) anti-KLC1 antibody with Alexa 594 conjugated secondary (c) merged 
images and (d) Subtraction image showing regions of colocalisation. Scale bar 20 
µm. More than 10 cells were counted for colocalisation analysis. 
!
3.3.5.1 Duolink Proximity Ligation Assay (PLA) 
To confirm that calsyntenin-1 and KLC1 were interacting closely in Huh7 cells, 
and not just in the same intracellular region, proximity ligation assay (PLA) was 
performed, as described in methods section 2.2.7.2. PLA is a technique that 
directly detects protein- protein interactions and modifications, with high 
specificity and sensitivity. Two primary antibodies raised in different species 
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recognize the target protein or proteins. Species-specific secondary antibodies, 
called PLA probes, each with a unique short DNA strand attached to it, bind to the 
primary antibodies. When secondary antibodies are in close proximity, the DNA 
strands interact through a subsequent addition of oligonucleotides. The enzymatic 
ligation ligates these oligos and then rolling circle amplification by DNA 
polymerase takes place. Several fold amplification of DNA occurs and addition of 
fluorescent probes highlights the newly formed product. This high concentration 
of fluorescence is easily visible by fluorescent microscope (Figure 3.13B). 
As shown in the figure 3.13B, in cells labelled with antibodies against 
calsyntenin-1 and KLC1, multiple bright spots were seen by immunofluorescence, 
which were not present in the negative antibody control. This confirms that 
calsyntenin-1 and KLC1 were indeed in very close proximity, consistent with a 
direct interaction. This data supports a role for calsyntenin-1 in mediating kinesin-
based transport of vesicular cargo in hepatocytes, similar to its role in neurons.  
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Figure 3.13 Proximity ligation assay (PLA). Huh7 cells were fixed with 4% PFA, 
immunolabelled for calsyntenin-1 and KLC1 using specific PLA probes and imaged 
under a Deltavision microscope. The image shows association of KLC1 with 
calsyntenin-1 in Huh 7 cells (>10 cells/treatment). (a) Control (only calsyntenin-1 
antibody), (b) KLC1 & calsyntenin-1 antibody and (c) Graph showing significantly 
higher number of interactions. Scale bar 15 µm. n=3 (D) PLA method as explained 
by Duolink (Reproduced from 
http://www.abnova.com/products/products_detail.asp?catalog_id=DP0002). 
Error bars indicate Standard Error of the Mean (SEM).  
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3.4 Discussion and Conclusion 
In this chapter we have described our analysis of the secreted proteome of HCV 
infected hepatocytes, identification of a highly secreted factor i.e. calsyntenin-1 
and its association with the microtubule motor kinesin. Full-length calsyntenin-1 
was present in conditioned media from HCV infected cells, suggesting its role in 
the HCV replication cycle. Previously calsyntenin-1 has been extensively studied 
in neurons (Steuble et al., 2010; Ludwig et al, 2009), where it is highly expressed, 
but no published data are available for its role in hepatocytes.  
The first aim was to optimise our in vitro HCV cell culture model for this project. 
Therefore we compared Jc1 and JFH1 virus constructs for their replication 
efficiencies and infectivity in Huh7 and Huh7.5 cell lines. We observed higher 
HCV RNA expression in Jc1 infected Huh7 cells compared to JFH1 infected 
cells. Jc1 is a GT2a/2a chimera containing sequences coding for J6CF structural 
proteins and JFH1 non-structural proteins, joined at the NS2/NS3 junction 
(Pietschmann et al., 2006). The higher infectious titres with Jc1 suggest an 
important role for structural proteins, which are responsible for virus assembly 
and release (Pietschmann et al., 2006).  Surprisingly, in our hands, Huh7 cells 
produced slightly higher virus titres than Huh7.5 cell line, regardless of which cell 
type was being infected, which differs from some published studies (Zhong et al., 
2005: Lindenbach et al., 2005). This may be due to the heterogeneous 
permissiveness of different Huh7 clones for HCV infection, due to mutation in 
retinoic acid-inducible gene I (RIG-I), essential for resistance to HCV (Gale and 
Foy., 2005).  
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We found increased amounts of calsyntenin-1 protein in conditioned media from 
JFH1 infected cells using a SILAC screen. This result was confirmed in Jc1 
infected cell lysates and supernatant by western blot, which showed an increase in 
full-length calsyntenin-1. However an important point to consider is calsyntenin-1 
cleavage events. As figure 3.7 shows, after cleavage of calsyntenin-1, the two 
final products are the N-terminal fragment (NTF) and C-terminal fragment (CTF). 
In our western blot analysis of lysates from Jc1 infected Huh7 cells, we observed 
three bands for calsyntenin-1: i.e. full-length calsyntenin-1, NTF and CTF. The 
NTF and CTF bands showed increased amounts in HCV infected cells while full-
length calsyntenin-1 was decreased. This suggests increased cleavage of full-
length calsyntenin-1 in HCV infected cells. There are few studies showing the 
coexistence of all three forms of calsyntenin-1 in neurons and pituitary membrane 
using C-terminal antibodies i.e R71 and R82 respectively (Vogt et al., 2001; 
Rindler et al., 2008).  
In contrast, we observed increased amounts of full-length calsyntenin-1 protein in 
supernatant from HCV infected cells, which was not detectable in media from 
uninfected control cells. The fact that only full-length calyntenin-1 was present 
suggests it was attached to membranes, rather than in a free soluble form. Full-
length calsyntenin-1 (150 kDa) contains a trans-membrane domain, but following 
cleavage a 115 kDa N-terminal soluble fragment is released, leaving a 33 kDa 
trans-membrane stump (Vogt et al., 2011). The presence of increased amounts of 
membrane-bound calsyntenin-1 in the supernatant of infected cells suggests an 
important role in HCV egress, most likely involving membranous vesicles. 
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Our study clearly shows that calsyntenin-1 and kinesin light chain 1 (KLC1) are 
associated with each other in Huh7 cells. High levels of colocalization in 
immunofluorescence studies demonstrated this initially. Subsequent proximity 
ligation assays confirmed their close association, and suggests direct interaction. 
The interaction of calsysntenin-1 with KLC1 is as an adapter, linking vesicular 
cargo to the microtubule based motor kinesin 1 (Ludwig et al, 2009). Two binding 
motifs, known as KLC1 binding segment 1 and 2 (KBS1 and KBS2) are located 
in the cytoplasmic fragment (CTF) of calsyntein-1, and interact with 
tetratricopeptide repeats (TPR) in KLC1. These motifs KBS1 and KBS2 consist 
of short peptide sequences KENEMDWDDS and ATRQLEWDDS, respectively. 
The consensus sequence of these motifs has been formulated as L/M–E/D–W–D–
D–S (Konecna et al., 2006).  
Calsyntenin-1 participates in endosomal transport by virtue of its role as a 
membrane bound adapter protein to kinesin light chain1 (KLC1) (Steuble et al., 
2010), thus facilitating the transport of these organelles along microtubules. 
Microtubules are polarized cytoskeletal filaments that allow polarised transport of 
different cellular cargoes, such as membranous organelles and proteins, to their 
particular subcellular destinations (Gunderson, 2002). A wide variety of studies 
have indicated that the retrograde and anterograde movement of viruses in the cell 
is dependent on microtubules and their associated motors i.e. kinesin and dynein 
(Dohner et al., 2005; Dodding and Way, 2011). The kinesin family of motors 
typically moves cargo towards the plus end of microtubules, while cytoplasmic 
dynein is the main minus-end directed motor (Goldstein, 2001).  
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Viruses hijack the endosomal pathway for their replication and progression 
because they contain few genes and depend on host factors for their survival. The 
endosomal pathway is involved in both HCV viral entry and egress (Lai et al., 
2010), so calsyntenin-1 may play a role in both processes. The decrease in HCV 
infection observed when we knocked down calsyntenin-1 protein indicates that it 
is necessary for efficient viral entry/early infection. When calsyntenin-1 was 
silenced and cells were infected with HCV, they contained less HCV core protein 
and only a small number of them became infected, as shown by 
immunofluorescence studies.  
In conclusion, our findings suggest an essential role for calsyntenin-1 in kinesin-
mediated transport of HCV in hepatocytes at early stages of infection, following 
receptor-mediated entry, and perhaps also at later stages of the HCV replication 
cycle. 
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CHAPTER 4: ROLE OF CALSYNTENIN-1 IN THE 
EARLY INFECTION OF HEPATITIS C VIRUS. 
 
 
4.1 Introduction 
Chapter three demonstrated an increased amount of calsyntenin-1 in HCV 
infected cells and in culture supernatant from infected cells, compared to 
uninfected cells. It also demonstrated an association between calsyntenin-1 and 
kinesin light chain 1, which was a novel finding for hepatocytes. Calsyntenin-1 
plays a key role in early endosome trafficking in neurons and HCV also interacts 
with early endosomal pathways, suggesting a possible role for calsyntenin-1 in 
early HCV infection. Previously, one study identified calsyntenin-1 to be 
involved in early HCV infection but no further evaluation was conducted (Li et 
al., 2009). We have therefore studied the role of calsyntenin-1 in HCV 
replication and hepatocyte biology in detail, and propose that it is a key player in 
kinesin mediated HCV trafficking in hepatocytes. 
HCV is the sole member of genus Hepacivirus of the family Flaviviridae 
(Maniloff, 1995). It is an enveloped virus with a positive, single-stranded RNA 
genome of ~9.6 kb length flanked by 5` and 3` un-translated regions (Choo et 
al., 1991). The 5 'UTR has a ribosome binding site  (IRES - Internal ribosome 
entry site) that starts the translation of a 3010 amino acid protein that is later 
cleaved by cellular and viral proteases into 10 active structural and non-
structural proteins. These proteins are arbitrarily divided into three structural 
(core, E1, and E2) and six non-structural proteins (NS2, NS3, NS4A, NS4B, 
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NS5A, and NS5B) while p7 is currently unassigned into either category 
(Lindenbach & Rice, 2005; Otto & Puglisi, 2004).    
HCV circulates as a lipoviral particle comprising lipoproteins (ApoA & ApoE), 
which help it to evade the immune system (Komurian-Pradel et al., 2004). HCV 
encodes two envelope glycoproteins i.e. E1 and E2, which mediate attachment to 
the cell. HCV entry is a multi step process involving first recognition and then 
attachment of the lipoviral particle with glycosaminoglycans on the cell surface 
(Monazahian et al., 1999; Morikawa et al., 2007). Subsequently, HCV is 
internalized by orchestral engagement of a complex set of receptors and proteins 
including the tetraspanin CD81, scavenger receptor B-1 (SR-BI), and the tight 
junction proteins claudin (CLDN) and occludin (OCDN), then is finally 
internalized by clathrin mediated endocytosis (Coller et al., 2009).  Immediately 
after internalization, the encapsulated viral particle is taken up by early 
endosomes (Figure 4.1), where pH dependent envelope and endosome fusion 
results in release of the viral genomic contents into the cytoplasm (Blanchard et 
al., 2006; Koutsoudakis et al., 2006; Meertens et al., 2006). 
The early endosome is the first highly dynamic compartment that receives 
internalized incoming cargo from the plasma membrane and is the major sorting 
endosome in the endosomal trafficking pathway (Gruenberg et al., 1989).  Rab5 
is the most studied and characterised GTPase of the early endocytic pathway. It 
regulates cargo entry from the plasma membrane to early endosomes, motility of 
early endosomes on actin and microtubular tracks and activates several 
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signalling and trafficking pathways involving early endosomes (Miaczynska et 
al., 2004; Schenck et al., 2008).  
 
 
 
 
 
 
Figure 4.1 HCV Entry. The HCV virion is internalised through the clathrin-
mediated pathway and then taken up by early endosomes. The endosome 
subsequently releases the HCV genome as a result of low pH mediated 
membrane fusion. This released RNA then goes to ER to initiate virus protein 
translation within the host cell (Reproduced from 
http://fyeahmedlab.tumblr.com/post/37090103139/volextus-hepatitis-c-virus-
life-cycle-this). 
 
The crucial and most important function of the early endosomes is to sort 
internalized cargo to its particular intracellular destinations, in a precise and 
highly controlled manner. Most of the endocytosed ligands are degraded but 
their receptors are recycled back to the plasma membrane for additional rounds 
of internalization (Dunn et al., 1989). For example, proteins like transferrin 
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receptor and low-density lipoprotein receptor are recycled back to the cell 
surface. In contrast, low-density lipoprotein itself and epidermal growth factor 
receptor (EGFR) are trafficked to late endosomes/lysosomes for degradation 
(Dautry-Varsat et al., 1983; Herbst et al., 1994).  
Calsyntenin-1 is a type 1 membrane bound protein, abundant in neurones, that 
interacts directly with kinesin light chain 1 via its C-terminal domain and takes 
part in the transport of amyloid precursor protein (APP). Disruption of 
Calsyntenin-1 associated axonal trafficking of APP is a pathogenic mechanism 
leading to Alzheimer’s disease (Vagnoni et al., 2012). It is an established fact 
that calsyntenin-1 docks Kinesin-1 to diverse endosomal carriers and contributes 
to several developmental processes in neurons including axonal growth, path 
finding and also affects cell polarity in the adult nervous system (Steuble et al., 
2010). Characterization of the proteome of calsyntenin coated organelles in 
neurones shows that they contain components of the endosomal trafficking 
pathway i.e. early and recycling endosomes (Steuble et al., 2010). Calsyntenin-1 
plays a key role in endosomal dynamics, affecting its distinct subpopulations and 
is required for transport of rab5 endosomes, as revealed by a recent in vivo study 
(Ponomareva et al., 2014).  
This chapter will focus on calsyntenin-1 dynamics during HCV early 
infection/entry, in particular its interactions with early endosomes. Furthermore, 
evaluation of the effect of calsyntenin-1 knockdown on HCV endocytosis, 
endosomal trafficking, cellular localization, endosomal functioning, velocity and 
transport within hepatocytes will be assessed.  
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4.2 Experimental Outline And Results 
4.2.1 HCV core protein interacts with early endosomes during early 
infection 
To determine the association between HCV core and early endosomes, we 
labelled HCV-infected cells for HCV core and early endosome antigen (EEA1), 
using specific antibodies. Early endosomes are the first compartments that take 
the internalized cargo and sort out its fate. In the case of HCV, they take up 
HCV virions (containing core) and release its genome after acidification, as 
mentioned above. We observed colocalization of HCV core protein with early 
endosomes after 48-72 h of infection as shown in figure 4.2. This confirms the 
association of HCV core with early endosomes for various pathogenesis related 
activities within hepatocytes. 
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Figure 4.2 Association of HCV core and early endosomes in HCV (Jc1) 
infected Cells. Jc1 infected Huh7 cells (24-48 h p.i) were labelled for 
calsyntenin-1 (green) and HCV core (red), nuclei were stained with DAPI and 
the cells examined by immunofluorescence under 60 × magnification. A) 
Distribution of HCV core with early endosomes in HCV infected cells. Scale bar 
15 µm. B) Magnified (3-fold) image of highlighted region in A showing HCV 
Core (C) Early endosomes. D) Merged image. E) Colocalized regions only 
(yellow). 
 
To look for an association between early endosomes and the HCV particle soon 
after it enters the cell, Huh7 cells were infected with concentrated Jc1 virus on 
ice. After 1 h, cell media was replaced and cells were then incubated for 30 
minutes, 60 minutes, 90 minutes and 2 hours. At each time point cells were fixed 
using 4% paraformaldehyde (PFA), labelled for HCV core and early endosomes, 
A. Core & EEA1 B. HCV Core 
D. A Merge 
B. EEA1 
E. Colocalisation 
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and then studied under Deltavision microscope at 60× magnification. Incoming 
virus could not be detected at early time points, but as shown in Figure 4.2 it was 
clearly visualised after 2 hours. At that time we observed core and early 
endosomes to be in close proximity, with some overlap. This suggests close 
association of incoming virus with early endosomes just 2 hours after its 
receptor-mediated entry. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Association of HCV core with early endosomes two hours after 
virus receptor mediated entry.  Huh7 cells were infected with concentrated Jc1 
virus on ice for one hour, replaced with new cell media and shifted to 37 °C. 
After two hours, cells were fixed with 4 % PFA and immunolabelled for HCV 
core and early endosomes (EEA1). (A) Image showing close proximity between 
incoming virus (HCV core) in red and early endosomes in green. Nucleus is 
stained blue using DAPI. (B) Merged image and (C) Colocalized regions only 
(yellow). Arrows indicate the area of colocalization where incoming virus enters 
early endosomes soon after its entry into the cell. Scale bar 15 µm.  
Early endosomes
HCV core
Colocalization Colocalized regions
A 
B C 
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4.2.2 Evaluation Of The Association Of Calsyntenin-1 And Early 
Endosomes In Huh7 Cells 
To look for the role of calsyntenin-1 in early endosome trafficking by live cell 
imaging, we cloned early an endosome marker (Rab5A) into the pEGFP-N1 
plasmid containing enhanced green fluorescent protein (EGFP). Calsyntenin-1 
was cloned into DsRed-monomer-C1, containing tetrameric Discosoma sp. Red 
fluorescent protein.  
4.2.2.1 Construction of Green fluorescent protein tagged Rab5a (Early 
endosome marker) 
Amplification of the gene for early endosome marker Rab5A was performed as 
described in chapter 2 section 2.2.5. The amplified PCR product was run on an 
agarose gel, which confirmed the correct size for the Rab5A gene (687 bp) 
(Figure 4.4A). This amplified product was cloned into pEGFP-N1 vector using 
restriction digestion as explained in methods section 2.2.5. Cloned plasmids 
were checked for the presence of our insert using restriction digestion (Figure 
4.4B), then the correct and proper clones were confirmed by sequencing. 
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Figure 4.4 Cloning of early endosome marker (Rab5A) into pEGFP-N1 plasmid 
for live cell imaging.  Total RNA was extracted from Huh7 cells and then cDNA 
was synthesised as described in section 2.2.4. cDNA was used as a template to 
amplify the Rab5A open reading frame and cloned into a pEGFP-N1 plasmid, 
containing enhanced green fluorescent protein (EGFP) tag, using restriction 
enzyme sites i.e. Xho1 and BamH1 which were engineered in our amplified 
product using primers and were already present in pEGFP-N1 plasmid. (A) 
Agarose gel shows amplified Rab5a gene size of 687 bp using Huh7 cDNA as 
template. Lane 1: 1kb ladder; Lane 1-4: Amplified product. (B) Cloned plasmids 
amplification confirms the presence of Rab5A insert in three plasmids. Lane 1: 
1kb Ladder, Lane2-3 Negative controls (Uncut plasmid), Lane 5,8,13: isolated 
plasmids with Rab5A at the proper size. 
 
 
 
 
  1      2      3       4      5      6       7       8     9      10    11     12     13 
B 
687bp 
A 
Rab5A 
  1              2                3               4                5 
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4.2.2.2. Construction of Red fluorescent protein tagged Calsyntenin-1 
Total RNA was extracted from Huh7 cells and cDNA was synthesised as 
detailed in section 2.2.5 while brain cDNA was used to amplify full-length 
calsyntenin-1 (NTF and CTF). Full length calsyntenin-1 and C-terminal 
fragment (CTF) open reading frames were amplified using hot start DNA 
polymerase (Figure 4.5A) and the amplified products were then cloned into a 
DsRed-monomer-C1 plasmid separately using restriction digestion as described 
in the methods section 2.2.6. It was difficult to amplify full-length calsyntenin-1 
from Huh7 cells because of its low expression, so a brain cDNA library was 
used, where it is highly expressed. 
DNA plasmids were then extracted as described in section 2.2.6 and investigated 
for the presence of the required genes by PCR gene amplification (Figure 4.5 B) 
and plasmid restriction digestion (Figure 4.5 C), which confirmed successful 
cloning into some of the plasmids. NTF plasmid number 7 & 8 and CTF plasmid 
number 8 & 9 with confirmed presence of insert were sequenced and then used 
for live cell imaging. 
 
 
 
 
!!!!!!!Chapter!4:!Role!Of!Calsyntenin41!In!The!Early!Infection!Of!Hepatitis!C!Virus! !
 116 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Figure 4.5 Cloning of Calsyntenin-1 into pDsRed-Monomer-C1 for live cell 
imaging. Full-length calsyntenin-1 was amplified from brain cDNA while CTF 
from Huh7 cDNA (section 2.2.4). Since the pDsRed-monomer-C1 plasmid and our 
amplified products already had restriction enzyme sites, the amplified products 
were cloned into plasmid separately using Xho1 and EcoR1 restriction enzymes. 
(A) PCR amplified bands of both fragments of calsyntenin-1. Lane 1 & 4: 10 kb 
ladder, Lane 2: Full-length (FL) calsyntenin-1 (2.8kb) Lane 3: C-terminal 
fragment (CTF) (0.44kb). (B) PCR plasmid gene amplification (Top panel) and 
restriction digestion (Bottom panel) of cloned plasmid for full-length calsyntenin-
1 gene (2.8 kb). (C) Gene amplification (Top panel) and restriction digestion 
(lower panel) of cloned plasmid for calsyntenin-1 CTF with a band size of 0.44 
kb. Lane 7: 1 kb Ladder, lanes 2-6,8,9; isolated plasmids.  
1 
2  
1 432
FL
2.8 kb
CTF
0.44 kb
A
B
1       2       3       4       5       6      7      8      9      10
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4.2.2.3 Plasmid Sequencing Analysis 
All plasmid constructs containing cloned genes were sequenced for 
confirmation. Sequence analysis of the plasmid DNA of constructed vectors was 
performed to confirm the cloned Rab5A and calsyntenin-1 (Full-Length and 
CTF) in pEGFP-N1 and pDsRed-monomer-C1, respectively. The consensus 
sequences of the inserted nucleotide sequences of both genes and their proteins 
were compared with the original NCBI submitted isolates of the respective 
genes. A BLAST online software comparison yielded 100% match in the 
sequences for all plasmids. This confirmed the proper and correct sequence for 
our clones.  
4.2.2.4 Live Cell Imaging 
To evaluate the role of calsyntenin-1 in trafficking of early endosomes, we 
overexpressed our GFP tagged Rab5A (early endosome marker) and RFP tagged 
calsyntenin-1 clones in live cells. Huh7 cells were transfected with calsyntenin-1 
containing RFP plasmids (FL (Amino acid 29-981) and CTF (Amino acid 826-
981) separately) along with the Rab5A containing GFP plasmid. After 24 h, 
localization studies were performed using Deltavision microscope at 100X 
magnification. The purpose of using two types of calsyntenin-1 clones was to 
determine which part of calsyntenin-1 is associated with early endosomal 
movement, as there was no previous evidence of their association in 
hepatocytes. Both of the calsyntenin-1 gene products (Full-length and CTF) 
were found to colocalise with Rab5A, but colocalisation was more apparent with 
the CTF (Figure 4.6) than full-length calsyntenin-1 (Figure 4.7), due to its 
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brighter fluorescence. This observation suggests the close association of the C-
terminal fragment of calsyntenin-1 with motile early endosomes within Huh7 
hepatoma cells. This is a novel finding, as it has previously only been described 
in neurons (Steuble et al., 2010), with no previous evidence of such an 
association in hepatocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Association of early endosomes with the C-terminal fragment of 
Calsyntenin-1 (DsRed-CTF) in live Huh7 cells. Huh7 cells were transfected with 
fluorescent tagged constructs of early endosome marker Rab5A and C-terminal 
fragment of calsyntenin-1. After 24 hours, live cell imaging was performed using 
Deltavision microscope at 100 X magnification. (A) GFP tagged early endosomal 
marker Rab5A (B) Ds-Red tagged C-terminal fragment of calsyntenin-1. (C) 
Merged image. D) Colocalized regions in yellow. Scale bar 15 µm. Cells counted 
were >10.  
A.pEGFP(Rab5A- B.pDsRed(CTF-
C.-Merged- D.-Colocaliza=on-regions-
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Figure 4.7 Live cells imaging of full-length calsyntenin-1 (DsRed-FL) and early 
endosomes in live Huh7 hepatoma cell line. Huh7 cells were transfected with 
GFP tagged Rab5A (early endosome marker) and RFP tagged full-length 
calsyntenin-1 clone. After 24 hours of transfection, live cell imaging was 
performed on Deltavision microscope using 100× magnification. (A) GFP tagged 
early endosomal marker Rab5A (pEGFP-Rab5A). (B) Ds-Red tagged full-length 
calsyntenin-1 (DsRed-FL) (C) Merged image (D) Colocalized regions in white. 
Scale bar 15 µm. Cells counted were >10. 
 
 
 
A. pDsRed-FL 
D. Colocalization C. Merged 
B. pEGFP-Rab5A  
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4.2.3 Effects of Decreased Calsyntenin-1 Expression on Early Endosomes in 
Huh7 Cells 
4.2.3.1   Early Endosome Distribution 
It is well established that early endosomes play a vital role in the early infection of 
HCV. Calsyntenin-1 is involved in early endosomal movement in neurons and 
affects their trafficking (Ponomareva et al., 2014). However, to date all published 
studies on calsyntenin-1 have been in neurons, rather than other cell types. As 
shown in Figure 4.6, we observed colocalisation between calsyntenin-1 and early 
endosomes in Huh7 hepatoma cells (a hepatocyte model), so we were keen to 
examine the role of calsyntenin-1 in endosome trafficking within hepatocytes.  
Calsyntenin-1 was silenced in Huh7 cells for 48 h, cells were fixed, early 
endosomes were labelled using anti-EEA-1 antibody and their cytoplasmic 
distribution was analysed using the analyze particle plugin of Image J software (as 
described in section 2.2.20). We observed that early endosomes were widely 
dispersed throughout the cell in control cells transfected with scrambled RNA, but 
in cells treated with calsyntenin-1 siRNA they were confined to the peri-nuclear 
region (Figure 4.8 A & B). 
As a result of this distribution change, early endosomes were only partially 
available at the plasma membrane to carry internalized cargo. To quantify the 
change in distribution, the percentage of the total cell area containing early 
endosomes was calculated in both control and silenced cells. This was performed 
using the Analyze plugin of the ImageJ software package (Figure 4.8C), the 
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values obtained from 20 cells were averaged and summarised as bar graphs 
(Figure 4.8D). For measuring early endosome distribution within calsyntenin-1 
silenced and control cells, the area occupying early endosomes, the cell nuclei and 
the whole cell were outlined manually. The limits of cells were visualized by 
differential interference microscopy (DIC) and the percentage of the total area 
containing early endosomes was calculated using the following formula: 
   Percentage area = d/(a-c) × 100  
where  a = area of total cytoplasm in the cell, c = area of nucleus and d = area of 
cytoplasm showing early endosomes (Boulant et al., 2008). 
To determine whether silencing calsyntenin-1 had any effect on the total amount 
of EEA1 protein in the cells, cells were silenced and analysed by western blot 
analysis. This showed no change in the total quantity of EEA1 protein in the 
calsyntenin-1 silenced cells (Figure 4.8E). So in summary, silencing calsyntenin-1 
dramatically affected the distribution of the early endosome protein (EEA1) 
within the cell, but had no effect on the total amount of EEA1. This supports our 
hypothesis that calsyntenin-1 is involved in the trafficking of early endosomes 
within the hepatic Huh7 cell line. 
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Figure 4.8 Distribution of early endosomes is altered in cells silenced for 
calsyntenin-1, compared to control cells. (A) Immunolabelling of early 
endosomes (EEA1) in scrambled Huh 7 control. (B) EEA1 antibody labelled cells 
treated with calsyntenin-1 siRNA. (C) Method for calculating the percentage of 
cytoplasm occupied by early endosomes in Image J (Analyze particle plugin), using 
the formula Percentage area = d/(a-c) × 100. (a = area of total cytoplasm in the cell, 
c = area of nucleus, d = area of cytoplasm showing early endosomes) (D) Graph 
shows significant reduction (p-value*** <0.0001) in cytoplasmic early endosomal 
percentage in the absence of calsyntenin-1 as compared to scrambled control. (E) 
Western Blot analysis of early endosomes in scrambled control and silenced 
calsyntenin-1 cells with beta actin control. Scale bar 15 µm. Calsyntenin-1 
(CLSTN-1). 
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4.2.3.2  Velocity Of Early Endosomes 
We have observed previously that (1) calsyntenin-1 colocalises with early 
endosomes (Figure 4.6 & 4.7) and (2) silencing the calsyntenin-1 gene affects the 
intracellular distribution of early endosomes (Figure 4.8). We therefore 
hypothesized that if we silence calsyntenin-1, there should be a decrease in the 
movement velocities of early endosomes.  
To test this hypothesis, Huh-7 cells were silenced for calsyntenin-1 with siRNA, 
transfected with pEGFP-Rab5A plasmid (Early endosome marker) and then 
examined by live cell imaging using a Deltavision microscope. Velocities of at 
least 10 early endosomes per cell (total 10 cells counted) were measured using 
Deltavision software. Velocities were measured for peripheral early endosomes 
(near the cell membrane) as well as for early endosomes in the peri-nuclear 
region, in equal proportions. Interestingly there was a significant 57% reduction 
(p-value <0.0001) in the velocities of peripheral as well as peri-nuclear early 
endosomes in calsyntenin-1 siRNA treated cells, compared to controls (Figure 
4.9).  
This supports our hypothesis that calsyntenin-1 plays a vital role in the movement 
of early endosomes within hepatic cells, which are a vital part of cellular 
machinery for the HCV replication cycle.  
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Figure 4.9 Velocities of early endosomes are significantly reduced after silencing 
calsyntenin-1 in hepatic cells. (A) Velocities of peri-nuclear early endosomes. (B) 
Velocities of peripheral early endosomes. Grey bars show siRNA calsyntenin-1 
treatment.  p-value*** <0.0001. Black and grey bars represent control and silenced 
Calsyntenin-1 cells, respectively. Error bars show standard error of the mean (SEM).  
Cells counted were >10/treatment. Calsyntenin-1 (CLSTN-1). 
 
4.2.3.3 Pattern of Early Endosome Movement  
To further assess the pattern of early endosome movement from previous 
experiments (section 4.3.2), we used the same images for scrambled control and 
silenced calsyntenin-1 cells and analysed them using a particle analysis 
(MTrack2) plugin of ImageJ software. The total number of early endosome 
movement events was also reduced within calsyntenin-1 silenced cells. Figure 
4.10A and 4.10B show the motility of early endosomes in control and 
calsyntenin-1 silenced Huh7 cells. Fewer movement events were observed in the 
absence of calsyntenin-1 than in controls. This further shows the importance of 
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calsyntenin-1 in mediating early endosome trafficking, as movement is restricted 
in its absence. 
 
 
Figure 4.10 Early endosomes become less motile in the absence of calsyntenin-1.  
Early endosome movement trajectories were traced for early endosomes in live cell 
imaging, using a pEGFP-Rab5A construct, with the help of particle analysis 
(MTrack2) plugin of ImageJ software (A) EEA1 traced paths and pEGFP-Rab5A live 
imaging in scrambled control Huh7 cells. (B) EEA1 pathways and pEGFP-Rab5A 
live cell imaging in silenced calsyntenin-1 Huh7 cells. (Lines show the movement 
pattern of early endosomes). N = 3. Scale bar 15 µm. 
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4.2.4 Calsyntenin-1 disrupts the function of early endosomes in hepatocytes 
A primary function of the early endosome is to sort out internalized cargo to 
different intracellular destinations (Jovic et al., 2010). Transferrin (Tfn) is one of 
the receptors that is recycled by early endosomes back to the plasma membrane. 
Our aim was to look for a change in the functioning of early endosomes in the 
absence of calsyntenin-1, by looking for changes in the distribution and/or amount 
of this receptor in siRNA treated cells, using immunolabelling and western blot 
techniques. We therefore transfected Huh7 cells with calsyntenin-1 siRNA or 
scrambled control for 48 h, fixed with 4% PFA and then labelled with transferrin 
receptor antibody and early endosome antigen 1 (EEA1). Immunofluorescent 
imaging and colocalization analysis were performed on Deltavision microscope. 
We observed a change in the distribution of both early endosomes and transferrin 
receptor, as shown in figure 4.11B. In control cells, transferrin receptor was 
distributed throughout the cell, particularly near the plasma membrane. However 
in calsyntenin-1 silenced cells, this distribution was altered and confined to the 
perinuclear region of the cell. A similar distribution was observed with early 
endosomes in scrambled control and silenced cells. This finding suggests that 
early endosomes are no longer cabaple of recycling transferrin back to the plasma 
membrane once calsyntenin-1 is silenced. Their reduced colocalization (~50%) in 
silenced cells compared to controls further supports that early endosomes become 
unavailable at the cell surface to recycle transferrin receptor (Figure 4.11 A & B). 
Western blot did not show any significant difference in the total amount of 
transferrin receptor protein between silenced and control cells, which shows that 
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calsyntenin-1 is only affecting the distribution and trafficking of this protein 
(Figure 4.11C). Our data overall confirms that calsyntenin-1 does not only affect 
the distribution, transport and velocity of early endosomes, but also disrupts its 
function. 
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Figure 4.11 Loss of early endosomal ability of recycling transferrin receptor 
back to the plasma membrane in the absence of calsyntenin-1. Huh7 cells were 
treated with calsyntenin-1 siRNA for 48 hours, immuno-labelled for the 
transferrin receptor and the early endosome marker EEA1, using specific 
antibodies, then examined by fluorescence microscopy. (A) Immunolabelling of 
early endosomes (EEA1) and transferrin receptor in scrambled control, showing 
their distribution throughout the cell, particularly near the plasma membrane. 
Scale bar 15 µm. (B) Immunolabelling of early endosomes (EEA1) and transferrin 
receptor in Huh7 cells silenced for calsyntenin-1, showing peri-nuclear 
distribution. (C) Western blot analysis confirms reduced amounts of calsyntenin-1 
but no change in the transferrin receptor. The cellular gene beta actin was used 
as a housekeeping control. n=3. 
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4.2.5 Calsyntenin-1 Depletion Does Not Affect Hepatitis C Virus Receptor 
Mediated Entry into Hepatocytes.  
We have already shown that silencing calsyntenin-1 affects the early stages of 
HCV replication cycle, by showing lower HCV RNA expression and less viral 
infection (Figure 3.6). Virus binding and entry involves receptor binding and 
clathrin mediated endocytosis, but NOT early endosomes, which are the next step 
involved in virus uncoating and entry to the cytoplasm. Therefore in this section 
we wanted to show that calsyntenin-1 silencing did NOT affect virus entry or 
internalization per se, in line with our hypothesis of calsyntenin-1 acting on early 
endosomes. 
To directly look for the effect of loss of calsyntenin-1 expression on endocytosis 
of the hepatitis C virus, incoming virus was visualized by fluorescence 
microscopy, using antibodies against HCV core. Briefly, Huh7 cells were silenced 
for calsyntenin-1 expression for 48 h, as in previous experiments. Concentrated 
Jc1 virus (as detailed in section 2.2.16) was added to the cells on ice for one hour 
to allow virus binding, then shifted to 37 oC to allow virus internalisation. Infected 
cells were fixed at different time points i.e. 0 min, 30 min, 60 min, 90 min and 
120 minutes after moving to 37 oC. Immunolabelling was performed for HCV 
core and early endosomes (EEA1) at each time point.  
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Figure 4.12 Effect of silenced calsyntenin-1 on viral entry and uptake by early 
endosomes. Huh7 cells were silenced for calsyntenin-1 and then infected with 
concentrated Jc1 virus on ice. After 1 h, cells were washed with PBS and shifted 
to 37 oC. Cell fixation was done using 4% PFA followed by Immunolabelling for 
early endosomes (red) and incoming virus (green) after  0, 30, 60, 90 and 120 
minutes of incubation. Immunolabelled EEA1 and HCV core in (A) scrambled 
control cells and (B) in silenced control. Scale bar 15 µm. 
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Unfortunately, it was not possible to image incoming virus reliably, because of 
the small amount of virus protein and the low signal:noise ratio (Figure 4.12), 
compared to infected cells where much larger amounts of virus protein is 
produced. 
We therefore decided to study the effect of silencing calsyntenin-1 on virus entry 
using the estabilished HCV pseudoparticle model (Drummer et al., 2003). This 
specialised model was not available in our laboratory, so we designed an 
experiment and collaborated with Dr Heidi Drummer at the University of 
Melbourne, who routinely uses this model for HCV entry studies. 
4.2.6 HCV Pseudoparticle Entry Assay 
To evaluate the effect of calsyntenin-1 on HCV entry, the H77c pp (HCV 
genotype 1a (H77c) derived pseudo-particles) assay was used, as described by 
Drummer et al, 2003. These HIV-1 derived pseudo-particles are coated in full-
length HCV E1 and E2 glycoproteins from HCV genotype 1a strain (H77), and 
contain a firefly luciferase reporter (Drummer et al., 2003). For our experiment, 
Huh7 cells were seeded at 250 000 cells/well in a 48 well plate for 1 day and then 
silenced for calsyntenin-1. After 24 h, silenced cells were washed and further 
transfected with HCV genotype 1a (H77c) derived pseudo-particles, or empty 
pseudoparticles. After 3 days post infection, H77c pp infectivity was measured in 
relative luciferase units (RLUs). 
We observed that calsyntenin-1 knock down did not inhibit HCV pseudo particle 
entry, as luciferase reporter activity was unchanged in calsyntenin-1 silenced 
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cells, compared to control (Figure 4.13). Thus there was no effect on HCV entry, 
consistent with our hypothesis that calsyntenin-1 is involved in trafficking of 
HCV through early endosomes, which occurs after receptor-mediated entry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13 HCV receptor mediated entry remains unaffected in calsyntenin-1 
silenced cells (HCV pseudoparticle assay). Huh7 cells were treated with 
calsyntenin-1 siRNA for 48 hours, or scrambled RNA as control, then infected 
with HCV pseudoparticles (H77c pp). Empty pseudoparticles were used as an 
additional control. After 3 days, cells were lysed and luciferase activity was 
measured. CLSTN1=Calsyntenin-1, Error bars indicate Standard Error of the 
Mean (SEM), n=2. 
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 4.3 Discussion and Conclusion 
In Chapter three we demonstrated that calsyntenin-1 is involved in HCV infection 
through knockdown studies. In subsequent chapters we aimed to clarify the 
specific roles that calsyntenin-1 plays at different stages of viral infection. 
Previous studies of calsyntenin-1 in neurons alerted us to its vital role in the 
trafficking of endosomes within cells. Early endosomes have also been 
demonstrated as key players in HCV entry. Together, these facts prompted us to 
look at the early steps of HCV infection involving early endosomes and their 
association with calsyntenin-1. 
Live cell imaging is a very effective tool for observing direct association between 
proteins within cells. Overexpression of our cloned constructs pEGFP-Rab5a and 
DsRed-FL or DsRed-CTF using live cell imaging showed a high degree of 
association between early endosomes and calsyntenin-1. This finding is consistent 
with a recent live cell imaging based in vivo analysis of their association with 
axon branching within neurons (Ponomareva et al., 2014). Calsyntenin-1 consists 
of two domains i.e. N-terminal domain and C-terminal cytoplasmic domain. The 
interaction between calsyntenin-1 and kinesin light chain-1 is mediated via its 
intracellular domain, thus serving as a molecular adapter to vesicular cargo 
(Konecna et al., 2006; Araki et al., 2007; Ludwig et al., 2009; Vagnoni et al., 
2011, 2012) as discussed in chapter 3. Consistent with these finding, we observed 
more colocalization between pEGFP-Rab5a and DsRed-CTF (intracellular 
domain) as compared to DsRed-FL (Figure 4.5 and 4.6 respectively). This is the 
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first report on their association in hepatocytes, or indeed in cells other than 
neurons.  
The connections between viral envelope glycoproteins and cellular receptors are 
responsible for virus entry through the plasma membrane (Meertans et al., 2006). 
Receptor mediated internalization occurs by the clathrin mediated pathway 
followed by early endosomal uptake.  Viral envelope and endosome membrane 
fusion then occurs, triggered by low pH within endosomes (Pelkmans & 
Helenius., 2003). In the case of HCV, following clathrin-mediated internalization, 
the virus envelope fuses with the endosome at low pH, release the genomic 
contents from the endosome. In this study we observed that calsytnenin-1 is 
involved in a post receptor mediated HCV entry step, namely the uptake into 
endosomes, affecting their trafficking with the cell. This phenomenon was 
confirmed by a pseudoparticle entry assay, where siRNA mediated knockdown of 
calsyntenin-1 had no effect on the infectivity of HCV pseudoparticles (H77c pp) 
containing HCV glycoproteins (E1 and E2). This supports the idea that 
calsyntenin-1 is not interacting with surface receptors and HCV envelope directly, 
but affects HCV core trafficking at a post endosomal stage. 
Early endosomes need to be at the periphery of the cell, ready to take up newly 
entered viral particles. Our data show that early endosomes in calsytnenin-1 
silenced cells are more condensed around the nucleus and occupy a smaller 
proportion of the cytoplasm. This is consistent with the identity of calsyntenin-1 
as an adaptor for KLC1, which is a plus-end microtubule motor. This means when 
calsyntenin-1 is silenced, early endosomes accumulate near the nucleus (minus 
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end), lacking the ability to reach the plasma membrane by plus end directed 
movement (Figure 4.14). It is well known that many other viruses depend on 
microtubule motors (kinesin and dynein) for their intracellular transport (Dodding 
& Way., 2011). 
 
 
Figure 4.14 Early endosomes lose their ability to show plus end directed 
movement in the absence of calsyntenin-1. Control cell shows even distribution 
of early endosomes in the cell while calsyntenin-1 silenced cells shows restricted 
kinesin-1 mediated, plus end directed movement. This results in peri-nuclear 
accumulation of early endosomes. 
 
The functional deficit in early endosomal function was confirmed by 
colocalisation studies using transferrin receptor. Cells, silenced for calsyntenin-1 
showed decreased overlap of transferrin receptor with early endosome markers, 
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indicating the internalised receptor was not being taken up by early endosomes. 
Moreover, lack of calsyntenin-1 causes early endosomes to be restricted to the 
peri-nuclear region and move slower. Condensed, less motile early endosomes 
would be less like to encounter internalised viral particles, resulting in a decreased 
rate of infection, as we have shown. 
In conclusion, we provide evidence for a direct role of calsyntenin-1 in kinesin-
mediated transport of early endosomes in hepatocytes. Calsyntenin-1 siRNA 
mediated knock down leads to unavailability of early endosomes at the plasma 
membrane, reduces their velocity and disrupts their function. As a result, HCV 
enters hepatocytes less efficiently, leading to reduced rates of infection. 
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CHAPTER 5: EVALUATION OF THE ROLE OF 
CALSYNTENIN-1 IN HEPATITIS C VIRUS 
REPLICATION. 
 
5.1  Introduction 
Chapter four identified calsyntenin-1 as an essential host factor involved in early 
endosome mediated transport of HCV, during early viral infection in hepatocytes. 
These studies were performed using various cell-imaging techniques and 
calsyntenin-1 siRNA mediated silencing. We found an association of calsyntenin-
1 with early endosomes and kinesin light chain 1, suggesting a role in kinesin 
mediated intracellular transport along microtubules. After decapsidation of the 
viral nucleocapsid in early endosomes, HCV positive-strand RNA is released into 
the cell cytoplasm, where it acts as an RNA template for synthesis of the HCV 
polyprotein. 
Previous studies on the role of early endosomes in HCV infection suggest that 
they contribute to formation of HCV replication complexes (RCs) (Stone et al., 
2007) and that these complexes require functional microtubule network to 
replicate viral RNA (Lai et al., 2008). We therefore hypothesised that, by 
affecting trafficking of early endosomes, calsyntenin-1 may also play a role in 
establishing HCV replication. In Chapter five we will test this hypothesis. 
After its release into the cytoplasm, HCV RNA reaches the endoplasmic 
reticulum (ER), where it is translated by ribosomes into a single viral polyprotein 
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(~ 3010 amino acids). This polyprotein is cleaved by host and viral proteases into 
ten mature structural and non structural viral proteins (Jones & McLauchlan., 
2010). Expression of the HCV viral polyprotein, or the non-structural protein 
NS4B alone, induces the formation of a multi-vesiculated structure called the 
“membranous web”, through distinct ER membrane alterations (Berger et al., 
2009). This site contains numerous small double membrane vesicles, ranging in 
size from ~150nm in diameter, embedded in the membranous matrix, which form 
the replication complexes (Romero-Brey et al., 2012; Gosert et al., 2003). This is 
the site where viral RNA is amplified by NS5B RNA-dependent RNA 
polymerase, in association with other non structural proteins and host factors, 
including cyclophilin A (Figure 5.1) (Bartenschlager et al., 2010). However, the 
molecular processes involving membranous web and replication complex 
formation are still poorly understood. 
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Figure 5.1 Hepatitis C Virus Replication Cycle in hepatocytes. After receptor 
mediated entry, endosome fusion and uncoating, the viral genome undergoes 
translation and replication. The encircled area represents the replication 
process, occurring at special sites on the endoplasmic reticulum called the 
membranous web. This is the site where HCV RNA translation occurs, resulting 
in viral proteins. HCV non-structural viral proteins, with the help of various host 
factors, then carry out different steps of HCV replication (Adopted from Paulina 
Godzik., 2012).  
 
Replication complexes (RC) are membrane-associated structures containing viral 
proteins, replicating RNA, cellular membranes and host factors involved in virus 
replication (Figure 5.2). RC formation involve several cellular host proteins and 
pathways including fatty acid and cholesterol synthesis pathways, Rab4, Rab5, 
vesicle-associated proteins (VAP) and early endosomes (Berger et al., 2009). 
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Their movement within the cell is dependent on the association of HCV NS3 and 
NS5a proteins with actin filaments and microtubules (Lai et al., 2008).  
 
 
 
 
 
 
 
 
 
 
Figure 5.2 HCV replication complex. (1) Virus genome encodes viral structural 
and non-structural proteins. (2) Different non-structural proteins (Particularly 
NS4B & NS5A) are responsible for ER membrane alterations. (3) HCV 
replication complex containing non-structural proteins, viral RNA and a variety 
of host factors (Miller S., 2008).  
 
 
Two types of replication complexes have been reported, classified according to 
their size and movement: i.e. small dot like motile structures and relatively larger 
static complexes. When observed by NS5A-GFP live cell analysis, the small 
structures exhibited rapid, microtubule-associated transport, while the larger 
structures showed limited or no intracellular movement (Wolk et al., 2008). Thus 
intracellular trafficking dynamics, including the organisation of ER and 
microtubule network, plays a vital role in the proper functioning of HCV RCs. 
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Within these vesicular structures HCV RNA replication occurs, in a semi-
conservative and asymmetric manner (Quinkert et al., 2005). The positive 
stranded HCV RNA is copied into a negative strand, which often base pairs with 
the parent strand to produce a double stranded replicative form (RF) 
(Bartenschlager et al., 2010).  When examined by fluorescence based 
hybridization methods, this replicative double stranded RNA appears as discrete 
foci, associated with HCV core and NS5A (Target-Adams et al., 2008).  
To date, an essential role for HCV NS5A in HCV replication has been well 
established. Its role is either direct, in association with viral RNA replication, or 
indirect, by modulating host cell pathways in favour of the virus (Wolk et al., 
2008). NS5A is a proline-rich, hydrophilic phosphoprotein that has no intrinsic 
enzymatic activity, but which acts as an adaptor protein for a variety of host 
factors involving signalling, membrane trafficking and lipoprotein synthesis 
pathways (Vogt et al., 2013). A key role is as a transport vehicle, bringing newly 
synthesised HCV RNA from replication sites to lipid droplets for encapsidation 
(Miyanari et al., 2007; Evans et al., 2004). Indeed, motility of NS5A and efficient 
HCV replication are dependent on the microtubule network, the molecular motor 
cytoplasmic dynein and several host factors including vesicle associated protein-A 
(VAP-A) and (early endosome marker) Rab5a (Eyre et al., 2014).  
We have shown (in Chapter 3) that calsyntenin-1 acts as a kinesin light chain 1 
(KLC1) adaptor protein. In neurons, this calsyntenin-1 bound kinesin-1 mediated 
transport has been shown to drive cargo transportation via microtubule mediated 
cellular endosomal pathways (Steuble et al., 2010). Therefore the main aim of 
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this chapter is to determine the role of calsyntenin-1 in HCV replication, 
including replication complex formation and motility, through its proposed 
association with NS5A and replicating HCV RNA. 
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5.2 Experimental Outline and Results 
5.2.1 Loss of calsyntenin-1 expression delays the set up of HCV replication 
complexes. 
To examine the effect of silencing calsyntenin-1 on HCV replication, a sub 
genomic replicon assay was used, based on the JFH1 HCV strain (genotype 2a), 
which expresses non-structural proteins NS3 to NS5B (Kato et al., 2003). This 
system bypasses all the steps of viral entry and viral particle uptake into early 
endosomes, as replicon RNA is delivered directly in to the cell for replication. In 
this transient replicon model, a firefly luciferase reporter was substituted for the 
neomycin (G418) resistance gene, to provide a readout of virus replication (Figure 
5.3A) (Targett-Adams & McLauchlan., 2005).  
For these experiments, RNA was transcribed from the HCV subgenomic replicon 
pSGR-luc-JFH1 and its replication defective mutant pSGR-luc-JFH1-GND, used 
as a control. Huh7 cells were treated with siRNA against calsyntenin-1 (or 
scrambled control RNA) for 48 h, then transfected with replicon RNA by 
electroporation. Luciferase activity of cell extracts was assayed at 10, 12, 14, 16, 
18, 20, 22, 24, 48, 72 and 96 hours. We demonstrated that there was a deficit in 
the replication of HCV RNA in calsyntenin-1 silenced cells compared with 
scrambled controls (Figure 5.3B). In scrambled control Huh7 cells, SGR 
luciferase activity increased up to 48 hours. However in calsyntenin-1 silenced 
cells, luciferase activity was significantly delayed/decreased (p<0.0001) compared 
to controls. By contrast, the GND mutant had minimal activity due to the mutation 
in the polymerase active site and hence served as a negative control. 
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Figure 5.3 Silencing calsyntenin-1 in Huh7 hepatoma cells delays the 
formation of HCV replication complexes. RNA transcribed separately from 
pSGR-luc-JFH1 and its replication defective GND control was electroporated 
into scrambled control and calsyntenin-1 silenced Huh7 cells. Luciferase 
activities (Relative Light Units = RLU) were assayed in cell extracts at 10 h and 
then every 2 h up to 24 h, then at 48 h, 72 h and 96 h. (A) Summary of the pSGR-
luc-JFH1 and pSGR-luc-JFH1-GND HCV subgenomic replicons (Target-adams 
P & McLauchlan J., 2005). (B) RNA synthesis luciferase values for Huh7 control 
(!) and calsyntenin-1 silenced Huh7 cells (") electroporated with RNAs 
transcribed from pSGR-Luc-JFH1 (solid line) and pSGR-Luc-JFH1/GND (dotted 
line). N=2, (p-value <0.0001). 
  
In this model, the increase in luciferase reporter activity usually starts 12 to 14 
hours post electroporation and coincides with the set up of HCV replication 
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complexes (Jones et al., 2007). Our observation suggests that the absence of 
calsyntenin-1 reduced HCV replication, by delaying the set up of replication 
complexes (Figure 5.3B). 
5.2.2 Association of Calsyntenin-1 Protein with HCV Replication 
Complexes in HCV (Jc1) Infected Cells. 
To look for a direct association of calsyntenin-1 with the HCV replication 
complex protein NS5A, we performed image analysis. This interaction was 
visualized using antibody specific immunofluorescence. HCV infected Huh7 cells 
and control cells were fixed using 4% PFA and then labelled for NS5A and 
calsyntenin-1 using specific antibodies. Cells were then imaged using Deltavision 
microscope and colocalisation analysis was performed using Deltavision software. 
The results showed clear co-localisation of NS5A with calsyntenin-1 in HCV 
infected cells (Figure 5.4D). Proximity ligation assay was used to show direct 
interaction of NS5A and calsyntenin-1 in HCV infected Huh7 cells. This assay 
provides a simple method to simultaneously visualize and locate protein-protein 
interactions (within 5-10 nm) within cells with exceptional specificity and 
sensitivity (Söderberg et al., 2006). The interaction between two proteins becomes 
visible as distinct spots under fluorescence microscopy. Figure 5.4 F shows a 
large number of spots in HCV-infected cell but none in Huh7 uninfected control. 
This suggests a specific association between calsyntenin-1 (cytoplasmic fragment) 
and the HCV replication complex protein NS5A. This suggests that the 
cytoplasmic fragment of calsyntenin-1, which is associated with the early 
endosome pathway, may facilitate HCV replication. 
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Figure 5.4 Association of Calsyntenin-1 and HCV non-structural NS5A protein 
in Jc1 infected cells. Huh7 hepatoma cells were electroporated with HCV RNA 
transcribed from the Jc1 plasmid then passaged twice. These infected cells were 
then fixed with 4% PFA and labelled for (A) HCV NS5A  (B) Calsyntenin-1 (C) 
merged image (D) Colocalisation between NS5A & calsyntenin-1. (E) Uninfected 
Control (F) Proximity ligation assay showing spots, indicating interaction 
between NS5A and Calsyntenin-1 within a distance of 5-10 nm.  More than 10 
cells were visualized, Scale bar 15 µm. 
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5.2.3 Evaluation of the Interaction between Calsyntenin-1 and Actively 
Replicating HCV Replication Complexes   
To confirm association of calsyntenin-1 with active HCV RNA replicating sites, 
rather than random NS5A protein in the cell, we performed fluorescent labeling 
for dsRNA, NS5A and calsyntenin-1 in HCV infected cells. Monoclonal 
Antibody J2 dsRNA antibody was used to label dsRNA that was greater than or 
equal to 40bp in replication complexes (Section 2.1.1). In infected cells, HCV 
dsRNA is a replicative intermediate and appear as discrete foci within replication 
complexes, surrounded by NS5A protein (Target-Adams et al., 2008). 
As shown in Figure 5.5 A, discrete labeling of NS5A and dsRNA was clearly seen 
in HCV infected cells, but not in the uninfected Huh7 controls. Higher 
magnification and 3D reconstruction (Fig 5.5 B) shows a close association 
between NS5A, dsRNA and calsyntenin-1. There appears to be a network of 
calsyntenin-1 (blue) in which NS5A (red) and dsRNA foci (green) are embedded 
(Figure 5.5 B). The presence of dsRNA confirms the location of active replication 
complexes, which are also rich in NS5A and associated with calsyntenin-1.  
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Figure 5.5 Calsyntenin-1 is associated with active HCV RNA replication sites 
in the presence of NS5A. Huh 7 hepatoma cells were infected with supernatant 
from HCV (Jc1) infected cells for 48-72 hours, then fixed for immunolabelling 
using 4 % PFA. Triple colour labeling for calsyntenin-1 (blue), NS5A (Red) and 
dsRNA (green) was performed using specific antibodies and cells were imaged by 
Deltavision microscopy. (A) Top panel: Huh7 uninfected cells as control. Scale 
bar 15µm. Bottom panel: HCV infected Huh7 cells. Scale bar 15µm (B) 3D 
reconstruction was performed using Deltavision software. Arrows indicate 
regions of colocalization between NS5A, dsRNA and calsyntenin-1. Scale bar 
5µm. 
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To look for close association of calsyntenin-1 with HCV replicative intermediate 
dsRNA, colocalisation studies and proximity ligation assay was performed 
(Figure 5.6). As shown in figure 5.6 A and B, calsyntenin-1 has a high degree of 
association/ colocalization with dsRNA in HCV infected cells. Proximity ligation 
assay (Figure 5.6 C) confirmed very close association between calsyntenin-1 and 
dsRNA, as positive spots indicate that the proteins of interest are in close 
proximity. Together, these data suggest that calsyntenin-1 may be playing a role 
in trafficking of active HCV replication complexes within infected cells. 
Uninfected Huh7 cells were used as PLA control. 
 
 
 
 
Figure 5.6 Interaction of calsyntenin-1 with dsRNA, a HCV replication 
intermediate in HCV infected cells. Huh7 cells were infected with Jc1 
supernatant and then fixed using 4% PFA. Then they were labelled for (A) 
calsyntenin-1 (blue) & dsRNA (green), (B) Shows co-localization of both proteins 
suggesting their interaction. Scale bar 5 µm (C) Proximity ligation assay (PLA) 
showing close proximity between two proteins. Scale bar 15 µm. 
A!
B. Colocalization C. PLA A. Calsyntenin-1 
dsRNA 
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5.2.4 HCV Replication Complexes Move in Association with Calsyntenin-1. 
As calsyntenin-1 mediates trafficking of cellular vesicles, our aim was to evaluate 
movement of HCV RCs using live cell imaging. For this purpose we used a HCV 
replicon (pSGR-luc-GFP-JFH1) containing an NS5a-GFP fusion, to image the 
replication complexes in real time (Jones et al., 2007). Previous studies have 
shown that NS5A containing a green fluorescent protein (GFP) tag in its C-
terminal domain successfully incorporates into functional HCV replication 
complexes, making them visible under a fluorescence microscope (Moradpour et 
al., 2004).  
In a previous study, GFP tagged (pSGR-Luc-GFP-JFH1) small replication 
complexes showed rapid, microtubule-associated transport (Wolk et al., 2008). 
We used the same replicon (pSGR-Luc-GFP-JFH1) and observed a strong 
interaction between GFP tagged replication complexes and calsyntenin-1 red 
entities. Huh7 cells were silenced for calsyntenin-1 (and scrambled control) for 
48 hours and then transfected with pSGR-Luc-GFP-JFH1 using Lipofectamine® 
RNAiMAX (Invitrogen). After 24 hours, cells were shifted to the live cell 
imaging chamber of the Deltavision microscope and observed under 60 × 
magnification. So this indicates involvement of calsyntenin-1 in HCV replication 
through interaction with replication complexes (Figure 5.7). 
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Figure 5.7 Saltatory movement of HCV replication complexes associated with 
calsyntenin-1 in live cells. Huh7 hepatoma cells were transfected with pSGR-Luc-
GFP-JFH1 and pDSRed-CTF calsyntenin-1. After 24 hours, cells were imaged live 
under a Deltavision microscope for 2-3 minutes under 60 × magnification. (A) GFP 
tagged NS5A (pSGR-Luc-GFP-JFH1), showing HCV replication complexes (B) Ds-
Red tagged CTF calsyntenin-1 (C) merged image, and (D) colocalized regions. “N” 
indicates cell nucleus. Scale bar is 15µm. 
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5.2.5 The Effect of Calsyntenin-1 on Velocities of HCV Replication 
Complexes 
To evaluate the effect of calsyntenin-1 on HCV replication complex dynamics, 
Huh7 cells were silenced for calsyntenin-1 and then transfected with the HCV 
construct pSGR-luc-GFP-JFH1, which contains GFP-tagged NS5A (Jones et al., 
2007). After 24 hours, live cell imaging was performed on a Deltavision 
microscope. At least 10 cells per treatment group  (Calsyntenin-1 siRNA and 
scrambled RNA controls) were observed for 1-3 minutes. GFP-tagged replication 
complexes showed less long-range movement in silenced calsyntenin-1 cells as 
compared to control (Figure 5.8 A & B).  
Velocities of at least ten small replication complexes/cell were quantified in 
control as well as silenced calsyntenin-1 cells using Deltavision microscope 
software according to manufacturers manual. During a 1-2 min observation period 
of live cell analysis, few GFP positive structures showed saltatory movement 
events. Their peak average velocities ranged from 0.6 µm/s to 1.3 µm/s in 
scrambled control cells. On the other hand, in calsyntenin-1 silenced cells overall 
reduced replication complexes movement was observed, with average velocities 
ranging from 0.16 µm/s to 0.54 µm/s. The usual movement speed for microtubule 
motor kinesin is 0.02 to 2 µm/sec (Kapitein et al., 2005). Figure 5.8 C 
demonstrates a highly significant reduction in the velocity of RCs in the absence 
of calsyntenin-1, compared to scrambled controls (p value <0.0001). This 
reduction suggests disruption of kinesin-mediated microtubule transport, due to 
the loss of calsyntenin-1.  
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Figure 5.8 siRNA mediated loss of calsyntenin-1 inhibits the MT dependent 
saltatory movement of HCV replication complexes. Huh 7 cells were silenced for 48 
hours using calsyntenin-1 siRNA (or scrambled control RNA) then transfected with 
the HCV replicon pSGR-Luc-GFP-JFH1. After 24 hour, Deltavision live cell 
microscopy was performed. The distribution of GFP- tagged NS5A (replication 
complexes) was assessed in (A) Huh7 scrambled control; (B) Calsyntenin-1 silenced 
cells. Scale bar is 15µm. N is for nucleus.  (C) Scatter graph for velocities (µm/s) of 
replication complexes in at least ten cells per treatment group. (***p-value 
<0.0001). 
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5.3 Discussion and Conclusion 
This chapter demonstrates that calsyntenin-1 is an important host factor 
facilitating HCV replication, by acting as an adaptor to kinesin-1 for microtubule 
associated trafficking. After virus entry and uptake by the early endosome, release 
of the HCV RNA genome from the viral capsid is mediated by acidification of the 
early endosome, after which the RNA is translated at the ER to form one 
polypeptide which is cleaved by viral and host proteases (Blight et al., 2000). 
After a threshold level of specific non-structural proteins (namely NS4B and 
NS5A) is reached, formation of the membranous web is induced. This site houses 
many HCV replication complexes, which carry out active HCV RNA replication 
with the help of various host factors (Wolk et al., 2008). The replication complex 
is the site of NS5B, the viral polymerase that replicates the HCV RNA genome, 
which is then either translated into new virus proteins, or transported and 
packaged into a viral capsid for export.  
Microtubules are well documented to move HCV replication complexes, as 
treatment with the microtubule stabiliser colchicine resulted in inhibition of 
replication complex movement (Lai et al., 2008). Other studies have demonstrated 
that the location of viral RNA replication is important, as it needs to be in close 
proximity to the site of either translation or packaging (Söderberg et al., 2006). 
Thus, the dynamic nature of the replication complex is of great importance to the 
HCV replication cycle.  
Our earlier data (Chapter 3) shows association of calsyntenin-1 with kinesin-1 
mediated transport and with early endosomes. We also showed association of the 
                Chapter(5:(Evaluation(Of(The(Role(Of(Calsyntenin81(In(HCV(Replication(
! 155!
HCV nonstructural protein NS5A with early endosome markers Rab5A and 
EEA1.   
Moreover, recent studies have further validated the role of the endosomal pathway 
in HCV infection and its importance for viral replication (Eyre et al., 2014). One 
study reported a significant decrease in HCV RNA synthesis when Rab5 was 
silenced (Stone et al., 2007). On the other hand, calsyntenin-1 has been 
extensively studied in neurons, where it is involved in endosomal pathways 
(Steuble et al., 2010).  
In this chapter, we found the adaptor protein calsyntenin-1 was associated with 
NS5A, a key player in the formation of HCV replication complexes. Importantly 
live cell colocalisation analysis suggested their interaction during productive 
replication. To determine the effect of loss of calsyntenin-1 on formation of 
replication complexes within hepatocytes, we transfected Huh7 cells with a 
luciferase tagged HCV replicon and measured viral replication over a time course. 
There was almost 50% reduction in replication seen in cells silenced for 
calsyntenin-1 up to 48 hours, compared to controls, suggesting a negative effect 
on initiation HCV replication following loss of calsyntenin-1. This result is 
similar to a study that shows that microtubule inhibition blocked the ability of 
HCV replication complexes to replicate RNA (Bost et al., 2003). This suggests 
that calsyntenin-1 acts as an adaptor for NS5A trafficking, so reducing 
calsyntenin-1 affects the ability of NS5A to form HCV replication complexes, 
reducing virus replication. 
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An important step in studying the role of calsyntenin-1 in HCV replication was to 
identify the RNA replicating complexes, as other NS5A positive structures are 
also found in infected cells. To do this, we labelled cells with specific antibody 
against dsRNA, as a confirmatory test. HCV dsRNA is a replication intermediate, 
formed as a result of negative strand RNA base pairing with the parent positive 
strand RNA template. Our results clearly showed colocalization of calsyntenin-1 
not only with NS5A, but also with dsRNA foci at the same time.  
The impact of our protein of interest calsyntenin-1 on the dynamics of replication 
complexes was studied by live cell imaging. In HCV infected cells, we observed 
populations of both small and large replication complexes. The larger structures 
were almost non motile, while smaller structures showed rapid saltatory 
movements, as seen previously (Wolk et al., 2008). When calsyntenin-1 was 
silenced, there was an obvious change in the distribution and movement of 
replication complexes, which were accumulated/halted within cells and not able to 
move around freely. This was similar to the findings in a previous study, using 
live cell imaging of the same HCV replicon, when cells were treated with the 
microtubule depolymerizing agent nocodazole (Wolk et al., 2008). In this study, 
the redistribution persisted while the drug remained in the cell media, but once it 
was removed saltatory movement of the replication complexes reappeared (Wolk 
et al., 2008). Unfortunately there is no reversible inhibitor of calsyntenin-1 
available, so we were not able to replicate these experiments in our model.  
We propose that calsyntenin-1 regulates trafficking of HCV replication 
complexes, so we evaluated effects on movement velocity. We therefore 
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quantified the velocities of HCV replication complexes in live cells, using a 
replicon containing GFP-tagged NS5A (pSGR-luc-GFP-JFH1). In HCV-infected 
cells, RC velocities were comparable to those typically associated with 
microtubule transport (Wolk et al., 2008) ranging from 0.6 µm/s to 1.3 µm/s. 
However, after silencing calsyntenin-1 there was a highly significant (p value 
<0.0001) reduction in the average velocity of replication complexes when 
compared to the scrambled control. This demonstrates the important role of our 
protein of interest in the movement of replication complexes, providing a key link 
between RNA replication and translation/packaging of the viral genome. 
In summary, this chapter has shown that the kinesin light chain 1 adaptor protein 
calsyntenin-1 is involved in HCV replication. It is required for the formation of 
new HCV replication complexes, and silencing of calsyntenin-1 had a negative 
impact on established HCV replication complexes, disrupting their transport and 
distribution within the cell. These observations suggest that calsyntenin-1 acts as 
an adapter for microtubule-associated transport of NS5A, to establish and 
maintain efficient viral replication.  
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CHAPTER 6: ROLE OF CALSYNTENIN-1 IN THE 
SECRETION OF HCV INFECTED CELLS.  
 
6.1. Introduction  
In Chapter Five, we discussed HCV replication dynamics, highlighting the key 
role which calsyntenin-1 plays in association with replication complexes. After 
replication, HCV genomic RNA along with other viral and host factors are 
transported to lipid droplets (LDs) where HCV virion assembly takes place, with 
the help of HCV core protein (Coller et al., 2012). Core protein regulates LD 
accumulation and recruits replication complexes to assembly sites but the 
underlying precise mechanism is still unknown. In addition, several non-structural 
proteins including p7, NS2, NS3 and NS5A also take part in HCV assembly events 
(Boulant et al., 2008), but their precise roles are unclear.  
Following assembly of HCV virions, the processes involved in virus export are 
still under study. HCV hijacks the very low-density lipoprotein (VLDL) secretion 
pathway for the production of infectious particles. This pathway is usually 
involved in export of triglycerides and cholesterol from liver to peripheral tissues 
(Ye J., 2007). In infected individuals, circulating HCV particles are associated 
with lipoproteins in VLDL-like particles called lipoviral particles (LVPs) 
(Gastaminza et al., 2010). In this way, the viral genome and capsid remain hidden 
in the hydrophobic core of the LVP, evading the host immune system (Gastaminza 
et al., 2010). These circulating structures are rich in triglyceride, viral RNA, core 
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protein, cholesterol ester and VLDL structural components i.e. apolipoprotein-B 
(apoB) and apolipoprotein-E (apoE) (Andre et al., 2002; Merz et al., 2011). A lot 
of evidence suggests that the VLDL pathway is required for the formation of 
infectious virus, however, the formation of the infectious viral particles and the 
process of egress still remain unclear.  
Another cellular pathway involved in HCV release is the host endosomal pathway, 
containing components of late endosome derived multivesicular bodies (Coreless 
et al., 2010) and recycling endosomes (Coller et al., 2012). Within late endosomes, 
when intraluminal vesicles (ILVs) are formed by inward invaginations of 
endosomal membrane, the whole endosome structure becomes a multivesicular 
body (MVB) (Fevrier et al., 2004). This inward budding process is analogous to 
viral envelopment during assembly and release (McDonald & Martin-Serrano, 
2009). Cargo sorting into MVBs is coordinated by several factors, collectively 
called endosomal-sorting complexes required for transport (ESCRT). Specific 
ESCRT proteins such as ESCRT- III, VPS4, TSG101, and Alix contribute to HCV 
release but the detailed mechanism is still unknown (Ariumi et al., 2011; Corless et 
al., 2010). The fate of MVBs is either to fuse with lysosomes for degrading cargo 
or with plasma membrane to release intraluminal vesicles called exosomes (Van 
Niel G et al., 2006). An important cellular factor called hepatocyte receptor 
tyrosine kinase substrate (Hrs) is the part of ESCRT-0, which is the first complex 
to bind cargo on endosomes (Tamai et al., 2012). Dendritic cells require Hrs for  
secretion and antigen presentation on exosomes (Tamai et al., 2012). 
Exosomes are extracellular nanovesicles (30-100nm) derived from MVBs and 
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secreted from a variety of cell types (Urbanelli et al., 2013). In recent years, a 
number of studies have shown that exosomes mediate indirect cell-to-cell 
communication and transfer macromolecules, functional proteins and RNA 
between cells (Bukong et al., 2014). For HCV, exosomes have been identified in 
media from HCV infected cells and in plasma of HCV infected patients 
(Gastaminza et al., 2010; Masciopinto et al., 2004). Recently they were shown to 
transfer HCV RNA to co-cultured plasmacytoid dendritic cells (pDCs), which 
prompted the production of type I interferon (IFN) (Dreux et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Endosome based pathway showing MVB formation and release of 
exosomes. Early endosomes mature into late endosomes or MVBs and 
communicate with Golgi apparatus through bidirectional vesicle transport. 
Intraluminal vesicles (ILVs) formed by invaginations of late endosome membranes 
are released into the extracellular space in the form of exosomes (Adopted from 
Borges et al., 2013). 
ILVs 
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An additional pathway identified in the release of HCV particles is the recycling 
endosomal pathway, which is regulated by the Rab family GTPase Rab11A 
(Coller et al., 2012). These GTPases are the main regulators of intracellular vesicle 
trafficking and Rab11A is specific for recycling endosomes. Cargoes are sorted in 
secretory vesicles, called Rab11A positive recycling endosomes, on their journey 
to the plasma membrane for exocytosis (Folsch H., 2005). An RNAi screen for 
host factors involved in HCV pathogenesis identified Rab11A as an important 
factor involved in exocytosis (Lai et al., 2010). An immunofluorescence based 
study (Coller et al., 2010) visualized HCV core interaction with Rab11A. Further, 
they silenced Rab11A and found decreased trafficking of HCV core from Golgi to 
the plasma membrane.  
In neurons, calsyntenin-1 is involved in the transport of post trans-golgi network 
(TGN) cargo in association with kinesin light chain 1 (Ludwig et al., 2010). This 
anterograde transport of TGN cargo to the plasma membrane is mediated by 
recycling endosomes (Steuble et al., 2010). On the other hand, calsyntein-1 has 
also been found in exosomes released from colon carcinoma and prostate cancer 
cells (Tauro et al., 2012; Beheshti et al., 2012). 
This chapter examines the association of calsyntenin-1 with export of HCV 
virions, involving endosome based cellular pathways. The function of calsyntenin-
1 in the HCV secretome, trafficking of multivesicular bodies and subsequent 
release of exosomes will be studied. Coordination of HCV core and calsyntenin-1 
with the recycling pathway via recycling endosomes will also be evaluated. 
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Finally, the effect of siRNA knockdown of calsyntenin-1 on the distribution of 
MVBs, exosome infectivity and recycling endosomes will also be assessed. 
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6.2  Experimental Outline and Results  
6.2.1 Effect of Calsyntenin-1 on the Production of HCV Infectious Particles 
To determine the effect of calsyntenin-1 on the production of infectious particles, 
we performed infectivity assays using TCID50. TCID50 is defined as tissue culture 
infectious dose of a pathogen such as virus that will produce a cytopathic effect in 
50% of the cultures inoculated. We used variations of this infectious assay, using 
serial dilutions and the same algorithm, to determine titre. Huh7 cells were 
infected with supernatant (MOI = 3) from HCV (Jc1) infected cells for 48-72 
hours and then silenced for calsyntenin-1 using siRNA. After 48 hours of 
silencing, supernatant was collected and used to infect naïve Huh7 cells in serial 
dilutions, then incubated at 37 °C for 72 hours. Cells were then labelled for NS5A 
using specific antibody and infectious foci were counted using an Olympus CK2 
inverted microscope at 20 × magnification. TCID50 was calculated according to a 
published algorithm (Carrere-Kremer et al., 2004).  
 As shown in Figure 6.2, there was no change observed in total HCV particle 
infectivity in virus from cells silenced for calsyntenin-1 compared to control cells 
treated with scramble RNA (Figure 6.2). 
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Figure 6.2 Effect of calsyntenin-1 on HCV infectious virus production as 
determined by TCID50 infectivity assay. HCV infected Huh7 cells were silenced 
for calsyntenin-1 for 48 h. Supernatant was used to infect naïve Huh7 cells for 72 
hours, NS5A immunolabelling was performed and infectious foci were counted. 
Error bars indicate SEM. 
 
 
6.2.2 Protein Analysis of HCV Infected Cells’ Secretion Using Sucrose 
Density Gradient Fractionation. 
 
To study the dynamics of HCV infected cells’ secretion and its relation with 
calsyntenin-1 we did sucrose density gradient fractionation on cell culture 
supernatants. Technically it is a challenge to completely separate viral particles 
from exosomes, because both have overlapping densities. The buoyant density of 
exosomes is 1.10-1.19 g/ml, while that of HCV virus particles is 1.06 to 1.16 g/ml 
in blood or infected cell supernatant (Dao et al., 2012). Supernatant was collected 
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from Jc1 infected Huh7 cells and virus was concentrated using PEG concentration, 
as explained in the Methods chapter (section 2.2.16). Concentrated virus was 
subjected to 60% to 10% sucrose density gradient as explained previously. 
Individual fractions were analysed for the presence of proteins of our interest such 
as calsyntenin-1 and HCV core, to look for possible interactions.  
For HCV, exosomes have been identified in media from HCV infected cells and in 
plasma of HCV infected patients (Gastaminza et al., 2010; Masciopinto et al., 
2004). Therefore we also examined fractions for the presence of exosome marker 
CD63, using western blot and specific antibody. Interestingly, same fraction was 
positive for calsyntenin-1, exosome marker CD63 and HCV core proteins (Figure 
6.3). This observation suggests a possible role for calsyntenin-1 in release of HCV 
through the exosomal secretory pathway. There was not complete overlap, as 
fractions either side were relatively enhanced for calsyntenin-1 and core (in 
different fractions).  
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Figure 6.3 Localization of calsyntenin-1 and HCV core protein in exosome rich 
density fraction. Concentrated HCV virus was subjected to sucrose density 
gradient ultracentrifugation and fractions 1-5 were analysed for protein content 
by western blot. Top panel: calsyntenin-1 protein bands. Middle panel: exosome 
marker CD63 protein. Bottom panel: HCV core protein. The highlighted area 
shows the presence of all bands in one common fraction. 
 
 
6.2.3 Evaluation of the Role of Calsyntenin-1 in the Production Of Exosomes  
To study the effect of calsyntenin-1 on exosome production, we used the 
Exoquick-TC (System biosciences) kit to isolate exosomes from serum free 
supernatants of uninfected Huh7 cells and HCV (Jc1) infected Huh7 cells. HCV 
infected Huh7 cells were maintained in serum free media for 24 h and the serum 
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free supernatants were collected. Fetal bovine serum (FBS) used as a growth 
supplement in cell culture media is reported to contain high amounts of cow 
exosomes (Hata et al., 2010). So to avoid any contamination from FBS we used 
serum free media for exosome isolation. 
To look for the effect of silenced calsyntenin-1 on exosome infectivity, a TCID50 
infectivity assay was performed. Isolated exosomes were used to infect naïve 
Huh7 cells for 72 hours and then NS5A positive infectious foci were counted. 
Interestingly, we found a significant reduction in the infectivity of exosomes 
isolated from media of HCV infected cells silenced for calsyntenin-1 as compared 
to control cells, treated with scrambled RNA (Figure 6.4A). As previously we 
didn’t find any change in the infectivity of total infectious virus produced from 
silenced calsyntenin-1 cells infected with HCV (Figure 6.2). We have also shown 
that exosomes are minor pathway for HCV export as compared to total virus. But 
silencing cansyntenin-1 has reduced exosome infectivity (Figure 6.4B). 
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Figure 6.4 Exosome infectivity is reduced when released from Jc1 infected cells 
silenced for calsyntenin-1. (A) Jc1 infected Huh7 cells were transfected with 
scrambled RNA or calsyntenin-1 siRNA and their serum free media were used to 
extract exosomes using Exoquick-TC kit (System biosciences). These extracted 
exosomes were then used to infect naïve Huh7 cells for 72 h. NS5A labelling was 
performed and infectious foci were counted in both treatments. n=3, (p-value*** 
= 0.0006) (B) Comparison of infectivity of total virus and exosomes in control and 
silenced calsyntenin-1 cells. n=3. 
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6.2.4 Exosomes are increased in Plasma Samples from HCV Infected 
Patients, Compared to Uninfected Controls. 
To test for the presence of exosomes in plasma from HCV infected patients, we 
obtained plasma samples from HCV infected patients and uninfected healthy 
individuals. Total protein was extracted (section 2.2.11) and the samples were 
analysed for the presence of exosome marker CD63 by western blot. We observed 
an increase in CD63 protein in plasma from HCV infected patients, compared to 
healthy controls (Figure 6.5).  
 
 
 
 
 
 
 
 
 
 
Figure 6.5 HCV infected blood plasma shows an increase in exosome proteins 
compared to healthy controls. Protein analysis was performed using blood plasma 
samples from HCV infected patients and also from healthy individuals (n=3). (A) 
Western blot analysis showing an increase in the expression of an exosome marker 
protein (CD63) in blood plasma samples from HCV infected patients (n=3). 
Complement 3 protein (C3) was used as supernatant protein control. (B) Graph 
showing CD63 band intensity in both control and HCV infected patients. (p-
value** = 0.0013).  
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6.2.5 Calsyntenin-1 is Associated with Multivesicular Bodies (MVBs) and 
Recycling Endosomes in Huh7 Cells  
To evaluate the interaction between calsyntenin-1 and multivesicular bodies (also 
known as late endosomes), we performed immunofluorescence analysis. The 
tetraspanin protein CD63 was used as MVB marker within cells because it is 
present within them and carry out MVB trafficking via exocytic pathway 
(Kobayashi et al., 2000). Huh7 cells were immune-labelled for calsyntenin-1 and 
the MVB marker CD63, visualised under the Deltavision microscope and 
colocalisation analysis was performed. We observed association of MVBs with 
calsyntenin-1, suggesting a potential role in cellular MVB trafficking (Figure 6.6).   
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Figure 6.6 Calsyntenin-1 colocalises with multivescicular bodies (MVB) in 
Huh7 cells. Huh7 cells were fixed with 4% PFA and then labelled for calsyntenin-
1 (green) and MBVs (red), nuclei were stained with DAPI and the cells examined 
by immuno fluorescence under 60 × magnification. (A) Association of MVBs with 
calsyntenin-1 in Huh7 cells (B) anti-CD63 antibody with Alexa-594 conjugated 
secondary (C) anti-calsyntenin-1 antibody with Alexa-488 conjugated secondary (D) 
Colocalization regions and (E) Magnified image shows association between 
calsyntenin-1 and MVBs. Scale bar 15 µm.  
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To look for an association of calsyntenin-1 with recycling endosomes, we labelled 
Huh7 cells with calsyntenin-1 antibody and antibody against a recycling endosome 
marker (Rab11A). A close colocalisation between calsyntenin-1 and recycling 
endosomes was observed en route to plasma membrane (Figure 6.7) that suggests 
trafficking of recycling endosomes in association with calsyntenin-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Chapter(6:(Role(of(Calsyntenin31(in(the(Secretion(of(HCV(Infected(Cells.((
                                                                   
 173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Association of recycling endosomes with calsyntenin-1 in Huh7 
hepatoma cells. Huh7 cells were labelled for calsyntenin-1 (green) and recycling 
endosome (red), nuclei were stained with DAPI and the cells examined by immuno 
fluorescence under 60 × magnification. (A) Association of recycling endosomes 
with calsyntenin-1 in Huh7 cells (B) anti-Rab11A antibody with Alexa-594 
conjugated secondary (C) anti-Calsyntenin-1 antibody with Alexa-488 conjugated 
secondary (D) Colocalization regions and (E) Magnified image shows association 
between calsyntenin-1 and recycling endosomes. Scale bar 15 µm.  
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6.2.6 HCV Core Protein interacts with MVBs and Recycling Endosome 
Mediated Secretory Pathways within HCV Infected Huh7 Cells. 
To study the localization of HCV core within MVBs, Jc1 infected Huh7 cells (48-
72 h) were labelled for MVB marker CD63 and HCV core. Colocalization study 
was performed using the Deltavision microscope as previously. We observed a 
unique kind of association between the two, which were localised around the 
plasma membrane. This suggests the release of HCV core out of the cell via the 
exosome secretory pathway, via CD63 positive MVBs (Figure 6.8). The 
distribution of CD63 positive foci around plasma membrane looks totally 
different than uninfected cells (Figure 6.6B). 
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Figure 6.8 Association of HCV core with MVB mediated cell secretory pathway 
in HCV infected Huh7 cells. HCV infected Huh7 cells were labelled for 
calsyntenin-1 (green) and multivesicular bodies (red), nuclei were stained with 
DAPI and the cells examined by immunofluorescence under 60 × magnification. 
(A) Distribution of recycling endosomes and HCV core in HCV infected cells (B) 
anti-CD63 antibody with Alexa-594 conjugated secondary (C) anti-HCV core 
antibody with Alexa-488 conjugated secondary (D) Colocalization regions and (E) 
Magnified image of the selected area. Scale bar 15 µm. 
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To further assess the connection between HCV core and recycling endosomes 
within HCV infected cells, HCV infected cells were imaged under deltavision 
microscope after labelling with HCV core and recycling endosome marker 
Rab11A antibodies. We observed colocalisation of recycling endosomes with 
HCV core (figure 6.9) suggesting interaction of HCV egress pathway with 
recycling endosomal pathway as reported previously (Coller et al., 2010).  
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Figure 6.9 Recycling endosomes are associated with HCV core secretory 
pathway in HCV infected Huh7 cells. HCV infected Huh7 cells were fixed with 
4% PFA and then labelled for calsyntenin-1 (green) and recycling endosome 
(red), nuclei were stained with DAPI and the cells examined by 
immunofluorescence under 60 × magnification. (A) Distribution of recycling 
endosomes and HCV core in HCV infected cells (B) anti-HCV core antibody with 
Alexa-488 conjugated secondary (C) anti-Rab11A antibody with Alexa-594 
conjugated secondary (D) Colocalisation regions and (E) Magnified image of the 
selected area. Scale bar 15 µm.  
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6.2.7 Effect of Suppressed Calsyntenin-1 on the Distribution of Recycling 
Endosomes and MVBs. 
To assess if silenced calsyntenin-1 has any effect on the distribution of recycling 
endosomes (Rab11A) and MVBs, Huh7 cells were silenced for calsyntenin-1. 
After 48 h, they were infected with HCV supernatant for 48-72 hours and then 
immunolabelled for recycling endosomes (Rab11A) or MVBs (CD63) and imaged 
under the Deltavision microscope.  
We saw a change in distribution of both recycling endosomes and MVBs within 
silenced infected cells as compared to controls. Both recycling endosomes and 
MVBs were observed to cluster around the perinuclear region (Figure 6.10). We 
observed this for more than 10 cells for both recycling endosomes and MVBs in 
three different experiments. This suggests that calsyntenin-1 silencing is affecting 
the transport of both these endosomes within HCV-infected cells, hence having a 
significant effect on HCV egress. 
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Figure 6.10 Distribution of recycling endosomes and MVBs is altered in the 
absence of calsyntenin-1 in HCV infected cells. Huh7 hepatoma cells were 
silenced for calsyntenin-1 for 48 hours, infected with HCV supernatant and then 
fixed with 4% PFA. Representative immunolabelling of cells was performed using 
anti-Rab11A in (A) scrambled control infected cells (B) in silenced calsyntenin-1 
HCV infected cells. MVB distribution was visualized using anti-CD63 in (C) 
Scrambled HCV infected control cells and (D) silenced calsyntenin-1 infected 
cells. Scale bar 15 µm.  
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6.3  Discussion and Conclusion 
Our initial SILAC screen (Figure 3.1) identified calsyntenin-1 as highly increased 
in the supernatant of HCV (JFH1) infected Huh7 cells. This was confirmed in 
western blot of HCV infected supernatant and cell lysates. This dramatic up 
regulation made us interested to examine its role in different stages of the HCV 
life cycle. In earlier chapters, we demonstrated a role for calsyntenin-1 in 
trafficking of HCV during early infection (Chapter 4) and subsequent replication 
(Chapter 5). In this chapter we specifically examined the role of calsyntenin-1 in 
HCV secretion. 
To investigate the possibility that calsyntenin-1 is involved in the release of 
infectious virus particles, we silenced it in HCV infected cells and performed 
infectivity assays on the supernatant. To our surprise, there was no obvious effect 
(Figure 6.2). The conventional VLDL pathway is involved in the secretion of 
infectious HCV particles, which form larger VLDL like particles known as 
‘lipoviral particles’. Our observation that there was no change in infectivity of 
secreted viral particles after silencing calsyntenin-1 suggested it was not involved 
in the typical HCV egress pathway. However, there remained the possibility that 
calsyntenin-1 contributed to other HCV secretory pathways.  
We performed sucrose density gradient fractionation of media from HCV infected 
cells, and found calsyntenin-1 and HCV core in the same fraction. This evidence 
suggests the simultaneous release of HCV with calsyntenin-1, probably in a 
secreted vesicle. Recently, it has been shown that HCV can also be secreted via 
multi-vesicular bodies (MVBs), endosomal sorting complex required for transport 
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(ESCRT) and hepatocyte receptor tyrosine kinase substrate (Hrs), which together 
are involved in MVB biogenesis and secretion of exosomes (Lai et al., 2014). 
Consistent with this, transmission of HCV via exosomes has been demonstrated, 
both in vitro and in vivo (Gastaminza et al., 2010; Masciopinto et al., 2004). 
Within MVBs, intraluminal vesicles (ILVs) are formed by inward invaginations of 
endosomal membranes (Fevrier et al., 2004). Further protein analysis of our 
density fraction showed the presence of an exosome marker (CD63) in the same 
fraction, suggesting that the secreted vesicles containing HCV core and 
calsyntenin-1 were exosomes. We therefore propose a model where in HCV 
infected hepatocytes, the transmembrane protein calsyntenin-1 is embedded within 
exosomes undergoing egress, and stays attached to the exosome once it has been 
secreted (Figure 6.10).  
Moreover we have also shown that siRNA induced loss of calsyntenin-1 
significantly reduced the infectivity of exosomes released from HCV infected 
cells. This further supports the model where calsyntenin-1 facilitates HCV particle 
egress out of the cell, in close association with exosomes. The presence of 
calsyntenin-1 has been reported in exosomes of cancer cells, indicating its 
participation in the spread of colon and prostate cancer (Tauro et al., 2012; 
Beheshti et al., 2012). Our observations may also suggest a role of calsyntenin-1 
in development of liver cancer, a major complication of chronic hepatitis C. 
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Figure 6.10. Proposed model highlighting the role of calsyntenin-1 in the release 
of HCV containing exosomes. Calsyntenin-1 is involved in the transportation of 
MVBs containing CD63 and HCV core within the cell, by kinesin mediated 
microtubule (MT) associated transport. As a result exosomes are released from the 
cell that contain CD63, calsyntenin-1 and HCV core.  MT: Microtubules, MVB: 
Multivesicular Bodies, ILV: Intraluminal vesicles.  
 
The clinical significance of exosomes was evaluated by analysis of plasma 
samples from HCV infected patients for exosome markers. Similar to previous 
studies (Gastaminza et al., 2010; Masciopinto et al., 2004), we found increased 
amount of an exosome protein (CD63) in plasma samples of HCV infected 
patients, compared to healthy controls. It has recently been reported that 
circulating HCV exosomes from HCV infected patients are capable of infecting 
primary human hepatocytes through cell-to-cell, receptor independent 
transmission (Bukong et al., 2014). 
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In addition to extracellular studies, we also conducted intracellular 
immunofluorescence analysis, to look for MVBs that release exosomes. We found 
close association of calsyntenin-1 with multivesicular bodies within Huh7 cells. 
Furthermore, these MVB were in close proximity with HCV core protein. It has 
previously been reported that HCV core interacts with host factors involved in 
MVB biogenesis, especially the ECSRT complex (Ariumi et al., 2011; Corless et 
al., 2010). Finally, siRNA mediated knockdown of calsyntenin-1 restricted the 
distribution of MVB within HCV infected Huh7 cells, suggesting a loss of their 
trafficking capability. These observations together identify a key role of 
calsyntenin-1 mediated trafficking of MVB within cells, in association with HCV 
core, for the release of HCV particles from the cell in exosomes.  
A possible role for calsyntenin-1 in facilitating cell secretion is suggested through 
its association with recycling endosomes in neurons (Steuble et al., 2010).  
Furthermore, HCV core traverses the cellular recycling pathway on its journey 
from the trans-golgi network (TGN), en route to the plasma membrane, through 
interaction with recycling endosomes (Lai et al., 2010). Therefore, to investigate 
the possibility of calsyntenin-1 mediated recycling of HCV core, we performed 
imaging analysis. RCs are identified by the presence of Rab family GTPase 
Rab11A and are involved in recycling various proteins, in an anterograde manner. 
Our study observed localization of calsyntenin-1 with Rab11A positive structures 
in Huh7 cells using Deltavision microscopy.  
We found change in the distribution of recycling endosomes and MVBs in HCV 
infected Huh7 cells silenced for calsyntenin-1, suggesting a movement 
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discrepancy without calsyntenin-1. In addition, these recycling endosomes were 
also seen colocalised with HCV core near the plasma membrane in HCV infected 
Huh7 cells (Figure 6.9). Therefore we propose that there is a role for calsyntenin-
1 in mediating trafficking of the recycling endosomes containing HCV core 
protein, a hypothesis that warrants investigation in future studies. 
In conclusion, this chapter suggests that calsyntenin-1 is involved in the secretion 
of HCV from infected cells, accompanied by exosomes. It mediates intracellular 
trafficking of MVBs and release of infectious exosomes. Furthermore, it aids 
recycling of viral proteins within HCV infected cells, by regulating the movement 
of recycling endosomes. 
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CHAPTER 7: GENERAL DISCUSSION 
 
7.1 Study Aims 
A SILAC screen to characterize different host factors involved in HCV secretion 
identified calsyntenin-1 to be highly increased. This protein is a type I trans 
membrane protein involved in kinesin 1 mediated intracellular transport in 
neurons. On further investigation we found that siRNA mediated silencing of 
calsyntenin-1 in HCV infected cells, reduced viral infection. These observations 
laid the foundation of this project to investigate for the first time the specific 
function of calsyntenin-1 in HCV infected hepatocytes at different stages of the 
viral replication cycle including HCV entry, replication and egress.  
7.2 Findings and Significance 
The results of our project demonstrated the role of calsyntenin-1 for the first time 
in hepatocytes, involving HCV pathogenesis. Although calsyntenin-1 has not 
previously been studied in the context of HCV, a literature search revealed that it 
was among >30 essential host factors identified in a small interfering RNA 
(siRNA) screen (Li et al., 2009). Calsyntenin-1 is a membrane-bound adaptor 
protein for the microtubule based motor kinesin 1 in neurons (Steuble et al., 
2010). It binds specifically to kinesin light chain 1 (KLC1), facilitating the 
trafficking of vesicular cargo along the microtubule network (Vagnoni, et al. 
2011). 
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Chapter 3 demonstrates increased calsyntenin-1 protein levels in HCV infected 
cells and culture supernatant, suggesting its involvement in HCV pathogenesis. 
The association of calsyntenin-1 with KLC1 was also observed in hepatocytes for 
the first time, suggesting its role in kinesin-1 mediated transport. When 
calsyntenin-1 silenced Huh7 cells were infected with HCV, they contained less 
HCV core protein and only a small proportion of them became infected, as shown 
by immunofluorescence studies. In light of this result, we decided to study the 
kinesin-1 mediated role of calsyntenin-1 in viral pathogenesis. We know that 
retrograde and anterograde movement of viruses in the cell are dependent on 
microtubules and their associated motors i.e. kinesin and dynein (Dohner et al., 
2005; Dodding & Way, 2011). The kinesin family of motors typically moves 
cargo towards the plus end of microtubules, while cytoplasmic dynein is the main 
minus-end directed motor (Goldstein, 2001). Based on these observations, we 
went further to step by step evaluate specific roles of calsyntenin-1 associated, 
kinesin-1 mediated transport at different stages of the HCV replication cycle.  
In Chapter 4 we looked for an association between calsyntenin-1 and early HCV 
infection. We know from various reports that after receptor-mediated entry of 
HCV into the hepatocytes, it is taken up by early endosomes, which are the first 
compartment to receive and sort internalised cargo (Meertans et al., 2006; 
Pelkmans & Helenius 2003). Previous studies in neurons have also shown the role 
of calsyntenin-1 in early endosome transport via its association with KLC1 
(Steuble et al., 2010). In our HCV entry experiment, HCV core and early 
endosomes were colocalised as early as 2 h after HCV entry, while an association 
between calsyntenin-1 and early endosomes was also observed in Huh7 hepatoma 
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cells using live cell imaging.  The effect of silenced calsyntenin-1 on trafficking 
of early endosomes was further evaluated. We showed that depletion of 
calsyntenin-1 in Huh7 cells altered the distribution of early endosomes and they 
were thus no longer available at the plasma membrane to pick up internalised 
cargo. This deficit was accompanied by reduction in early endosome velocity, 
altered movement pattern and disruption of its function in silenced calsyntenin-1 
cells. Collectively, this malfunction was suggestive of the disruption of plus end 
directed movement of early endosomes along microtubules, using kinesin-1 
mediated transport. Unfortunately, we were unable to show the effect of silenced 
calsyntenin-1 on HCV entry by immunofluorescence. This is likely due to the 
small amount of viral protein present on incoming virus particles and a low 
signal:noise ratio. However, entry experiments using a HCV pseudoparticle assay 
demonstrated that there was no change in HCV binding  and entry in calsyntenin-
1 silenced cells. This supports our hypothesis that calsyntenin-1 is involved in 
early HCV infection at steps subsequent to receptor-mediated entry. Altogether, 
our data indicate a specific role for calsyntenin-1 in the trafficking of early 
endosomes, which in turn affect the entry of HCV into the hepatocytes.  
In Chapter 5, the role of calsyntenin-1 in HCV replication was investigated. 
Following its release from early endosomes, translation of the HCV genome into 
viral proteins at the ER, and subsequent RNA replication, proceed with the help of 
host and viral factors (Bartenschlager et al., 2010). This process requires 
establishment of special viral RNA replicating structures, called replication 
complexes, at specific sites (membranous web) on the endoplasmic reticulum 
(Berger et al., 2009). One of the most important viral replication complex proteins 
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involved at this step is NS5A, which we found moved in association with 
calsyntenin-1 in our live cell imaging experiments. NS5A has no intrinsic 
enzymatic activity, but acts as an adapter protein for a variety of host factors 
involved in cell signaling and membrane trafficking (Vogt et al., 2013). It 
transports newly synthesised HCV RNA from replication sites to lipid droplets for 
encapsidation (Miyanari et al., 2007; Evans et al., 2004). Similarly, a close 
association was also seen between calsyntenin-1 and the HCV RNA replication 
intermediate (dsRNA), highlighting interaction between actively replicating viral 
RNA, intracellular transport and calsyntenin-1.  
To further monitor HCV replication kinetics over time, we transfected control or 
calsyntenin-1 silenced Huh7 cells with a sub genomic replicon containing a 
luciferase reporter (pSGR-luc-JFH1). Our results showed >80% decrease in HCV 
replication owing to late onset of HCV replication complex formation, suggesting 
discrepancy in essential NS5A transport in the absence of calsyntenin-1. To 
directly study NS5A transport, we used a HCV replicon (pSGR-luc-GFP-JFH1) 
containing an NS5A-GFP fusion and imaged the replication complexes in real 
time (Jones et al., 2007). Previous studies have shown that NS5A containing a 
green fluorescent protein (GFP) tag in its C-terminal domain successfully 
incorporates into functional HCV replication complexes, making them visible 
under a fluorescence microscope (Moradpour et al., 2004). A significant reduction 
in the velocity and distribution of these replication complexes was also seen 
within calsyntenin-1 silenced cells. Motility of NS5A and efficient HCV 
replication are dependent on the microtubule network and several host factors 
including vesicle associated protein-A (VAP-A) and (early endosome marker) 
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Rab5a (Eyre et al., 2014). On the whole, our results suggest that calsyntenin-1 
acts as an adapter for microtubule-associated transport of NS5A, to establish and 
maintain efficient viral replication.   
The final chapter (Chapter 6) of this thesis examines the role of calsyntenin-1 in 
HCV secretion through endosomal pathways. Increased secretion of calsyntenin-1 
from HCV-infected cells in the SILAC screen prompted us to investigate the level 
of calsyntenin-1 in HCV infected cell lysates and supernatants. To our surprise, 
when we silenced calsyntenin-1 in HCV infected cells and measured the 
infectivity of total virus released, it remained unaffected. Hence, calsyntenin-1 
release is not dependent on the conventional VLDL-based HCV secretion 
pathway. Keeping in mind the endosome trafficking role of calsyntenin-1 at other 
stages of viral infection, we investigated endosome based secretory pathways 
involved in HCV egress. Recently, it has been shown that HCV can also be 
secreted via multi-vesicular bodies (MVBs), endosomal sorting complex required 
for transport (ESCRT) and hepatocyte receptor tyrosine kinase substrate (Hrs), 
which together are involved in MVB biogenesis and secretion of exosomes (Lai et 
al., 2014). Exosomes are released from the cell through the fusion of 
multivesicular bodies (MVBs) with the plasma membrane. Several recent studies 
showed that exosomes mediate indirect cell-to-cell communication and transfer 
macromolecules, functional proteins and RNA between cells (Bukong et al., 
2014). For HCV, exosomes have been identified in media from HCV infected 
cells and in plasma of HCV infected patients (Gastaminza et al., 2010; 
Masciopinto et al., 2004). Another study has reported that circulating HCV 
exosomes from HCV infected patients are capable of infecting primary human 
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hepatocytes through cell-to-cell, receptor independent transmission (Bukong et 
al., 2014).  
To evaluate the involvement of calsyntenin-1 in the HCV exosome secretory 
pathway, we concentrated virus from the supernatant of HCV infected cells and 
performed sucrose density gradient fractionation. Different fractions were then 
analysed for calsyntenin-1, HCV core and exosome marker (CD63) proteins, 
which were commonly all present in the one fraction. This suggests that the 
release of HCV virions takes place in association with exosomes and calsyntenin-
1. To further examine this association, we silenced HCV infected cells for 
calsyntenin-1 and isolated exosomes from their serum free supernatants. We 
observed that the infectivity of exosomes was reduced in the absence of 
calsyntenin-1 as compared to control cells treated with scrambled RNA. Thus, the 
calsyntenin-1 protein may be involved in exosome-mediated release of HCV 
particles from infected cells. 
From intracellular studies, we know that within late endosomes, inward 
invaginations of the endosomal membrane results in intraluminal vesicles (ILVs) 
which form the multivesicular body (MVB) (Fevrier et al., 2004). These MVBs 
then fuse with the plasma membrane to release the ILVs from the cell, which are 
then called exosomes (Van Niel G et al., 2006). We have demonstrated the 
association of MVBs with calsyntenin-1 and HCV core within HCV infected 
cells, suggesting a possible role in viral pathogenesis. This was further confirmed 
by demonstrating altered MVB distribution in HCV infected cells after siRNA 
mediated loss of calsyntenin-1. This observation suggests the adapter protein 
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calsyntenin-1 is involved in kinesin-1 mediated transport of MVBs within cells 
and finally release of exosomes after fusion with plasma membrane.  
Finally, previous reports propose a possible role for calsyntenin-1 in facilitating 
cell secretion, through its association with recycling endosomes in neurons 
(Steuble et al., 2012).  Similarly, HCV core also interacts with recycling 
endosomes of the cellular recycling pathway on its journey from the trans-golgi 
network (TGN), en route to the plasma membrane (Lai et al., 2010). Interestingly, 
we observed colocalization of calsyntenin-1 with both recycling endosomes and 
HCV core, which indicates a role for recycling endosomes, in association with 
calsyntenin-1, for trafficking HCV core within virus infected cells.  Further loss 
of calsyntenin-1 in HCV infected cells restricted the distribution or recycling 
endosomes, suggesting a vital role for calsyntenin-1 in the HCV virus recycling 
pathway, an hypothesis that warrants further elucidation.  
7.3 Future Directions 
The results in this thesis suggest an in vitro role of calsyntenin-1 in HCV 
pathogenesis at all stages of the virus life cycle. Future aims include 
1. To evaluate the in vivo role of calsyntenin-1 in HCV infected mouse 
models or primary cells.  
2. To examine the kinetics of HCV exosome release in HCV infected clinical 
samples thus identifying its role in disease spread.  
3. To investigate the role of calsynteinin-1 in pathogenesis of other viruses.  
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7.4 Conclusion 
Throughout the course of this thesis I have addressed all the specific aims and 
have confirmed the original hypothesis (Figure 7.1). In summary, I have shown 
that HCV infection up regulates the release of calsyntenin-1 through exosomes. 
The other specific aims were achieved as follows; 
(1) Role of calsyntenin-1 in HCV early infection was evaluated by observing its 
association with early endosome trafficking after receptor mediated virus entry.  
(2) Interaction between HCV replication and calsyntenin-1 was assessed through 
its association with HCV replication complexes and its effect on their replication 
efficiency and trafficking ability within HCV infected cells.  
(3) Process of HCV egress was examined and a role of calsyntenin-1 was 
demonstrated in HCV endosome based secretory pathways including recycling 
endosomes, multivesicular bodies and exosomes. 
Overall, our interpretations show the insights of HCV replication cycle dynamics 
and the importance of cellular trafficking pathways. It opens the door to several 
new and exciting avenues of HCV replication cycle investigation. Using 
calsyntenin-1 as a target for HCV therapeutic approach would be challenging.  It 
depends on using a specific liver delivery system to avoid side effects on other 
body organs, particularly the nervous system. However insights gained from this 
thesis improve our understanding of HCV-associated pathogenesis, and have 
implications not only for HCV, but potentially also for other viruses that interact 
with cellular endosomal pathways.  
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Figure 7.1 Calsyntenin-1 is involved in HCV pathogenesis at various stages. It 
interacts with (1) HCV early infection through early endosomes (Rab5a) & Core, 
(2) HCV Replication by association with HCV NS5A and dsRNA, (3) HCV egress 
through exosome release and (4) recycling pathway via recycling endosomes 
(Rab11A). 
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